Midazolam and ketamine for enhanced sedation

Abstract

Provided herein are pharmaceutical compositions comprising midazolam and ketamine, and methods of inducing sedation (e.g., procedural sedation) in a subject using administration of such compositions, the compositions optionally including a pharmaceutically active compound of a third class. Compositions may be in sublingual or buccal form, or incorporated into vehicles for extended release. Methods for fabricating the compositions and using them for anesthesiological applications are also described.

Description

Atty. Docket No.: 109520-846634 MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Application No. 63 / 661,385, filed June 18, 2024, theentire contents of which are incorporated by reference herein. FIELD OF THE TECHNOLOGY

[0002] The present invention relates generally to the field of pharmacology and more specifically tocompositions comprising midazolam and ketamine, which have anesthetic properties that are useful in various kinds of medical practice, such as surgery or a medical procedure, and to methods of preparing and using such compositions (e.g., for sedation). BACKGROUND

[0003] The present disclosure relates to pharmaceutical formulations comprising a combination ofmidazolam and ketamine, and optionally one or more pharmaceutically active compounds of third class (e.g., an anesthetic, antiemetics, antianxiety medications and / or analgesics), and methods for using the same for providing anesthesia (e.g., inducing sedation) by administering such compositions orally, including such administrations as sublingual or buccal. The formulations may also include slow release reversal agents that would counteract the initial anesthesia effect.

[0004] It is necessary in many cases to use local anesthesia in the course of various surgical procedures,e.g., ophthalmic surgeries or urological interventions. For instance, when local anesthesia is employed during or prior to intraocular operations (e.g., topically applied local anesthesia), the occurrences of pain, anxiety, peri-operative stress, nausea, agitation, vomiting and the like are less frequent, which will typically have a very beneficial effect on the surgical experience and reducing the number of intraocular complications such as bleeding, secretions, cardiac and / or pulmonary complications, etc. The severity of those complications when they do occur will also be less pronounced when local anesthesia is used.

[0005] Traditionally, an intravenous route is used to administer medications. Alternatives to intravenousmethods and therapies have been suggested and previously used for the treatment. In particular, oral administration of benzodiazepines, opioid analgesics, propofol, ketamine or etomidate utilizing the MAC procedure (monitored anesthesia care) has been suggested and tried, but no more than minimal to moderate improvement has been achieved by such methods. Therefore, there remains a need for better treatments of these disorders. 103923302.1Atty. Docket No.: 109520-846634

[0006] This patent specification discloses such pharmaceutical compositions suitable foranesthesiological applications (e.g., procedural sedation) that can achieve positive patient outcomes while free of drawbacks and deficiencies of existing methods and formulations. Methods of fabricating and administering the same are also discussed. SUMMARY OF THE INVENTION

[0007] In one aspect, provided herein is a method of inducing procedural sedation in a subject, themethod comprising administering (e.g., sublingually administering) a pharmaceutical composition comprising midazolam and ketamine, wherein the administration achieves a level of sedation for procedural sedation in the subject. The time period of sedation may last for a time period of 1 hour or less (e.g., 45 minutes or less, 30 minutes or less, or 15 minutes or less).

[0008] In another aspect, provided herein is a method of inducing procedural sedation in a subject, themethod comprising administering (e.g., sublingually administering) to the subject a first dose of a pharmaceutical composition comprising midazolam and ketamine; and administering (e.g., sublingually administering) to the subject a second dose of the pharmaceutical composition after the sublingual administration of the first dose, wherein the administration achieves a level of sedation for procedural sedation in the subject. The time period of sedation may last for a time period of 1 hour or less (e.g., 45 minutes or less, 30 minutes or less, or 15 minutes or less). The sublingually administration of the second dose of the pharmaceutical composition may occur within 30 minutes (e.g., within 15 minutes) after administering the first dose of the pharmaceutical composition.

[0009] In another aspect, provided herein is a method of reducing the occurrence of rescue, the methodcomprising administering (e.g., sublingually administering) a pharmaceutical composition comprising midazolam and ketamine to achieve procedural sedation in a subject. The rescue may be performed when the subject’s level of sedation is a 1 on the Ramsay sedation scale. The rescue may be pre-operative or intra-operative. The occurrence of rescue may be reduced as compared to administration of midazolam alone or ketamine alone.

[0010] In such methods, the level of sedation achieved in the subject may be measured via the Ramsaysedation scale. The level of sedation achieved may be greater than achieved by administering midazolam alone, or ketamine alone. 103923302.1Atty. Docket No.: 109520-846634

[0011] In such methods, the weight ratio of midazolam to ketamine in the pharmaceutical compositionmay be about 1:5 to about 1:20, optionally about 3:25 (e.g. about 3 mg of midazolam and about 25 mg of ketamine) or about 3:50 (e.g., about 3 mg of midazolam and about 50 mg of ketamine).

[0012] Such methods may result in a Cmax of midazolam in the subject that is at least about 10% lower,at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, at least about 70% lower, or at least about 80% lower than a Cmax of midazolam resulting from intravenous administration of an equivalent amount of midazolam (e.g., less than or equal to about 140 ng / mL). Such methods may also result in an AUC0-t of midazolam in the subject that is not statistically different from or at least about 10% lower, at least about 20% lower, about least about 30% lower, at least about 40% lower, or at least about 50% lower than an AUC0-t of midazolam resulting from intravenous administration of an equivalent amount of midazolam. Such methods may also result in an AUCinf of midazolam in the subject that is not statistically different from or at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, or at least about 50% lower than an AUCinf of midazolam resulting from intravenous administration of an equivalent amount of midazolam.

[0013] Such methods may result in a Cmax of 1 hydroxymidazolam in the subject that is at least about25% greater, at least about 50% greater, at least about 100% greater, or at least about 200% greater than a Cmax of 1 hydroxymidazolam resulting from intravenous administration of an equal amount of midazolam (e.g., greater than or equal to about 6 ng / mL).

[0014] Such methods may result in a Cmax of ketamine in the subject that is at least about 10% lower, atleast about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, at least about 70% lower, or at least about 80% lower than a Cmax achieved from intravenous administration of an equal amount of ketamine (e.g., less than or equal to about 275 ng / mL). Such methods may also result in an AUC0-t of ketamine in the subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least 40% about lower, at least about 50% lower, at least about 60% lower, or at least about 70% lower than an AUC0-t of ketamine resulting from intravenous administration of an equivalent amount of ketamine. Such methods may also result in an AUCinf of ketamine in the subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, or at least about 70% lower than an AUCinf of ketamine resulting from intravenous administration of an equivalent amount of ketamine. Such methods may also result in a half-life (t1 / 2) of ketamine in the subject that is at 103923302.1Atty. Docket No.: 109520-846634 least 1 hr, 2 hr, 3 hr, 4 hr, or 5 hr shorter than a half-life of ketamine resulting from intravenous administration of an equivalent amount of ketamine.

[0015] Such methods may result in a Cmax of norketamine in the subject that is at least about 10%greater, at least about 25% greater, at least about 50% greater, at least about 100% greater, at least about 150% greater, at least about 200% greater, at least about 300% greater, or at least about 400% greater than a Cmax of norketamine achieved from intravenous administration of an equal amount of ketamine (e.g., greater than or equal to about 30 ng / mL).

[0016] In another aspect, provided herein is a solid pharmaceutical composition formulated forsublingual and or buccal administration comprising about 3 mg of midazolam and about 50 mg of ketamine. The solid pharmaceutical composition may further comprise a third pharmaceutically active (NSAID), or antihistamine medicament, or a combination thereof or pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof. The solid pharmaceutical composition may be in a solid dosage form selected from a troche, lozenge, capsule, pill, cap, or bolus. The solid pharmaceutical composition may further comprise a binder, optionally selected from a binder as described herein. The solid pharmaceutical composition may further comprise an excipient, optionally selected from an excipient as described herein. Said solid pharmaceutical composition may be used in a method of inducing sedation in a subject (e.g. as described herein). BRIEF DESCRIPTION OF THE DRAWINGS

[0017] FIG. 1 shows mean plasma concentration-time profiles of the analyte midazolam on the linearscale, from the pharmacokinetics population after administration of MELT-100 midazolam and ketamine formulations, and midazolam IV alone. Open circles depict Treatment A (Test 1) = A single MELT-100 sublingual tablet (3 mg midazolam and 25 mg ketamine). Open triangles depict Treatment B (Test 2) = A single MELT-100 sublingual tablet (2 x 3 mg midazolam and 25 mg ketamine administered sublingually, which 15 min apart, total dose = 6 / 50 mg). Open squares depict Treatment C (Reference 1) = A single dose of midazolam 3.5 mg administered as IV in 3 increments over 2 minutes of 1.5 mg, 1 mg, and 1 mg (2 minutes between each administration)

[0018] FIG. 2 shows mean plasma concentration-time profiles of the analyte 1-hydroxymidazolam onthe linear scale, from the pharmacokinetics population after administration of MELT-100 midazolam and ketamine formulations, and midazolam IV alone. Open circles depict Treatment A (Test 1) = A single 103923302.1Atty. Docket No.: 109520-846634 MELT-100 sublingual tablet (3 mg midazolam and 25 mg ketamine). Open triangles depict Treatment B (Test 2) = A single MELT-100 sublingual tablet (2 x 3 mg midazolam and 25 mg ketamine administered sublingually 15 min apart, total dose = 6 / 50 mg). Open squares depict Treatment C (Reference 1) = A single dose of midazolam 3.5 mg administered as IV in 3 increments over 2 minutes of 1.5 mg, 1 mg, and 1 mg (2 minutes between each administration).

[0019] FIG. 3 shows mean plasma concentration-time profiles of the analyte ketamine on the linearscale, from the pharmacokinetics population after administration of MELT-100 midazolam and ketamine formulations, and ketamine IV alone. Open circles depict Treatment A (Test 1) = A single MELT-100 sublingual tablet (3 mg midazolam and 25 mg ketamine). Open triangles depict Treatment B (Test 2) = A single MELT-100 sublingual tablet (2 x 3 mg midazolam and 25 mg ketamine administered sublingually 15 min apart, total dose = 6 / 50 mg). Open triangles depict Treatment D (Reference 2) = A single dose of ketamine 18 mg (10 mg / mL in a 20 mL vial) administered as IV over 5 minutes.

[0020] FIG. 4 shows mean plasma concentration-time profiles of the analyte norketamine on the linearscale, from the pharmacokinetics population after administration of MELT-100 midazolam and ketamine formulations, and ketamine IV alone. Open circles depict Treatment A (Test 1) = A single MELT-100 sublingual tablet (3 mg midazolam and 25 mg ketamine). Open triangles depict Treatment B (Test 2) = A single MELT-100 sublingual tablet (2 x 3 mg midazolam and 25 mg ketamine administered sublingually 15 min apart, total dose = 6 / 50 mg). Open squares depict Treatment D (Reference 2) = A single dose of ketamine 18 mg (10 mg / mL in a 20 mL vial) administered as IV over 5 minutes.

[0021] FIG. 5 shows a plot of a Kaplan-Meier Curve of time to achieve preoperative target sedationlevel for the all-treated analysis set of the Phase 3 MELT-300 study. It represents the time from the administration of study drug until the first Ramsay Sedation Scale (RSS) score of 2 or 3, calculated in minutes. The y-axis shows event-free survival (% of subjects who have not achieved the preoperative target sedation level) and the x-axis shows the number of minutes since administration of the study drug. Calculations were for subjects dosed with MELT-300 who achieve a preoperative RSS score of 2 or 3 using the Kaplan-Meier (KM) method. Analysis excluded subjects who receive preoperative rescue sedation medication. DETAILED DESCRIPTION

[0022] Discussed below are components of aspects of methods disclosed herein. These and othermaterials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc., of these materials are disclosed that while specific reference of each various individual and collective 103923302.1Atty. Docket No.: 109520-846634 combinations and permutation of these components may not be explicitly disclosed, each is specifically contemplated and described herein.

[0023] Other aspects and iterations of the invention are described more thoroughly below.1. Definitions

[0024] Unless specific definitions are provided, the nomenclatures utilized in connection with, and thelaboratory procedures and techniques of analytical chemistry, synthetic organic and inorganic chemistry described herein, are those known in the art. Standard chemical symbols are used interchangeably with the full names represented by such symbols. Thus, for example, the terms “hydrogen” and “H” are understood to have identical meaning. Standard techniques may be used for chemical syntheses, chemical analyses, formulating compositions and testing them. The foregoing techniques and procedures can be generally performed according to conventional methods well known in the art.

[0025] It is to be understood that both the foregoing general description and the following detaileddescription are exemplary and explanatory only and are not restrictive of the invention claimed. As used herein, the use of the singular includes the plural unless specifically stated otherwise. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0026] As used herein, “or” means “and / or” unless stated otherwise. Furthermore, use of the term“including” as well as other forms, such as “includes,” and “included,” is not limiting.

[0027] “About” as used herein means that a number referred to as “about” comprises the recited numberplus or minus 1-10% of that recited number. For example, “about” 100 degrees can mean 95-105 degrees or as few as 99-101 degrees depending on the context. Whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; i.e., meaning only 1, only 2, only 3, etc., up to and including only 20.

[0028] The term “pharmaceutical composition” is defined as a chemical or biological compound orsubstance, or a mixture or combination of two or more such compounds or substances, intended for use in the medical diagnosis, cure, treatment, or prevention of disease or pathology.

[0029] The terms “anesthetic,” “anesthesia,” “anesthesiology” and the like refer herein to substances,compounds, processes or procedures that induce insensitivity to pain such as a temporary loss of sensation. 103923302.1Atty. Docket No.: 109520-846634

[0030] The term “conscious sedation,” which for the purposes of this application, may be used inter-changeably with the term “procedural sedation”, and is used herein to refer to an induced state of sedation characterized by a minimally depressed consciousness such that the patient is able to continuously and independently maintain a patent airway, retain protective reflexes, and remain responsive to verbal cues and / or tactile or physical stimulation.

[0031] Conscious sedation is typically performed / induced to decrease the level of anxiety in a patientand to elicit an improved degree of cooperation from the patient prior to or during a procedure. Conscious sedation, therefore, refers to a condition that is medically different and distinct from deep sedation which is the next level of sedation defined as depression of consciousness when the patient’s ability to independently maintain ventilatory function may be impaired and he or she cannot be easily aroused; however, the patient will still purposefully respond to repeated or painful stimulation.

[0032] Conscious sedation is also clearly distinguishable for the purposes of the present application fromthe lower level of sedation (i.e., minimal sedation when the patient is able to maintain a normal response to verbal stimuli) as well as the highest level of sedation (i.e., general anesthesia when there is no response from the patient even with painful stimulus).

[0033] The term “pre-sedation” is defined for the purposes of this application as conscious sedation thatis induced some time before a procedure, e.g., between about 5 minutes and about 1 hour prior.

[0034] The terms “solvate” and “hydrate” are used herein to indicate that a compound or substance isphysically or chemically associated with a solvent for “solvates” such as water (for “hydrates”).

[0035] The term “NMDA antagonist” is defined as a compound that inhibits (“antagonizes”) the actionof the N-methyl-D-aspartate receptors and is inclusive of both competitive and noncompetitive antagonists, glycine antagonists and uncompetitive channel blockers, as these terms are under-stood by those having ordinary skill in the art.

[0036] of the adrenergic receptors responsible for increased cardiac action.

[0037] The term “antiemetic” is defined as a drug or medicament that treats, reduces, and / or preventsnausea and / or vomiting. 103923302.1Atty. Docket No.: 109520-846634

[0038] The term “non-steroid anti-inflammatory drug” or “NSAID” refers to a class of compounds thatare free of any steroid moieties yet are capable of providing analgesic, antipyretic and / or anti- inflammatory effects.

[0039] The term “antihistamine medicament” refers to any compound that is capable of inhibiting orcounteracting the physiological effects of histamine.

[0040] The term “polyglycol” is defined as a polymer or oligomer containing several etherglycol link-ages that yields one or more glycols when these linkages are cleaved, e.g., by hydrolysis.

[0041] The term “carrier” refers to a substance that serves as a vehicle for improving the efficiency ofdelivery and the effectiveness of a pharmaceutical composition.

[0042] The term “excipient” refers to a pharmacologically inactive substance that is formulated incombination with the pharmacologically active ingredient of pharmaceutical composition and is inclusive of bulking agents, fillers, and products used for facilitating drug absorption or solubility or for other pharmacokinetic considerations.

[0043] The term “binder” refers to a substance or compound that promotes, provides or improvescohesion, i.e., a substance that causes the components of a mixture to cohere to form a solid item that possesses integrity.

[0044] The term “troche” refers to a small tablet or lozenge (i.e., a medicated candy intended to be dis-solved in the mouth), typically in a form of a disk, a ball or rhombic in cross-section, comprising medication and processed into a paste and dried.

[0045] The term “therapeutically effective amount” is defined as the amount of a compound orpharmaceutical composition that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, medical doctor or other clinician.

[0046] The term “pharmaceutically acceptable” when used in the context of a carrier, diluent orexcipient, refers to a substance that is compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

[0047] The terms “administration of a composition” or “administering a composition” is defined toinclude an act of providing a compound of the invention or pharmaceutical composition to the subject in need of treatment. 103923302.1Atty. Docket No.: 109520-846634

[0048] The terms “oral administration” and “orally administering” are broadly defined as a route ofadministration where a medication is taken through the mouth including “sublingual administration” and “buccal administration” where the medication is placed under the tongue or be-tween the gums and the cheek, respectively, to be absorbed by the body, or to be administered sublingually or buccally as a liquid.2. Pharmaceutical compositions2.1. Midazolam and ketamine

[0049] According to embodiments of the present invention, there are provided pharmaceuticalcompositions for anesthetic purposes (e.g., comprising midazolam and ketamine). In particular embodiments, the anesthetic purpose is for conscious sedation in a subject (e.g., procedural sedation as described herein). The compositions comprise, consist of, or consist essentially of, a combination of therapeutically effective amounts of a pharmaceutically active compound of a first class and a pharmaceutically active compound of a second class, wherein the pharmaceutically active compound of the first class is midazolam and the pharmaceutically active compound of the second class is ketamine. In certain further embodiments, the compositions optionally comprise, in addition to the above-mentioned pharmaceutically active compounds of the first and second classes (i.e., midazolam and ketamine), at one or more (e.g. at least one) pharmaceutically active compound of a third class.

[0050] The pharmaceutically active compound of the first class that is used in a composition as describedherein (e.g., a composition of a method as described herein) is midazolam, or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof. Midazolam is of the benzodiazepine drug class, having a benzodiazepine moiety comprising a benzene ring condensed with a diazepine ring and a seven- member heterocycle having two nitrogen atoms. These two nitrogen atoms of a benzodiazepine may be at any positions of the ring (e.g., 1,2-diazepine, 1,3-diazepine or 1,4-diazepine). Midazolam is a 1,4- diazepine. The IUPAC name corresponding to midazolam is: 8-chloro-6-(2-fluorophenyl)-1-methyl-4H- imidazo[1,5-a][1,4]benzodiazepine. Commercially available formulations of midazolam include those having the tradenames: VERSED®, DORMICUM®, and HYPNOVEL®, each of which are contemplated for use herein. In some embodiments (e.g., of a method or composition as described herein), midazolam comprises the chemical structure depicted below as Structure (I): 103923302.1Atty. Docket No.: 109520-846634

[0051] The therapeutically effective amount of midazolam in the pharmaceutical composition (e.g., thatis administered to the subject) can be between about 0.2 mass % and about 5.0 mass % of the composition. In some embodiments, the therapeutically effective amount of midazolam in the pharmaceutical composition can be between about 1.0 mass % and about 3.0 mass %, for example, about 2.5 mass % of the composition.

[0052] The pharmaceutically active compound of the second class that is used in a composition asdescribed herein (e.g., a composition of a method as described herein) is ketamine, or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof (e.g., ketamine hydrochloride). Ketamine is in the NMDA antagonist drug class. The IUPAC name corresponding to ketamine is: 2-(2-chlorophenyl)-2- (methylamino)cyclohexanone. Commercially available formulations of midazolam include those having the tradenames: KETANEST®, KETASET®, or KETALAR® (HC1 salt) , each of which are contemplated for use herein. In some embodiments, (e.g., of a method or composition as described herein) ketamine comprises the chemical structure depicted below as Structure (II):

[0053] The therapeutically effective amount of ketamine in the pharmaceutical composition (e.g., that isadministered to the subject) can be between about 1.0 mass % and about 10.0 mass % of the composition. In some embodiments, the therapeutically effective amount of ketamine in the pharmaceutical composition can be between about 4.0 mass % and about 6.0 mass %, for example, about 5.0 mass % of the composition. 103923302.1Atty. Docket No.: 109520-846634

[0054] Accordingly, in some embodiments of a pharmaceutical composition as described herein, thecombined quantities of both the midazolam and the ketamine, taken together, are between about 1.2 mass % and about 15.0 mass % of the composition, such as between about 3.0 mass % and about 12.0 mass %, for example, about 10.0 mass % of the composition.

[0055] In particular embodiments of the pharmaceutical composition, the weight ratio of midazolam toketamine is about 1:5 to about 1:20. In some embodiments, the weight ratio of midazolam to ketamine is about 1:5. In some embodiments, the weight ratio of midazolam to ketamine is about 1:6. In some embodiments, the weight ratio of midazolam to ketamine is about 1:7. In some embodiments, the weight ratio of midazolam to ketamine is about 1:8. In some embodiments, the weight ratio of midazolam to ketamine is about 3:25. In some embodiments, the weight ratio of midazolam to ketamine is about 1:9. In some embodiments, the weight ratio of midazolam to ketamine is about 1:10. In some embodiments, the weight ratio of midazolam to ketamine is about 1:11. In some embodiments, the weight ratio of midazolam to ketamine is about 1:12. In some embodiments, the weight ratio of midazolam to ketamine is about 1:13. In some embodiments, the weight ratio of midazolam to ketamine is about 1:14. In some embodiments, the weight ratio of midazolam to ketamine is about 1:15. In some embodiments, the weight ratio of midazolam to ketamine is about 1:16. In some embodiments, the weight ratio of midazolam to ketamine is about 3:50. In some embodiments, the weight ratio of midazolam to ketamine is about 1:17. In some embodiments, the weight ratio of midazolam to ketamine is about 1:18. In some embodiments, the weight ratio of midazolam to ketamine is about 1:19. In some embodiments, the weight ratio of midazolam to ketamine is about 1:20.

[0056] In some embodiments, the pharmaceutical composition may comprise from about 1 mg to about10 mg of midazolam, such as about 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, or about 10 mg of midazolam. In some embodiments, the pharmaceutical composition may comprise from about 1 mg to about 2 mg, about 1 mg to about 4 mg, about 1 mg to about 6 mg, about 1 mg to about 8 mg, about 1 mg to about 10 mg, about 2 mg to about 10 mg, about 4 mg to about 10 mg, about 6 mg to about 10 mg, about 8 mg to about 10 mg, about 1 mg to about 5 mg, or about 2 mg to about 4 mg of midazolam.

[0057] In some embodiments, the pharmaceutical composition may comprise from about 20 mg to about80 mg of ketamine, such as about 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, or about 80 mg of ketamine. In some embodiments, the pharmaceutical composition may comprise from about 20 mg to about 30 mg, about 20 mg to about 40 mg, about 20 mg to about 50 mg, about 20 mg to about 60 mg, about 20 mg to about 70 mg, about 20 mg to about 80 mg, about 30 mg to about 80 mg, about 40 mg to about 80 mg, about 50 mg to about 80 mg, about 60 mg to about 80 mg, 103923302.1Atty. Docket No.: 109520-846634 about 70 mg to about 80 mg, about 20 mg to about 50 mg, about 30 mg to about 70 mg, or about 40 mg to about 60 mg of ketamine.

[0058] In specific embodiments, the pharmaceutical composition comprises about 3 mg of midazolamand about 25 mg of ketamine. In specific embodiments, the pharmaceutical composition comprises about 3 mg of midazolam and about 50 mg of ketamine. 2.2. Optional pharmaceutically active compounds

[0059] A pharmaceutical composition as described herein may further comprise one or more (e.g., atleast one) pharmaceutically active compound of a third class. The purpose of including a third class is for alleviation or control of a subject’s potential sensitivity to the pharmaceutical composition (e.g., sensitivity to midazolam and / or ketamine, or to sublingual administration generally). In some embodiments, the pharmaceutically active compound of the third class is selected from a benzodiazepine antiemetic medicament, non-steroid anti-inflammatory drug (NSAID), or antihistamine medicament. In some embodiments, more than one pharmaceutically active compound of the third class is included in the embodiments, more than one pharmaceutically active compound of the third class may be included in the antihistamine medicaments).

[0060] In certain situations a patient may be sensitive to benzodiazepines, generally, or to midazolam,specifically (e.g., may become excessively drowsy). For such patients, provided herein are certain further embodiments of the midazolam-containing pharmaceutical compositions described herein, further comprise an amount of a benzodiazepine receptor antagonists. Such a receptor antagonist may counteract the effect of midazolam after the surgical procedure is complete, effectively providing a slow release feature. In some embodiments, the one or more pharmaceutically active compound of a third class comprises a benzodiazepine receptor antagonist, or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof. In some embodiments, the benzodiazepine receptor antagonist is selected from an antagonist of the commercially available formulations : ANEXATE®, ROMAZICON®. Other benzodiazepine receptor antagonists known to a skilled artisan are also suitable for the composition. The use of said antagonists is also envisioned as a routine practice (i.e., not just for sensitive patients), for example, in situations when a larger than typical or usual dosage of midazolam is medically indicated, or recommended, or necessary. 103923302.1Atty. Docket No.: 109520-846634

[0061] In some embodiments, the one or more pharmaceutically active compound of a third classcomprises a non-benzodiazepine based sedative, or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof. In some embodiments, the benzodiazepine based sedative is selected from eszopiclone, ramelteon, zolpidem, or zaleplon. Other benzodiazepine based sedatives known to a skilled artisan are also suitable for the composition.

[0062] In some embodiments, the one or more pharmaceutically active compound of a third classacebutolol, nadolol, atenolol, betaxolol, esmolol, bisoprolol fumarate, carvedilol, nebivolol, penbutolol, timolol, or sotalol. Each of these is corresponds to a commercially available formulation as shown in also suitable for the composition. TABLE 1: TABLE 1 Compound Chemical Name (IUPAC) Trade Name(s)103923302.1Atty. Docket No.: 109520-846634 TABLE 1 Compound Chemical Name (IUPAC) Trade Name(s)adrenergic agonists known to a skilled artisan are also suitable for the composition.

[0064] In some embodiments, the one or more pharmaceutically active compound of a third classcomprises a pain reliever, or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof. In some embodiments, the pain reliever is acetaminophen. Other pain relievers known to a skilled artisan are also suitable for the composition.

[0065] In some embodiments, the one or more pharmaceutically active compound of a third classcomprises an antiemetic medicament (e.g., as described herein), or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof. In some embodiments, the antiemetic medicament is selected from ondansetron, dolasetron, granisetron, palonosetron, promethazine, imenhydrinate, or meclizine. Each of these corresponds to a commercially available formulation as shown in TABLE 2, which also discloses chemical names of such compounds. Other antiemetics known to a skilled artisan are also suitable for the compositions. TABLE 2: Examples of Antiemetics That Can Be Used in Compositions TABLE 2 Com ound Chemical Name (IUPAC) Trade Name(s)103923302.1Atty. Docket No.: 109520-846634 TABLE 2 Compound Chemical Name (IUPAC) Trade Name(s)comprises a non-steroid anti-inflammatory drug (NSAID) (e.g., as described herein or other NSAIDs known to a skilled artisan are also suitable for the composition).

[0067] In some embodiments, the one or more pharmaceutically active compound of a third classcomprises an antihistamine medicament (e.g., as described herein). In some embodiments, the antihistamine medicament is selected from hydroxyzine pamoate, hydroxyzine hydrochloride, diphenhydramine hydrochloride, meclizine, chlorpheniramine, clemastine, promethazine, or prochlorperazine. Other antihistamine medicaments known to a skilled artisan are also suitable for the composition.

[0068] The therapeutically effective amount of the one or more pharmaceutically active compound of thethird class in the pharmaceutical composition (e.g., that is administered to the subject) can be between about 0.1 mass % and about 5.0 mass % of the composition. In some embodiments, the therapeutic effective amount of the one or more pharmaceutically active compound of the third class can be between about 1.0 mass % and about 4.0 mass %, for example, about 2.5 mass % of the composition.

[0069] Accordingly, in some embodiments of a pharmaceutical composition as described herein, thecombined quantities of all the pharmaceutically active compounds (i.e., midazolam, ketamine, and all of the one or more pharmaceutically active compounds of the third class) taken together in the composition can be between about 1.3 mass % and about 20.0 mass % of the composition, such as between about 3.0 mass % and about 12.0 mass %, for example, about 10.0 mass % of the composition. Those having ordinary skill in the art will determine the most appropriate quantities of each the pharmaceutically active compound that are within the above-mentioned ranges and that are most suitable for a particular patient. In some embodiments, the mass ratios between the pharmaceutically active compounds as shown in blocker propranolol hydrochloride: TABLE 3: Exemplary Mass Ratios between Midazolam, Ketamine Hydrochloride and Propranolol Hydrochloride in a Composition 103923302.1Atty. Docket No.: 109520-846634 TABLE 3 Ratios Midazolam Ketamine Hydrochloride PropranololH hl i[midazolam, ketamine, and ondansetron. In some embodiments, the mass ratio of midazolam:ketamine:odansetron is about 3:25:2. In some embodiments, the mass ratio of midazolam:ketamine:odansetron is about 3:50:2. 2.3. Matrix Former

[0071] The pharmaceutical compositions described herein may further comprise one or more matrixforming ingredients (also referred to herein as “matrix formers”). The matrix formers are used to form the matrix, which disintegrates in a subject’s mouth to release the active ingredients. In some embodiments, the matrix forming ingredients may include gelatin, mannitol, cellulose derivatives (e.g., methylcellulose, ethylcellulose, hydroxypropylcellulose, hypromellose, carboxymethylcellulose, etc.), agar agar, carob gum, xanthan gum, pectin, chitosan, starches, trehalose, sucrose, acrylic acid polymers, acrylate polymers. In a preferred embodiment, the matrix forming ingredients may include gelatin, mannitol, and combinations thereof.

[0072] The matrix former(s) may be present in the pharmaceutical composition in an amount from about40% to about 95% by weight of the pharmaceutical composition. For example, the matrix former(s) may be present in the pharmaceutical composition in an amount from about 40% to about 50%, about 40% to about 60%, about 40% to about 70%, about 40% to about 80%, about 40% to about 90%, about 40% to about 95%, about 50% to about 60%, about 50% to about 70%, about 50% to about 80%, about 50% to about 90%, about 50% to about 95%, about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, about 60% to about 95%, about 70% to about 80%, about 70% to about 90%, about 70% to about 95%, about 80% to about 90%, about 80% to about 95%, or about 90% to about 95%. In some embodiments, the matrix former(s) may be present in the pharmaceutical composition in an amount of about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or about 95% by weight of the pharmaceutical composition. In a non-limiting embodiment, the matrix former(s) are present in an amount from about 80% to about 95% by weight of the pharmaceutical composition, such as about 90%. 103923302.1Atty. Docket No.: 109520-846634 2.4. Inactive or neutral compounds

[0073] The pharmaceutical compositions as described herein may further comprise one or more inactiveor neutral compound(s). In some embodiments, the inactive or neutral compound is a pharmaceutically acceptable excipient or carrier. Certain dosage formats described herein may require several pharmaceutically acceptable excipients or carriers. In some embodiment, the pharmaceutically acceptable excipient or carrier is selected from a binder, antioxidant, adjuvant, pH adjuster, synergist or preservative. In some embodiments of a pharmaceutical composition, the mass concentration of the one or more inactive or neutral compound(s) can be between about 80 mass % and about 99 mass % of the pharmaceutical composition, such as between about 85 mass % and about 95 mass %, e.g., about 90 mass %. It is noted that in some embodiments, the pharmaceutical composition does not include and / or does not require a reconstitution diluent for use.

[0074] Particular embodiments of the invention are directed to pharmaceutical formulations that areformulated as solid articles suitable for sublingual or oral administration (e.g., orally disintegrating tablets, troches, lozenges, capsules, pills, caps or boluses). Binder(s) and / or excipient(s) are useful or may be required for fabricating the solid articles. The compositions can be prepared by first mixing the pharmaceutically active compounds described above with suitable binder(s) and / or excipient(s) followed by molding or compressing the blend. In some embodiments, the solid article is hard (e.g., a hard lozenge or troche). In some embodiments, the solid article is chewable (e.g., a chewable lozenge or troche).In certain embodiments, the pharmaceutical composition comprises one or more binder(s). In some embodiments, the binder is a polyglycol (e.g., as described herein). In some embodiments, the polyglycol is selected from polyethylene glycol (PEG), polyethylene oxide (POE), methoxypolyethylene glycol, polypropylene glycol, polybutylene glycol, or a derivative thereof. In some embodiments, the binder has a molecular weight that is sufficient to provide the necessary hardness and time for dissolution of the composition form (e.g., a troche). In some embodiments, the molecular weight of the binder is between about 1,000 Daltons and about 8,000 Daltons. In some embodiments, the binder is PEG-1450 or PEG- 400. In some embodiments, the binder is a polyglycol derivative selected from: (a) PEG-laureates or dilaureates (e.g., PEG-10-; PEG-12-; PEG-20-; PEG-32-laurates; PEG-20- orPEG-32-dilaurates; PEG-20-glyceryl-; PEG-30-glyceryl- or PEG-40-glyceryl-laurates; or PEG- 80-sorbitan laurate); 103923302.1Atty. Docket No.: 109520-846634 (b) PEG-oleates, dioleates or trioleates (e.g., PEG-12-; PEG-15-; PEG-20-; PEG-32; PEG-200- orPEG-400-oleates; PEG-20- or PEG-32- dioleates; PEG-20-trioleate, PEG-25-glyceryl trioleate; PEG-20-glyceryl- or PEG-30-glyceryl-oleates; or PEG-40-sorbitan oleate); (c) PEG-stearates and distearates (e.g., PEG-15-; PEG-40-; PEG-100-stearates; PEG-32-distearate;or PEG-20-glyceryl stearate); (d) castor, palm kernel, corn or soya oil derivatives of PEG (e.g., PEG-35-; PEG-40- or PEG-60-castor oils; PEG-40-; PEG-50- or PEG-60-hydrogenated castor oils; PEG-40-palm kernel oil; PEG-60-corn oil; or PEG-30-soya sterol); (e) other PEG derivatives (e.g., PEG-24- or PEG-30-cholesterol; PEG-25-phytosterol; PEG-6- orPEG-8-caprate / caprylate glycerides; tocopheryl PEG-100 succinate; or PEG-15-100 octylphenol products or PEG-10-100 nonylphenol products); or (f) other products such as: polyglyceryl-10-laurate; POE-9- or POE-23-lauryl ethers; POE-10- orPOE-20-oleyl ethers; POE-20-stearyl ether; polysorbates-20 or 80; polyglyceryl-10-oleate; Tween 40; Tween 60; sucrose monostearate; monolaurate; monopalmitate; or various products of Poloxamer series. Other binders known to a skilled artisan are also suitable for the composition.

[0075] In some embodiments, the pharmaceutical composition comprises one or more sweeteners. Theone or more sweeteners may be selected from the group consisting of acesulfame, aspartame, dextrose, fructose, maltitol, saccharin, sorbitol, sucralose, sucrose, pharmaceutically acceptable salts thereof, and combinations thereof. The one or more sweeteners may be included in the pharmaceutical composition in an amount from about 0.5% to about 2% by weight of the pharmaceutical composition.

[0076] In some embodiments, the pharmaceutical composition may comprise a flavoring agent. Theflavoring agent may include synthetic or natural flavoring agents. The flavoring agent may include vanillin, menthol, methyl anthranilate, manganite, ethyl 2-methylpentanotate, isopentyl acetate, ethyl decadienoate, gamma-octalactone, allyl benzoate, allyl caproate, allyl hexanoate, d-limonene, ethyl butyrate, 3,7-dimethyl-2,6,octadienal, ethyl methylphenylglycidate, or other flavoring agents known in the art and combinations thereof. The flavoring agent may be present in an amount from about 0.5% to about 5% by weight of the pharmaceutical composition. 103923302.1Atty. Docket No.: 109520-846634

[0077] In certain embodiments, the pharmaceutical composition comprises one or more excipient(s)(e.g., a pharmaceutically acceptable excipient). In some embodiments, the excipient is selected from peppermint oil, or any natural or artificial fruit, vegetable, flower, beverage, or candy flavor, or a combination thereof. Other excipients known to a skilled artisan are also suitable for the composition.

[0078] In certain embodiments, the pharmaceutical composition comprises one or more antioxidant(s). Insome embodiments, the antioxidant is selected from atocopherol acetate, acetone sodium bisulfite, acetylcysteine, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, cysteine, cysteine hydrochloride, tocopherol natural, tocopherol synthetic, dithiothreitol, monothioglycerol, nordihydroguaiaretic acid, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium sulfite, sodium thiosulfate, thiourea, or tocopherol. Other antioxidants known to a skilled artisan are also suitable for the composition.

[0079] In certain embodiments, the pharmaceutical composition comprises one or more adjuvant(s)and / or synergists(s). In some embodiments, the adjuvant or synergists is selected from citric acid, EDTA (ethylenediaminetetraacetate) and salts thereof, hydroxyquinoline sulfate, phosphoric acid, or tartaric acid. Other adjuvants and synergists known to a skilled artisan are also suitable for the composition.

[0080] In certain embodiments, the pharmaceutical composition comprises one or more preservative(s).In some embodiments, the preservative is selected from benzalkonium chloride, benzethonium chloride, benzoic acid and salts thereof, benzyl alcohol, boric acid and salts thereof, cetylpyridinium chloride, cetyltrimethyl ammonium bromide, chlorobutanol, chlorocresol, chorhexidine gluconate, chlorhexidine acetate, cresol, ethanol, imidazolidinyl urea, metacresol, methylparaben, nitromersol, o-phenyl phenol, a paraben, phenol, phenylmercuric acetate / nitrate, propylparaben, sodium benzoate, sorbic acid and salts suitable for the composition.

[0081] In certain embodiments, the pharmaceutical composition comprises one or more pH adjusters.The pH adjuster may comprise acetic acid, citric acid, fumaric acid, hydrochloric acid, lactic acid, malic acid, nitric acid, propionic acid, phosphoric acid, sodium phosphate, sulfuric acid, tartaric acid, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium bicarbonate, sodium borate, sodium carbonate, sodium hydroxide, sodium phosphate, trolamine, or combinations thereof. In an example, the pH adjuster comprises citric acid.

[0082] The amount of the one or more pH adjusters added will vary depending on the desired pH of thepharmaceutical composition. The pH of the pharmaceutical composition may range from about 3 to about 103923302.1Atty. Docket No.: 109520-846634 6, such as from about 3 to about 4, about 3 to about 5, about 3 to about 6, about 4 to about 5, about 4 to about 6, or about 5 to about 6. In some embodiments, the pH of the pharmaceutical composition may be about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, or about 6. In a preferred embodiment, the pH of the pharmaceutical composition is about 3.5.

[0083] According to certain additional embodiments, the pharmaceutical compositions comprise, consistof or consist essentially of, a therapeutically effective amount of midazolam and ketamine. In some embodiments, the pharmaceutical composition does not comprise another benzodiazepine (e.g., midazolam is only benzodiazepine in the composition). In some embodiments, the pharmaceutical composition does not comprise another NMDA antagonist (e.g., ketamine is the only NMDA antagonist in the composition). 2.5. Vehicles

[0084] A vehicle can be used as a medium by which a pharmaceutical composition as described herein isadministered to a subject. In some embodiments, the vehicle comprises a polymer. In some embodiments, the polymer is selected from an ester of cellulose (e.g., methyl cellulose or hydroxypropyl methyl cellulose), poly(lactic-co-glycolic acid), polylactic acid, polyglycolide, dextrin, polyacetals, poly(N-(2- hydroxypropyl)methacrylamide), polycaprolactone, or poly-3-hydroxybutyrate. In some embodiments, the vehicle comprises one or more excipient(s), which may be selected from gelatin, sodium saccharin, stevioside, peppermint oil, or any natural or artificial fruit, vegetable, flower, beverage, or candy flavor, or a combination thereof. The use of extended release capsules ensconcing the pharmaceutical formulation, or matrix polymer structures is also provided for. A pharmaceutical composition as described herein can be formulated as a troche, a lozenge, a capsule, a pill, a cap, or a bolus.

[0085] In additional embodiments, the pharmaceutical compositions of the present invention may beincorporated into vehicles allowing extended release of the compositions over a period of time. To achieve this effect, the compositions may be combined with polymers forming such vehicles. The product will be extended release capsules ensconcing or enveloping the pharmaceutical formulation, or alternatively, a matrix polymer structure holding the pharmaceutical formulation that is embedded into the matrix.

[0086] The vehicle carrying the pharmaceutical formulation may be configured to allow the gradualrelease of the pharmaceutical formulation over a time period for sedation as described herein, or less than a time period for sedation as described herein (e.g., about 5 minutes or less, about 10 minutes or less, about 15 minutes or less, about 20 minutes or less, about 25 minutes or less, about 30 minutes or less, 103923302.1Atty. Docket No.: 109520-846634 about 25 minutes or less, about 30 minutes or less, about 35 minutes or less, about 40 minutes or less, or about 45 minutes or less). The rate of release may be uniform throughout the entire period of release; alternatively, those having ordinary skill in the art may formulate the release vehicle in such a way as to allow different rates of release at different times, for example, faster release at the beginning of the process of release and slower at later stages, or vice versa, or in any other way that may be necessary.

[0087] The vehicle may be manufactured from any pharmaceutically acceptable polymer that is capableof releasing at least 95 mass % of the pharmaceutical formulation that the vehicle incorporates within the above-mentioned time periods (e.g., a time period for sedation as described herein, or less than a time period for sedation as described herein). In some embodiments, the vehicle may be formulated to ensure the release of at least 97 mass % of the pharmaceutical formulation, for example, at least 99.5 mass %.

[0088] Those having ordinary skill in the art will select the most appropriate polymer for making thevehicle. As guidance only, some non-limiting examples of such polymers include, but are not limited to, esters of cellulose, e.g., methyl cellulose and hydroxypropyl methyl cellulose. Other acceptable polymers include, but are not limited to, poly(lactic-co-glycolic acid) (PLGA), polylactic acid, polyglycolide, dextrin, polyacetals, poly(N-(2-hydroxypropyl)methacrylamide), polycaprolactone, and poly-3- hydroxybutyrate.

[0089] In some embodiments, the vehicle comprises a water-soluble methylcellulose or hydroxypropylmethylcellulose polymer. In some embodiments, the water-soluble methylcellulose or hydroxypropyl methylcellulose polymer is selected from the METHOCEL® family of products, for example, a hydroxypropyl methylcellulose product METHOCEL®E4M, 20% METHOCEL®K4M, or 10% METHOCEL®K100 or, alternatively and particularly useful for hot melt extrusion, another hydroxypropyl methylcellulose product AFFINISOLTMHPMC (all mentioned hydroxypropyl methylcellulose polymers are available from Dow Chemical Co., Midland, Mich.). 2.6. Methods for fabricating

[0090] According to further embodiments, methods for fabricating a pharmaceutical composition asdescribed herein are provided. A one-batch formulation method may be used, where the components of the pharmaceutical composition can be combined in single container; the components may be added to the container simultaneously or consecutively. Alternatively, a two- or multiple-batch method(s) may be used if desired, where each component of the pharmaceutical composition can be combined in separate container followed by combining the contents of each container. 103923302.1Atty. Docket No.: 109520-846634

[0091] In one exemplary, non-limiting procedure, pre-measured quantities of each ingredient in the formof dry powder can be mixed to form a dry blend followed by mixing it with a pre-molten troche base. The composition can then be molded to form a troche.

[0092] In another embodiment, the pharmaceutical composition may be fabricated by a freeze-dryingprocess. The methods include: (a) dosing a formulation comprising a non-gelling matrix forming agent into a preformed mold; (b) dosing a formulation comprising a matrix former into the preformed mold; and (c) freeze drying the formulations dosed in steps (a) and (b) to form the pharmaceutical composition.

[0093] In step (a), the formulation comprising a non-gelling matrix forming agent includes themidazolam or a pharmaceutically acceptable salt thereof, ketamine or a pharmaceutically acceptable salt thereof, optionally one or more additional water-soluble inactive ingredients, and water. For example, the one or more additional water-soluble inactive ingredients may include pH adjusters, sweeteners, flavors, and the like. In some examples, mannitol may also be added to the formulation of step (a).

[0094] The formulation of step (a) is typically in the form of a solution or suspension. Accordingly, asolvent is also present in the formulation. A suitable solvent can be readily chosen by one of ordinary skill in the art once the final composition of the formulation is known, i.e., pharmaceutically active ingredient, excipient, etc. to be present. Preferred solvents include ethanol, isopropanol, other lower alkanols and water, and, more preferably, water. The amount of solvent, preferably water, present in the formulation of step (a) ranges preferably from about 50% to about 98%, more preferably from about 65% to about 98%, and most preferably from about 75% to about 95% based on weight of the formulation of step (a).

[0095] The formulation of step (a) can be made by any conventional method. Most typically, the inactiveingredients may be mixed together at any temperature, though preferably between about 20°C to about 80°C, to form a solution. The solution may then be cooled to a subambient temperature, if heated above an ambient temperature, preferably from about 1°C to about 30°C, more preferably from about 2°C to about 20°C, and most preferably from about 5°C to about 15°C, at which point the active ingredients may be added.

[0096] In some aspects, step (a) is repeated one or more times prior to performing step (b). In this way,additional layers may be formed. There is no limit to the number of layers that may be formed using step (a); however, step (b) must follow the performance of one or more step (a), such that the final layer contains a matrix former. 103923302.1Atty. Docket No.: 109520-846634

[0097] In step (b), a matrix former is dosed into the preformed mold. The formulation of step (b) istypically in the form of a solution or suspension. Accordingly, a solvent is also present in the formulation. A suitable solvent can be readily chosen by one of ordinary skill in the art once the final composition of the formulation is known, i.e., pharmaceutically active ingredient, excipient, etc. to be present. Preferred solvents include ethanol, isopropanol and water, and more preferably, water. The amount of solvent present in the formulation of step (b) ranges preferably from about 50% to about 98%, more preferably from about 65% to about 98%, and most preferably from about 75% to about 95% based on weight of the formulation of step (b).

[0098] The formulation of step (b) can be made by any conventional method. Most typically, the matrixformer, solvent and optional ingredients may be mixed together at any temperature, though preferably between about 20°C to about 80°C, to form a solution. The solution may then be cooled to ambient temperature, if heated above an ambient temperature, preferably from about 15°C to about 30°C, and more preferably from about 20°C to about 30°C.

[0099] In some aspects, step (b) may be repeated one or more times prior to performing step (c). In thisway, additional layers may be formed. Step (b) may be repeated one or more times regardless of whether step (a) is also repeated. Preferably, it is not repeated more than four times without also repeating step (a).

[0100] In step (c), the formulations dosed in steps (a) and (b) are freeze dried to form the pharmaceuticalcomposition. In a preferred embodiment, step (c) comprises the sub-steps of (cl) freezing the formulations dosed in steps (a) and (b) and then (c2) freeze drying the formulations dosed in steps (a) and (b) to form the pharmaceutical composition of the present invention. Typically, the dosed formulations in the preformed molds are frozen by any means known in the art, for example by passing them through a liquid nitrogen tunnel, preferably for about one to about ten minutes. One of ordinary skill in the art would readily understand the speed with which to pass them through the tunnel. The dosed formulations in the preformed molds are then freeze dried under vacuum.

[0101] In another embodiment, the method may include: (a) forming a formulation comprising a non-gelling matrix forming agent into a preformed mold; (b) forming a formulation comprising a matrix former into the preformed mold; (c) combining the formulations formed in steps (a) and (b) into a single- phase formulation; (d) dosing the single-phase formulation into a preformed mold; and (e) freeze drying the formulation dosed in step (d) to form the pharmaceutical composition.

[0102] The formulation of steps (a) and (b) can be made by any conventional method described in theembodiment above. 103923302.1Atty. Docket No.: 109520-846634

[0103] In step (a), the formulation comprising a non-gelling matrix forming agent includes themidazolam or a pharmaceutically acceptable salt thereof, ketamine or a pharmaceutically acceptable salt thereof, optionally one or more additional water-soluble inactive ingredients, and water. For example, the one or more additional water-soluble inactive ingredients may include pH adjusters, sweeteners, flavors, and the like. In some examples, mannitol may also be added to the formulation of step (a).

[0104] The formulation of step (a) is typically in the form of a solution or suspension. Accordingly, asolvent is also present in the formulation. A suitable solvent can be readily chosen by one of ordinary skill in the art once the final composition of the formulation is known, i.e., pharmaceutically active ingredient, excipient, etc. to be present. Preferred solvents include ethanol, isopropanol, other lower alkanols and water, and, more preferably, water. The amount of solvent, preferably water, present in the formulation of step (a) ranges preferably from about 50% to about 98%, more preferably from about 65% to about 98%, and most preferably from about 75% to about 95% based on weight of the formulation of step (a).

[0105] The formulation of step (a) can be made by any conventional method. Most typically, the inactiveingredients may be mixed together at any temperature, though preferably between about 20°C to about 80°C, to form a solution. The solution may then be cooled to a subambient temperature, if heated above an ambient temperature, preferably from about 1°C to about 30°C, more preferably from about 2°C to about 20°C, and most preferably from about 5°C to about 15°C, at which point the active ingredients may be added.

[0106] In step (b), a formulation comprising a matrix former is formed. The formulation of step (b) istypically in the form of a solution or suspension. Accordingly, a solvent is also present in the formulation. A suitable solvent can be readily chosen by one of ordinary skill in the art once the final composition of the formulation is known, i.e., pharmaceutically active ingredient, excipient, etc. to be present. Preferred solvents include ethanol, isopropanol and water, and more preferably, water. The amount of solvent present in the formulation of step (b) ranges preferably from about 50% to about 98%, more preferably from about 65% to about 98%, and most preferably from about 75% to about 95% based on weight of the formulation of step (b).

[0107] The formulation of step (b) can be made by any conventional method. Most typically, the matrixformer, solvent and optional ingredients may be mixed together at any temperature, though preferably between about 20°C to about 80°C, to form a solution. The solution may then be cooled to ambient temperature, if heated above an ambient temperature, preferably from about 15°C to about 30°C, and more preferably from about 20°C to about 30°C. 103923302.1Atty. Docket No.: 109520-846634

[0108] In step (e), the formulations made in steps (a) and (b) and dosed in step (d) are freeze dried toform the pharmaceutical composition. In a preferred embodiment, step (e) comprises the sub-steps of (el) freezing the formulation dosed in step (d) and then (e2) freeze drying the formulations dosed in step (d) to form the pharmaceutical composition of the present invention. Typically, the dosed formulations in the preformed molds are frozen by any means known in the art, for example by passing them through a liquid nitrogen tunnel, preferably for about one to about ten minutes. One of ordinary skill in the art would readily understand the speed with which to pass them through the tunnel. The dosed formulation in the preformed molds are then freeze dried under vacuum.3. Subjects

[0109] The pharmaceutical compositions described herein can be administered to a subject (e.g., apatient) in need of conscious sedation, procedural sedation, and / or pre-sedation, and in general for any kind of non-general anesthesia, by various local administrations. More specifically, the pharmaceutical compositions described herein may be prescribed by ordinarily skilled medical practitioners such as physicians, as the means of conscious sedation or pre-sedation. In certain embodiments, the subject experiences or expects to experience prior to or during a medical or surgical procedure any one of: anxiety (e.g., high anxiety), panic attack (e.g., bouts of panic attacks), disquietude, apprehension, angst, or a feeling of psychological discomfort or distress. In some embodiments, the subject is a human. In some embodiments, the human subject is of any age. In some embodiments, the subject is a child. In some embodiments, the subject is an adolescent. In some embodiments, the subject is an adult. In other contemplated embodiments, the subject is not human. 3.1. Subject procedures

[0110] A pharmaceutical composition as described herein is administered to a subject prior to anoutpatient surgery or medical procedure, both invasive and non-invasive. In some embodiments, the outpatient surgery or medical procedure is selected from an ophthalmic surgery, dental procedure, urological procedure, obstetric and gynecological procedure, gastrointestinal procedure, otolaryngological procedure, cosmetic surgery procedure, dermatological procedure, podiatric procedure, orthopedic procedure, emergency medical treatment, psychiatric treatment, or veterinarian procedure. In some embodiments, the outpatient or medical procedure comprises a cataract procedure, optionally a cataract extraction procedure. In some embodiments, the outpatient or medical procedure comprises lens replacement. In some embodiments, the outpatient or medical procedure is a cataract extraction with lens replacement (CELR) procedure. 103923302.1Atty. Docket No.: 109520-846634

[0111] Specific representative examples of surgeries or medical procedure that are amenable to use of apharmaceutical composition as described herein include, without limitation, cataract surgery, glaucoma surgery, corneal surgery, eyelid surgery, retinal surgery, tooth extraction, oral surgery, root canal surgery, medical imaging procedures (e.g., MRI or CAT scanning, especially for patients suffering from claustrophobia), biopsy, bone marrow harvesting, colonoscopy, endoscopy and laparoscopy.4. Methods for procedural sedation

[0112] According to embodiments of the present invention, there are provided methods of inducingprocedural sedation (e.g., conscious sedation) in a subject (e.g., a subject as described in Section 3) in need thereof, comprising administering to the subject a pharmaceutical composition as described herein (e.g., as described in Section 2). The procedural sedation may be successful (e.g., achieves a target sedation level (Ramsay Sedation Scale [RSS] level of at least 2 for a time period as described herein (e.g., as described in Section 4.5). A successful procedural sedation may be defined as achieving target sedation level (Ramsay Sedation Scale [RSS] level 2 or 3) by the start of a subject procedure (e.g., outpatient or medical procedure (e.g., surgery or operation)), optionally without a need for rescue sedation medication or intraoperative sedation medication, or wherein the subject is able to complete the surgery (e.g., is a procedural sedation responder).

[0113] The procedural sedation may be achieved pre-operatively without a need for rescue sedation (e.g.,administration of rescue sedation medication). In some embodiments, the subject achieves a target sedation level (e.g., RSS level 2 or 3) by the start of an outpatient or medical procedure (e.g., surgery or operation) without need for rescue sedation. The procedural sedation may be achieved intraoperatively without a need for rescue sedation (e.g., administration of rescue sedation medication). In some embodiments, the subject maintains a target sedation level (e.g., RSS level 2 or 3) throughout an outpatient or medical procedure (e.g., surgery or operation) without need for rescue sedation. In some embodiments, the subject is able to complete the outpatient or medical procedure (e.g., surgery or operation) without a need for rescue sedation. In some embodiments, the subject is able to complete the outpatient or medical procedure (e.g., surgery or operation) without a need for an intervention, optionally wherein the intervention is other than rescue medication.

[0114] The procedural sedation achieved in the subject may have an improved (e.g., reduced) likelihoodfor experiencing an adverse event (AE) (e.g., treatment emergent adverse event, or adverse event of special interest) in comparison to administration of midazolam or ketamine alone to the subject. The adverse event may be selected from one or more of: ketamine emergence delirium (e.g., hallucinations, 103923302.1Atty. Docket No.: 109520-846634 unpleasant / bad dreams, vivid imagery, confusional state, excitement, behavior abnormal, or agitation); respiratory AE (e.g., respiratory depression, hypoventilation, dyspnea, oxygen desaturation, respiratory arrest, or airway obstruction); cardiovascular AE (e.g., hypotension, blood pressure increased, hypertension (e.g., new onset or worsened), bradycardia / tachycardia, cardiac arrest, or cardiac decompensation); neurocognitive AE (e.g., confusional state, amnesia, memory impairment, attention impaired, disorientation, or delirium); abuse-related AE; oversedation (e.g., sedation excessive), optionally requiring the use of flumazenil; oral / pharyngeal AE (e.g., changes to tongue, oral cavity (e.g., active infection, mucositis, cold sores, canker sores, vesicles, viral lesions, stomatitis, or periodontal disease) and / or oral / pharyngeal function (e.g., hypoesthesia, taste disorders, or dysphagia)).

[0115] The procedural sedation achieved in the subject may have an improved vital sign in comparisonto administration of midazolam or ketamine alone to the subject. The improved vital sign may be selected from blood pressure (e.g., mean change from baseline in blood pressure); heart rate (e.g., mean change from baseline in heart rate); respiratory rate (e.g., mean change from baseline in respiratory rate); body temperature (e.g., mean change from baseline in body temperature); or pulse oximetry (e.g., mean change from baseline in pulse oximetry). 4.1. Single dosing

[0116] In one aspect, there are provided methods of inducing procedural sedation in a subject, themethods comprising sublingually administering to the subject a pharmaceutical composition as described herein (e.g., comprising midazolam and ketamine), wherein the administration achieves a level of sedation in the subject for procedural sedation that lasts for a time period of 60 minutes or less (e.g., 45 minutes or less). In some embodiments, the subject is administered one dose of a pharmaceutical composition as described herein. 4.2. Multiple dosing

[0117] In other aspects, there are provided methods of inducing procedural sedation in a subject, themethods comprising sublingually administering a first dose of a pharmaceutical composition as described herein (e.g., comprising midazolam and ketamine), and sublingually administering a further dose (e.g., second, third, or fourth dose, etc.) of the pharmaceutical composition after the sublingual administration of the first dose, wherein the administration achieves a level of sedation in the subject for procedural sedation that lasts for a time period of 60 minutes or less (e.g., 45 minutes or less). In some embodiments, the subject is administered two doses of a pharmaceutical composition as described herein. In some embodiments, the subject is administered three doses of a pharmaceutical composition as described 103923302.1Atty. Docket No.: 109520-846634 herein. In some embodiments, the subject is administered four doses of a pharmaceutical composition as described herein.

[0118] In certain embodiments, the second dose of the pharmaceutical composition occurs within 30minutes after administering the first dose of the pharmaceutical composition. In some embodiments, the second dose of the pharmaceutical composition occurs within 25 minutes after administering the first dose of the pharmaceutical composition. In some embodiments, the second dose of the pharmaceutical composition occurs within 20 minutes after administering the first dose of the pharmaceutical composition. In some embodiments, the second dose of the pharmaceutical composition occurs within 15 minutes after administering the first dose of the pharmaceutical composition. In some embodiments, the second dose of the pharmaceutical composition occurs within 10 minutes after administering the first dose of the pharmaceutical composition.

[0119] In certain embodiments, the third dose of the pharmaceutical composition occurs within 30minutes after administering the second dose of the pharmaceutical composition. In some embodiments, the third dose of the pharmaceutical composition occurs within 25 minutes after administering the second dose of the pharmaceutical composition. In some embodiments, the third dose of the pharmaceutical composition occurs within 20 minutes after administering the second dose of the pharmaceutical composition. In some embodiments, the third dose of the pharmaceutical composition occurs within 15 minutes after administering the second dose of the pharmaceutical composition. In some embodiments, the third dose of the pharmaceutical composition occurs within 10 minutes after administering the second dose of the pharmaceutical composition.

[0120] In certain embodiments, the fourth dose of the pharmaceutical composition occurs within 30minutes after administering the third dose of the pharmaceutical composition. In some embodiments, the fourth dose of the pharmaceutical composition occurs within 25 minutes after administering the third dose of the pharmaceutical composition. In some embodiments, the fourth dose of the pharmaceutical composition occurs within 20 minutes after administering the third dose of the pharmaceutical composition. In some embodiments, the fourth dose of the pharmaceutical composition occurs within 15 minutes after administering the third dose of the pharmaceutical composition. In some embodiments, the fourth dose of the pharmaceutical composition occurs within 10 minutes after administering the third dose of the pharmaceutical composition. 4.3. Reducing rescue103923302.1Atty. Docket No.: 109520-846634

[0121] In one aspect, there are provided methods of reducing the occurrence of rescue in a subject, themethods comprising sublingually administering a pharmaceutical composition as described herein (e.g., comprising midazolam and ketamine), wherein the administration achieves a level of sedation in the subject for procedural sedation. Rescue of a subject may comprise administration of a rescue sedation medication to the subject. The rescue sedation medication may comprise midazolam or ketamine. Rescue may be performed pre-operatively or intra-operatively. Rescue may be performed when the subject’s level of sedation is less than 2, or is 1 on the Ramsay sedation scale (RSS)). 4.4. Sedation levels

[0122] Sedation in a subject (e.g., in a method as described herein) may be measured in accordance toone or more sedation scales known to a skilled artisan, for instance, the Ramsay sedation scale (RSS), as summarized in TABLE 4, or the Richmond Agitation Sedation Scale (RASS), or Riker Sedation- Agitation Scale (SAS).

[0123] TABLE 4: Ramsay sedation scale (RSS)Score Description 1 Patient is anxious and agitated or restless, or both[012on scale(RSS). In some embodiments, a subject as described herein achieves a level of sedation as measured by RSS score when they exhibit characteristics as described in TABLE 4.

[0125] In some embodiments of a method as described herein, the level of sedation to achieve proceduralsedation in a subject is an RSS score of greater than 1 (e.g., an RSS score of 1 may require rescue). In some embodiments, the level of sedation to achieve procedural sedation in a subject is an RSS score of between 2 and 5, inclusive; preferably an RSS score of between 2 and 4, inclusive; and more preferably an RSS score of between 2 and 3, inclusive. In specific embodiments, the level of sedation to achieve procedural sedation in a subject is an RSS score of 2, 3, or 4.

[0126] In some embodiments, a subject as described herein requires further sedation when they areanxious, agitated, and / or restless (e.g., RSS score of 1). In some embodiments, a subject as described 103923302.1Atty. Docket No.: 109520-846634 herein may or may not require further sedation when they are co-operative, oriented, and / or tranquil (e.g., RSS score of 2). In some embodiments, a subject as described herein does not require further sedation when they respond to commands only (e.g., RSS score of 3). In some embodiments, a subject as described herein does not require further sedation when they exhibit a brisk response to light glabellar tap or loud auditory stimulus (e.g., RSS score of 4).

[0127] In certain embodiments of a method as described herein, the level of sedation requiring rescue ina subject (e.g., to achieve procedural sedation in the subject) is an RSS score of 1. In certain embodiments, the level of sedation requiring rescue in a subject is an RSS score of 2 or less, wherein the RSS score is falling or not improving over time in the subject.

[0128] In certain embodiments of a method as described herein, the decision to rescue a subject isdetermined via measurement of a pharmacokinetic parameter as described herein (e.g., of midazolam, 1-hydroxymidazolam, ketamine, or norketamine). In some embodiments, the level of sedation requiring rescue is determined via pharmacokinetic parameter as described herein (e.g., of midazolam, 1-hydroxymidazolam, ketamine, or norketamine).

[0129] In certain embodiments of a method as described herein, the level of sedation achieved is greaterthan achieved by administering midazolam alone. In certain embodiments of a method as described herein, the level of sedation achieved is greater than achieved by administering ketamine alone. 4.5. Time periods of sedation

[0130] In certain embodiments of a method as described herein (e.g., a single dosing method, a multipledosing method, or a method for reducing rescue), the procedural sedation in the subject lasts for a time period of 60 minutes or less. In some embodiments, the procedural sedation lasts for a time period of 55 minutes or less. In some embodiments, the procedural sedation lasts for a time period of 50 minutes or less. In some embodiments, the procedural sedation lasts for a time period of 45 minutes or less. In some embodiments, the procedural sedation lasts for a time period of 40 minutes or less. In some embodiments, the procedural sedation lasts for a time period of 35 minutes or less. In some embodiments, the procedural sedation lasts for a time period of 30 minutes or less. In some embodiments, the procedural sedation lasts for a time period of 25 minutes or less. In some embodiments, the procedural sedation lasts for a time period of 20 minutes or less. In some embodiments, the procedural sedation lasts for a time period of 15 minutes or less. In some embodiments, the procedural sedation lasts for a time period of 10 minutes or less. In preferred embodiments, the procedural sedation lasts for a time period of 45 minutes or less, 30 minutes or less, or 15 minutes or less. 103923302.1Atty. Docket No.: 109520-846634

[0131] In certain embodiments of a method as described herein (e.g., a single dosing method, a multipledosing method, or a method for reducing rescue), the procedural sedation in the subject is achieved in a time period of 5 minutes or less. In some embodiments, the procedural sedation is achieved in a time period of 10 minutes or less. In some embodiments, the procedural sedation is achieved in a time period of 15 minutes or less. In some embodiments, the procedural sedation is achieved in a time period of 20 minutes or less. In some embodiments, the procedural sedation is achieved in a time period of 25 minutes or less. In some embodiments, the procedural sedation is achieved in a time period of 30 minutes or less. In some embodiments, the procedural sedation is achieved in a time period of 35 minutes or less. In some embodiments, the procedural sedation is achieved in a time period of 40 minutes or less. In some embodiments, the procedural sedation is achieved in a time period of 45 minutes or less. In some embodiments, the procedural sedation is achieved in a time period of 50 minutes or less. In some embodiments, the procedural sedation is achieved in a time period of 55 minutes or less. In some embodiments, the procedural sedation is achieved in a time period of 60 minutes or less.

[0132] In some embodiments, the time period of procedural sedation is measured from the moment ofadministration of the pharmaceutical composition to the subject. In some embodiments, the time period of procedural sedation is measured from the time point that the subject becomes sedated. In some embodiments, the time period of procedural sedation is measured from the time point that the subject first reaches an RSS score (e.g., that is not zero). In some embodiments, the time period of procedural sedation is measured from the time point that the subject first reaches an RSS score of 1. In some embodiments, the time period of procedural sedation is measured from the time point that the subject first reaches an RSS score of 2. In some embodiments, the time period of procedural sedation is measured from the time point that the subject first reaches an RSS score of 3. In some embodiments, the time period of procedural sedation is measured from the time point that the subject first reaches an RSS score of 4. 4.6. Pharmacokinetics (PK) of midazolam and ketamine

[0133] The sublingual administration of a pharmaceutical composition as described herein produces apharmacokinetic profile in the subject. 4.6.1.Midazolam

[0134] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in a Cmax of midazolam in the subject that is lower than a Cmax of midazolam resulting from intravenous administration of an equivalent amount of midazolam. In some embodiments, the sublingual 103923302.1Atty. Docket No.: 109520-846634 administration results in a Cmax of midazolam in the subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, at least about 70% lower, or at least about 80% lower than a Cmax of midazolam resulting from intravenous administration of an equivalent amount of midazolam. In preferred embodiments of a single dosing method as described herein, the sublingual administration results in a Cmax of midazolam that is at least 50% lower, at least about 60% lower, at least about 70% lower, or at least about 80% lower, than a Cmax of midazolam resulting from intravenous administration of an equivalent amount of midazolam. In preferred embodiments of a multiple dosing method as described herein, the sublingual administration results in a Cmax of midazolam that is at least 30% lower, at least about 40% lower, at least about 50% lower, or at least about 60% lower, than a Cmax of midazolam resulting from intravenous administration of an equivalent amount of midazolam.

[0135] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in a peak concentration (Cmax) of midazolam in the subject of less than or equal to about 140 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 130 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 120 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 110 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 100 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 90 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 80 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 70 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 60 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 50 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 40 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 30 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 20 ng / mL. In some embodiments, the sublingual administration results in a Cmax of midazolam in the subject of less than or equal to about 10 ng / mL. In preferred embodiments of a single dosing method as described herein, the sublingual administration 103923302.1Atty. Docket No.: 109520-846634 results in a Cmax of midazolam of less than or equal to about 25 ng / mL in the subject. In preferred embodiments of a multiple dosing method as described herein, the sublingual administration results in a Cmax of midazolam of less than or equal to about 60 ng / mL in the subject.

[0136] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in an area under the curve up to the last quantified time-point (AUC0-t) of midazolam in the subject that is that is not statistically different from or lower than an AUC0-t of midazolam resulting from intravenous administration of an equivalent amount of midazolam. In some embodiments, the sublingual administration results in an AUC0-t of midazolam in the subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, or at least about 50% lower than an AUC0-t of midazolam resulting from intravenous administration of an equivalent amount of midazolam.

[0137] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in an infinity-extrapolated area under the cure (AUCinf) of midazolam in the subject that is not statistically different from or lower than an AUCinf of midazolam in the subject resulting from intravenous administration of an equivalent amount of midazolam. In some embodiments, the sublingual administration results in an AUCinf that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, or at least about 50% lower than an AUCinf of midazolam resulting from intravenous administration of an equivalent amount of midazolam.

[0138] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in a half-life (t1 / 2) of midazolam in the subject that is at least about 1 hr, 2 hr, 3 hr, 4 hr, or 5 hr shorter than a half-life of ketamine resulting from intravenous administration of an equivalent amount of ketamine.

[0139] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in a Cmax of 1-hydroxymidazolam in the subject that is greater than a Cmax of 1-hydroxymidazolam resulting from intravenous administration of an equal amount of midazolam. In some embodiments, the sublingual administration results in a Cmax of 1-hydroxymidazolam in the subject is at least about 10% greater, at least about 25% greater, at least about 50% greater, at least about 100% greater, at least about 125% greater, at least about 150% greater, at least about 175% greater, or at 103923302.1Atty. Docket No.: 109520-846634 least about 200% greater than a Cmax of 1-hydroxymidazolam resulting from intravenous administration of an equal amount of midazolam.

[0140] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in a Cmax of 1-hydroxymidazolam in the subject that is greater than a Cmax of 1-hydroxymidazolam that is greater than or equal to about 6 ng / mL, greater than or equal to about 7 ng / mL, greater than or equal to about 8 ng / mL, greater than or equal to about 9 ng / mL, greater than or equal to about 10 ng / mL, greater than or equal to about 11 ng / mL, greater than or equal to about 12 ng / mL, greater than or equal to about 13 ng / mL, greater than or equal to about 14 ng / mL, greater than or equal to about 15 ng / mL, or greater than or equal to about 16 ng / mL. In preferred embodiments of a single dosing method as described herein, the sublingual administration results in a Cmax of 1-hydroxymidazolam in the subject of greater than or equal to about 7 ng / mL in the subject (e.g., ~7.78 ng / mL). In preferred embodiments of a multiple dosing method as described herein, the sublingual administration results in a Cmax of 1-hydroxymidazolam in the subject of greater than or equal to about 16 ng / mL in the subject (e.g., ~16.2 ng / mL). 4.7. Ketamine

[0141] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in a Cmax of ketamine in the subject that is lower than a Cmax of ketamine resulting from intravenous administration of an equivalent amount of ketamine. In some embodiments, the sublingual administration results in a Cmax of ketamine in the subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, at least about 70% lower, or at least about 80% lower than a Cmax of ketamine resulting from intravenous administration of an equivalent amount of ketamine. In preferred embodiments of a single dosing method as described herein, the sublingual administration results in a Cmax of ketamine in the subject that is at least about 50% lower, at least about 60% lower, at least about 70% lower, or at least about 80% lower, than a Cmax of ketamine resulting from intravenous administration of an equivalent amount of ketamine. In preferred embodiments of a multiple dosing method as described herein, the sublingual administration results in a Cmax of ketamine in the subject that is at least about 40% lower, at least about 50% lower, at least about 60% lower, or at least about 70% lower, than a Cmax of ketamine in the subject resulting from intravenous administration of an equivalent amount of ketamine. 103923302.1Atty. Docket No.: 109520-846634

[0142] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in a peak concentration (Cmax) of ketamine in the subject of less than or equal to about 275 ng / mL. In some embodiments, the sublingual administration results in a Cmax of ketamine in the subject of less than or equal to about 250 ng / mL. In some embodiments, the sublingual administration results in a Cmax of ketamine in the subject of less than or equal to about 225 ng / mL. In some embodiments, the sublingual administration results in a Cmax of ketamine in the subject of less than or equal to about 200 ng / mL. In some embodiments, the sublingual administration results in a Cmax of ketamine in the subject of less than or equal to about 175 ng / mL. In some embodiments, the sublingual administration results in a Cmax of ketamine of less than or equal to about 150 ng / mL in the subject. In some embodiments, the sublingual administration results in a Cmax of ketamine in the subject of less than or equal to about 150 ng / mL. In some embodiments, the sublingual administration results in a Cmax of ketamine in the subject of less than or equal to about 125 ng / mL. In some embodiments, the sublingual administration results in a Cmax of ketamine in the subject of less than or equal to about 100 ng / mL. In some embodiments, the sublingual administration results in a Cmax of ketamine in the subject of less than or equal to about 75 ng / mL. In some embodiments, the sublingual administration results in a Cmax of ketamine in the subject of less than or equal to about 50 ng / mL in the subject. In preferred embodiments of a single dosing method as described herein, the sublingual administration results in a Cmax of ketamine of less than or equal to about 50 ng / mL in the subject (e.g., 31.2 ng / mL). In preferred embodiments of a multiple dosing method as described herein, the sublingual administration results in a Cmax of ketamine of less than or equal to about 75 ng / mL in the subject (e.g., 63.4 ng / mL).

[0143] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in an area under the curve up to the last quantified time-point (AUC0-t) of ketamine in the subject that is lower than an AUC0-t of ketamine resulting from intravenous administration of an equivalent amount of ketamine. In some embodiments, the sublingual administration results in an AUC0-t that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, or at least about 70% lower, than an AUC0-t of ketamine resulting from intravenous administration of an equivalent amount of ketamine.

[0144] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in an infinity-extrapolated area under the cure (AUCinf) of ketamine in the subject that is lower than an AUCinf of ketamine resulting from intravenous administration of an equivalent amount of 103923302.1Atty. Docket No.: 109520-846634 ketamine. In some embodiment, the sublingual administration results in an AUCinf that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, or at least about 70% lower than an AUCinf of ketamine resulting from intravenous administration of an equivalent amount of ketamine.

[0145] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in a half-life (t1 / 2) of ketamine in the subject that is at least about 1 hr, 2 hr, 3 hr, 4 hr, or 5 hr shorter than a half-life of ketamine resulting from intravenous administration of an equivalent amount of ketamine.

[0146] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in a Cmax of norketamine in the subject that is greater than a Cmax of norketamine resulting from intravenous administration of an equivalent amount of ketamine. In some embodiments, the sublingual administration results in a Cmax of norketamine in the subject that is at least about 10% greater, at least about 25% greater, at least about 50% greater, at least about 75% greater, at least about 100% greater, at least about 125% greater, at least about 150% greater, at least about 175% greater, at least about 200% greater, at least about 225% greater, at least about 250% greater, at least about 275% greater, at least about 300% greater, at least about 325% greater, at least about 350% greater, at least about 375% greater, or at least about 400% greater than a Cmax of norketamine resulting from intravenous administration of an equivalent amount of ketamine.

[0147] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), the sublingual administration results in a Cmax of norketamine in the subject of greater than a Cmax of norketamine resulting from intravenous administration of an equivalent amount of ketamine. In some embodiments, the sublingual administration results in a Cmax of norketamine in the subject of greater than or equal to about 30 ng / mL. In some embodiments, the sublingual administration results in a Cmax of norketamine in the subject of greater than or equal to about 50 ng / mL. In some embodiments, the sublingual administration results in a Cmax of norketamine in the subject of greater than or equal to about 75 ng / mL. In some embodiments, the sublingual administration results in a Cmax of norketamine in the subject of greater than or equal to about 100 ng / mL. In some embodiments, the sublingual administration results in a Cmax of norketamine in the subject of greater than or equal to about 125 ng / mL. In some embodiments, the sublingual administration results in a Cmax of norketamine in the subject of greater than or equal to about 150 103923302.1Atty. Docket No.: 109520-846634 ng / mL. In some embodiments, the sublingual administration results in a Cmax of norketamine in the subject of greater than or equal to about 175 ng / mL. In preferred embodiments of a single dosing method as described herein, the sublingual administration results in a Cmax of norketamine in the subject of greater than or equal to about 100 ng / mL (e.g., about 102 ng / mL). In preferred embodiments of a multiple dosing method as described herein, the sublingual administration results in a Cmax of norketamine in the subject of greater than or equal to about 175 ng / mL in the subject (e.g., 193 ng / mL). 4.8. Prodrugs

[0148] In other aspects, there are provided methods of inducing procedural sedation in a subject, themethods comprising sublingually administering a pharmaceutical composition comprising a prodrug of 1-hydroxymidazolam and prodrug of norketamine, wherein the administration achieves a level of sedation in the subject for procedural sedation that lasts for a time period of 60 minutes or less (e.g., 45 minutes or less).

[0149] In other aspects, there are provided methods of inducing procedural sedation in a subject, themethods comprising sublingually administering a first dose of administering a pharmaceutical composition comprising a prodrug of 1-hydroxymidazolam and prodrug of norketamine, and sublingually administering a further dose (e.g., second dose) of the pharmaceutical composition after the sublingual administration of the first dose, wherein the administration achieves a level of sedation in the subject for procedural sedation that lasts for a time period of 60 minutes or less (e.g., 45 minutes or less).

[0150] In other aspects, there are provided methods of reducing the occurrence of rescue in a subject, themethods comprising sublingually administering a pharmaceutical composition comprising a prodrug of 1-hydroxymidazolam and prodrug of norketamine, wherein the administration achieves a level of sedation in the subject for procedural sedation. Rescue may be performed when the subject’s level of sedation is a 1 on the Ramsay sedation scale (RSS)).

[0151] In some embodiments of a method as described herein, the method comprises administering tothe subject a pharmaceutical composition comprising a prodrug of 1-hydroxymidazolam, and a prodrug of norketamine. Such pharmaceutical compositions may be useful for achieving procedural sedation, as described herein. 4.9. Reducing rescue

[0152] In one aspect, there are provided methods of reducing the occurrence of rescue in a subject, themethods comprising sublingually administering a pharmaceutical composition comprising midazolam and 103923302.1Atty. Docket No.: 109520-846634 ketamine, wherein the administration achieves a level of sedation in the subject for procedural sedation. Rescue may be performed when the subject’s level of sedation is a 1 on the Ramsay sedation scale (RSS)). Rescue may be performed when the subject’s level of sedation is less than 2 (e.g., less than 2, less than 3, less than 4, or less than 5) on the Ramsay sedation scale (RSS)).

[0153] In certain embodiments of a method of reducing the occurrence rescue in a subject, the rescue ispre-operative. In certain embodiments, the rescue is intra-operative.

[0154] In certain embodiments, the occurrence of rescue is reduced as compared to administration ofmidazolam alone. In certain embodiment, the occurrence of rescue is reduced as compared to administration of ketamine alone.

[0155] In some embodiments, no opioids are administered to the subject when rescue is not performed.5. Routes of administration

[0156] In certain embodiments of a method for procedural sedation as described herein (e.g., a singledosing method, a multiple dosing method, or a method for reducing rescue), administration is to the subject local. In some embodiments, the local administration is by the oral route. In some embodiments, the oral route of local administration is sublingually or buccally. In some embodiments, the pharmaceutical composition is delivered to the patient in the form of a solid delivery vehicle such as a troche, a lozenge, a capsule, a pill, a cap, and a bolus, as described herein. In some embodiments, the pharmaceutical composition is formulated as a liquid item adapted for sublingual or buccal administration (in which case it will include all the pharmaceutically active compounds described above, but no pharmaceutically suitable binder); such liquid formulations may be delivered by any method to be selected by one having ordinary skill in the art of delivery of medications, e.g., via a syringe, dropper or pipette. Such local administration may be used instead of intravenous administration or to complement the latter, as appropriate.

[0157] It will be understood by those having ordinary skill in the art that the specific dose level andfrequency of dosage for any particular patient may be varied and will depend upon many factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, gender, and diet of the subject and the severity of the particular surgery or medical procedure. 103923302.1Atty. Docket No.: 109520-8466346. Kits

[0158] In additional embodiments, pharmaceutical kits comprising a pharmaceutical composition asdescribed herein are provided. A pharmaceutical kit may comprises a sealed container approved for the storage of pharmaceutical compositions (e.g., solid compositions), the container containing one of the pharmaceutical compositions described herein, and instructions for administering the composition. Such kits can facilitate performance of the methods described herein. When supplied as a kit, the composition may be packaged in one container, or a collection of separate containers.

[0159] The packaging of a pharmaceutical composition as described herein may comprise a pack ordispenser device, optionally which may contain one or more unit dosage forms containing the composition. The pack may, for example, comprise metal or plastic foil such as a blister pack.

[0160] The different components of the composition may also be packaged in one container, or acollection of separate containers. Said components of the composition may be optionally admixed immediately before use. Such packaging of the components separately can also, in certain instances, permit long-term storage without losing activity of the components.

[0161] Kits may also include reagents in separate containers such as, for example, sterile water or salineto be added to a lyophilized pharmaceutically active component of the composition that is packaged separately. For example, sealed glass ampules may contain a pharmaceutically active component of the composition and in a separate ampule, sterile water, sterile saline or sterile each of which has been packaged under a neutral non-reacting gas, such as nitrogen. Ampules may comprise or consist of any suitable material, such as glass, organic polymers, such as polycarbonate, polystyrene, ceramic, metal or any other material typically employed to hold reagents. Other examples of suitable containers include bottles that may be fabricated from similar substances as ampules, and envelopes that may consist of foil- lined interiors, such as aluminum or an alloy. Other containers include test tubes, vials, flasks, bottles, syringes, and the like. Containers may have a sterile access port, such as a bottle having a stopper that can be pierced by a hypodermic injection needle. Other containers may have two compartments that are separated by a readily removable membrane that upon removal permits the components to mix. Removable membranes may be glass, plastic, rubber, and the like 6.1. Labels and instructions for use

[0162] In certain embodiments, kits may be supplied with a label and / or instructions for use. The labeland / or instructions for use are to be affixed to the container or otherwise enclosed with it. Instructions 103923302.1Atty. Docket No.: 109520-846634 may be printed on paper or other substrate, and / or may be supplied as an electronic-readable medium or video. A detailed label or detailed instructions may not be physically associated with the kit; instead, a user of the kit may be directed to an Internet web site specified by the manufacturer or distributor of the kit to find said label or instructions.

[0163] In certain embodiments, the label comprises instructions for the use of a pharmaceuticalcomposition as described herein in a method as described herein. In specific embodiments, the label comprises instructions for use of a pharmaceutical composition as described herein (e.g., a weight ratio of midazolam to ketamine of 3 / 25 or 3 / 50, e.g., 3 mg and 25 mg or 3 mg and 50 mg of midazolam and ketamine, respectively, in the induction of procedural sedation in a subject in need thereof (e.g., for cataract surgery). ENUMERATED EMBODIMENTS

[0164] Embodiment 1: A method of inducing procedural sedation in a subject, the method comprisingsublingually administering a pharmaceutical composition comprising midazolam and ketamine, wherein the administration achieves a level of sedation for procedural sedation that lasts for a time period of 45 minutes or less.

[0165] Embodiment 2: The method of embodiment 1, wherein the procedural sedation lasts for a timeperiod of 30 minutes or less.

[0166] Embodiment 3: The method of embodiment 1 or 2, wherein the procedural sedation lasts for atime period of 15 minutes or less.

[0167] Embodiment 4: The method of any one of embodiments 1-3, wherein the level of sedationachieved is measured via the Ramsay sedation scale.

[0168] Embodiment 5: The method of any one of embodiments 1-4, wherein the level of sedationachieved is greater than achieved by administering midazolam alone.

[0169] Embodiment 6: The method of any one of embodiments 1-5, wherein the level of sedationachieved is greater than achieved by administering ketamine alone.

[0170] Embodiment 7: The method of any one of embodiments 1-6, wherein the weight ratio ofmidazolam to ketamine in the pharmaceutical composition is about 1:5 to about 1:20. 103923302.1Atty. Docket No.: 109520-846634

[0171] Embodiment 8: The method of any one of embodiments 1-7, wherein the weight ratio ofmidazolam to ketamine in the pharmaceutical composition is about 3:25.

[0172] Embodiment 9: The method of any one of embodiments 1-8, wherein the pharmaceuticalcomposition comprises about 3 mg of midazolam and about 25 mg of ketamine.

[0173] Embodiment 10: The method of any one of embodiments 1-7, wherein the weight ratio ofmidazolam to ketamine in the pharmaceutical composition is about 3:50.

[0174] Embodiment 11: The method of any one of embodiments 1-7 or 10, wherein the pharmaceuticalcomposition comprises about 3 mg of midazolam and about 50 mg of ketamine.

[0175] Embodiment 12: The method of any one of embodiments 1-11, wherein the sublingualadministration results in a Cmax of midazolam in the subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, at least about 70% lower, or at least about 80% lower than a Cmax of midazolam resulting from intravenous administration of an equivalent amount of midazolam.

[0176] Embodiment 13: The method of any one of embodiments 1-12, wherein the sublingualadministration results in a Cmax of midazolam in the subject of less than or equal to about 140 ng / mL.

[0177] Embodiment 14: The method of any one of embodiments 1-13, wherein the sublingualadministration results in an AUC0-t of midazolam in the subject that is not statistically different from or at least about 10% lower, at least about 20% lower, about least about 30% lower, at least about 40% lower, or at least about 50% lower than an AUC0-t of midazolam resulting from intravenous administration of an equivalent amount of midazolam.

[0178] Embodiment 15: The method of any one of embodiments 1-14, wherein the sublingualadministration results in an AUCinf of midazolam in the subject that is not statistically different from or at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, or at least about 50% lower than an AUCinf of midazolam resulting from intravenous administration of an equivalent amount of midazolam.

[0179] Embodiment 16: The method of any one of embodiments 1-15, wherein the sublingualadministration results in a Cmax of 1-hydroxymidazolam in the subject that is at least about 25% greater, at least about 50% greater, at least about 100% greater, or at least about 200% greater than a Cmax of 1-hydroxymidazolam resulting from intravenous administration of an equal amount of midazolam. 103923302.1Atty. Docket No.: 109520-846634

[0180] Embodiment 17: The method of any one of embodiments 1-16, wherein the sublingualadministration results in a Cmax of 1-hydroxymidazolam in the subject that is greater than or equal to about 6 ng / mL.

[0181] Embodiment 18: The method of any one of embodiments 1-17, wherein the sublingualadministration results in a Cmax of ketamine in the subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, at least about 70% lower, or at least about 80% lower than a Cmax achieved from intravenous administration of an equal amount of ketamine.

[0182] Embodiment 19: The method of any one of embodiments 1-18, wherein the sublingualadministration results in a Cmax of ketamine in the subject of less than or equal to about 275 ng / mL.

[0183] Embodiment 20: The method of any one of embodiments 1-19, wherein the sublingualadministration results in an AUC0-t of ketamine in the subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least 40% about lower, at least about 50% lower, at least about 60% lower, or at least about 70% lower than an AUC0-t of ketamine resulting from intravenous administration of an equivalent amount of ketamine.

[0184] Embodiment 21: The method of any one of embodiments 1-20, wherein the sublingualadministration results in an AUCinf of ketamine in the subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, or at least about 70% lower than an AUCinf of ketamine resulting from intravenous administration of an equivalent amount of ketamine.

[0185] Embodiment 22: The method of any one of embodiments 1-21, wherein the sublingualadministration results in a half-life (t1 / 2) of ketamine in the subject that is at least 1 hr, 2 hr, 3 hr, 4 hr, or 5 hr shorter than a half-life of ketamine resulting from intravenous administration of an equivalent amount of ketamine.

[0186] Embodiment 23: The method of any one of embodiments 1-22, wherein the sublingualadministration results in a Cmax of norketamine in the subject that is at least about 10% greater, at least about 25% greater, at least about 50% greater, at least about 100% greater, at least about 150% greater, at least about 200% greater, at least about 300% greater, or at least about 400% greater than a Cmax of norketamine achieved from intravenous administration of an equal amount of ketamine. 103923302.1Atty. Docket No.: 109520-846634

[0187] Embodiment 24: The method of any one of embodiments 1-23, wherein the sublingualadministration results in a Cmax of norketamine in the subject of greater than or equal to about 30 ng / mL.

[0188] Embodiment 25: A method of inducing procedural sedation in a subject, the method comprising:sublingually administering to the subject a first dose of a pharmaceutical composition comprising midazolam and ketamine; and sublingually administering to the subject a second dose of the pharmaceutical composition after the sublingual administration of the first dose, wherein the procedural sedation lasts 45 minutes or less.

[0189] Embodiment 26: The method of embodiment 25, wherein sublingually administering the seconddose of the pharmaceutical composition occurs within 30 minutes after administering the first dose of the pharmaceutical composition.

[0190] Embodiment 27: The method of embodiment 25 or 26, wherein sublingually administering thesecond dose of the pharmaceutical composition occurs within 15 minutes after administering the first dose of the pharmaceutical composition.

[0191] Embodiment 28: The method of any one of embodiments 25-27, wherein the method results in aCmax of midazolam in the subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, or at least about 60% lower than a Cmax of midazolam resulting from intravenous administration of an equivalent amount of midazolam.

[0192] Embodiment 29: The method of any one of embodiments 25-28, wherein the method results in aCmax of midazolam in the subject of less than or equal to 140 ng / mL.

[0193] Embodiment 30: The method of any one of embodiments 25-29, wherein the method results in aCmax of 1-hydroxymidazolam in the subject that is least about 25% greater, at least about 50% greater, at least about 100% greater, or at least about 200% greater than a Cmax achieved from intravenous administration of an equal amount of midazolam.

[0194] Embodiment 31: The method of any one of embodiments 25-30, wherein the method results in aCmax of 1-hydroxymidazolam in the subject that is greater than or equal to about 10 ng / mL.

[0195] Embodiment 32: The method of any one of embodiments 25-31, wherein the method results in aCmax of ketamine in the subject that is at least about 10% lower, at least about 20% lower, at least about 103923302.1Atty. Docket No.: 109520-846634 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, or at least 70% lower than a Cmax achieved from intravenous administration of an equal amount of ketamine.

[0196] Embodiment 33: The method of any one of embodiments 25-32, wherein the method results in aCmax of ketamine in the subject of less than or equal to 275 ng / mL in the subject.

[0197] Embodiment 34: The method of any one of embodiments 25-33, wherein the method results in aCmax of norketamine in the subject that is at least about 10% greater, at least about 25% greater, at least about 50% greater, at least about 100% greater, at least about 150% greater, at least about 200% greater, at least about 300% greater, or at least about 400% greater than a Cmax of norketamine in the subject achieved from intravenous administration of an equal amount of ketamine.

[0198] Embodiment 35: The method of any one of embodiments 25-34, wherein the method results in aCmax of norketamine in the subject of greater than or equal to about 30 ng / mL in the subject.

[0199] Embodiment 36: A method of reducing the occurrence of rescue, the method comprisingsublingually administering a pharmaceutical composition comprising midazolam and ketamine to achieve procedural sedation in a subject, and wherein rescue is performed when the subject’s level of sedation is a 1 on the Ramsay sedation scale.

[0200] Embodiment 37: The method of embodiment 36, wherein the rescue is pre-operative.

[0201] Embodiment 38: The method of embodiment 36 or 37, wherein the rescue is intra-operative.

[0202] Embodiment 39: The method of any one of embodiments 36-38, wherein the occurrence of rescueis reduced as compared to administration of midazolam alone.

[0203] Embodiment 40: The method of any one of embodiments 36-39, wherein the occurrence of rescueis reduced as compared to administration of ketamine alone.

[0204] Embodiment 41: The method of any one of embodiments 36-40, wherein no opioids areadministered to the subject when rescue is not performed.

[0205] Embodiment 42: A solid pharmaceutical composition formulated for sublingual and or buccaladministration comprising about 3 mg of midazolam and about 50 mg of ketamine.

[0206] Embodiment 43: The solid pharmaceutical composition of embodiment 42, further comprising athird pharmaceutically active compound selected from a benzodiazepine receptor antagonist, non- 103923302.1Atty. Docket No.: 109520-846634 non-steroid anti-inflammatory drug (NSAID), or antihistamine medicament, or a combination thereof or pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof.

[0207] Embodiment 44: The solid pharmaceutical composition of embodiment 42 or 43, wherein thesolid dosage form of the composition is selected from a troche, lozenge, capsule, pill, cap, or bolus.

[0208] Embodiment 45: The solid pharmaceutical composition of any one of embodiments 42-44, furthercomprising a binder.

[0209] Embodiment 46: The solid pharmaceutical composition of embodiment 45, wherein the binder isselected from a polyethylene glycol, polyethylene oxide, methoxypolyethylene glycol, polypropylene glycol, polybutylene glycol, PEG-laureates, PEG-dilaureates, PEG-oleates, PEG-dioleates, PEG- trioleates, PEG-stearates, PEG-distearates, castor oil derivatives of PEG, palm kernel oil derivatives of PEG, corn oil derivatives of PEG, soya oil derivatives of PEG, cholesterol derivatives of PEG, phytosterol derivatives of PEG, caprate / caprylate glycerides derivatives of PEG, tocopheryl succinate derivatives of PEG, octylphenol derivatives of PEG, nonylphenol derivatives of PEG, polyglyceryl-10- laurate, polyglyceryl-10-oleate, POE-lauryl ethers, POE-oleyl ethers, POE-stearyl ethers, polysorbates, monostearate, monolaurate and monopalmitate derivatives of sucrose, or products of poly(oxypropylene)- co-poly(propylene oxide) family.

[0210] Embodiment 47: The solid pharmaceutical composition of any one of embodiments 42-46, furthercomprising an excipient selected from a gelatin, sodium saccharin, stevioside, peppermint oil, or any natural or artificial fruit, vegetable, flower, beverage, or candy flavor, or a combination thereof.

[0211] Embodiment 48: The solid pharmaceutical composition of any one of embodiments 42-47, for usein a method of inducing sedation in a subject.

[0212] Embodiment 49: The solid pharmaceutical composition of any one of embodiments 42-48, for usein the manufacture of medicament for inducing sedation in a subject.

[0213] Embodiment 50: The solid pharmaceutical composition of any one of embodiments 42-49, for usein a method according to any one of embodiments 1-41. 103923302.1Atty. Docket No.: 109520-846634 EXAMPLES

[0214] The following examples are provided to further elucidate technical features of the presentinvention, but are not intended to limit the scope of the invention. The examples are for the illustrative purposes only. USP pharmaceutical grade products were used in preparing the formulations described in the Examples below. Example 1: MELT-100 Sublingual Tablet Phase I Safety Study Introduction:

[0215] A Phase 1 safety study of the MELT-100 formulation was conducted. MELT-100 is a sublingual,needle- and opioid-free formulation for procedural sedation during cataract surgery. MELT-100 combines fixed doses of midazolam (3 mg) and ketamine (25 mg) in one rapidly dissolving tablet (RDT) that is administered sublingually for procedural sedation. Administration of multiple doses of MELT-100 to the subject was also tested (e.g., 2 x 3 mg midazolam and 25 mg ketamine).

[0216] This Phase 1 study was randomized, single-dose, 4-Period, and a crossover relativebioavailability study comparing the MELT-100 formulation with intravenous (IV) midazolam, and IV ketamine under fasted conditions in healthy volunteers. Objectives:

[0217] The primary objectives of the study were:(a) to characterize the single-dose pharmacokinetic (PK) parameters of midazolam and ketamine(and major metabolites) after sublingual administration of MELT-100 and compare to IV midazolam and ketamine formulations; (b) to characterize the proportionality of exposure to midazolam, ketamine, and their metabolitesafter administration of MELT-1001×3 / 25 and 2×3 / 25 (6 / 50 total dose); (c) to establish early exposure / response models for sedation; and(d) to assess the safety and tolerability of the MELT-100 formulation.

[0218] The secondary objective of the study was(a) To evaluate the effects of single doses of MELT-100 on ECG parameters (e.g., heart rate, QTcF,PR and QRS intervals) 103923302.1Atty. Docket No.: 109520-846634 Study Methodology:

[0219] In this study, healthy adult subjects received under fasted conditions a single dose of MELT-100sublingual tablet, 3 / 25 mg (Test 1, Treatment A); two doses of a MELT-100 sublingual tablet , 6 / 50 mg (2×3 / 25 mg, each dose [1×3 / 25 mg] administered sublingually 15 minutes apart) (Test 2, Treatment B); midazolam 3.5 mg IV (Reference 1; Treatment C) administered in 3 increments over 2 minutes of 1.5 mg, 1 mg, and 1 mg (2 minutes between each administration), and ketamine 18 mg IV (Reference 2; Treatment D) administered over 5 minutes, each in 1 of 4 treatment periods followed by a 3-day washout.

[0220] After a 35-day screening period, up to 28 eligible subjects were randomized into 1 of 4 treatmentsequences (7 subjects in each sequence). Subjects who were withdrawn or withdrew from the study were not replaced. The number of subjects planned, enrolled, completed, and analyzed were 28, 25, 23, and 25 subjects, respectively.

[0221] TABLE 5: Tested Substances, Doses and Mode of AdministrationTABLE 5 Name Substance Dose and Mode of Administration

[0222] Four single-dose treatments were administered, a single dose in each of 4 treatment periods, witha 3-day washout period between doses. Diagnosis and Criteria for Inclusion:

[0223] 18.0 to 32.0 kg / m² (inclusive). Female subjects were surgically sterile or postmenopausal. 103923302.1Atty. Docket No.: 109520-846634 Criteria for Evaluation: Pharmacokinetics (PK):

[0224] PK blood samples were collected predose (0 hour, within 120 minutes prior to dosing), and 5, 10,15, 20, 30, and 45 minutes, and at 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours after study drug administration.

[0225] PK analysis was performed using noncompartmental methods in Phoenix WinNonlin® (Version8.1, Certara, L.P.) in conjunction with the internet-accessible implementation of the Pharsight® Knowledgebase ServerTM (PKSO; Version 4.0.4, Certara, L.P). PKSO provides protected and structured storage, audit trails, and version control for study data, analyses, and related files, supporting 21 CFR Part 11 compliance. The analysis was performed in accordance with the Statistical Analysis Plan (Version 1.0, 05 Jan 2021).

[0226] During the PK analysis, concentrations below the limit of quantitation (BLQ) up to the time ofthe first quantifiable concentration were treated as zero. Embedded (values between 2 quantifiable concentrations) and terminal BLQ concentrations were treated as “missing”. Calculation of the PK characteristics were based on actual elapsed times [h] (relative to time of dose).

[0227] The following PK parameters were determined for midazolam, l-hydroxymidazolam, ketamine,and norketamine, as appropriate: maximum concentration, determined directly from individual concentration-time data (Cmax); time to reach maximum concentration (Tmax); the observed terminal rate constant; estimated by linear regression through at least three data points in the terminal phase of the z); the observed terminal half-life (t1 / 2); area under the concentration- time curve from time-zero to the time of the last quantifiable concentration; calculated using the linear trapezoidal rule (AUC0-t); area under the concentration-time curve from time-zero extrapolated to infinity (AUCinf); the percentage of AUCinf based on extrapolation (AUCextrap%); last quantifiable concentration (Clast); time of the last quantifiable concentration (Tlast); clearance after extravascular administration for ketamine and midazolam only, after MELT-100 (CL / F); volume of distribution in the terminal phase for parent only, after MELT-100 (Vz / F); clearance after IV administration for ketamine and midazolam only (CL); volume of distribution after IV administration for ketamine and midazolam only (Vz); and molecular weight-corrected metabolite-to-parent ratios for AUCinf (1-hydroxymidazolam / midazolam; norketamine / ketamine). 103923302.1Atty. Docket No.: 109520-846634 Pharmacodynamics:

[0228] Pharmacodynamic parameters included sedation, defined as time to onset of sedation andsedation level, assessed using the Ramsay sedation scale (RSS), and cardiodynamics assessed by QTcF, heart rate, and PR and QRS intervals, and T-wave morphology and U-wave presence, extracted from ECGs collected via Holter monitor from predose through 24 hours postdose. Safety:

[0229] The Investigator evaluated safety using physical and oral examinations, O2 saturation (SpO2),vital sign measurements, clinical laboratory evaluations, electrocardiograms (ECGs), reported or observed adverse events (AEs), and assessments of neurocognitive function. Subjects were monitored for any AEs from the first dose through the end of the study. Efficacy:

[0230] No efficacy evaluations were performed in this Phase I study.Statistical methods: Analysis Populations:

[0231] PK Population: All evaluable subjects who were dosed and who had sufficient data to calculate atleast 3 of the planned PK parameters.

[0232] PK Analysis Population: All subjects in the PK Population for whom Cmax, AUC0-t, andAUCinf were estimated for at least 2 treatments.

[0233] Safety Population: Defined as all subjects who received at least 1 dose of study drug.Pharmacokinetics

[0234] All PK analyses were performed on the data from the PK Analysis Population. Comparisons ofthe log-transformed PK parameters Cmax, AUC0-t, and AUCinf for midazolam l-hydroxymidazolam, ketamine, and norketamine among treatments was performed using an analysis of variance (ANOVA) model and the 2 one-sided t-tests procedure. The ANOVA model included factors for sequence, subject within sequence, treatment, and period.

[0235] The following comparisons were performed:103923302.1Atty. Docket No.: 109520-846634 (a) MELT-100 Treatment A (Test 1) vs Treatment C (Reference 1) for midazolam and l-hydroxymidazolam (b) MELT-100 Treatment A (Test 1) vs Treatment D (Reference 2) for ketamine and norketamine(c) MELT-100 Treatment B (Test 2) vs Treatment C (Reference 1) for midazolam and l-hydroxymidazolam (d) MELT-100 Treatment B (Test 2) vs Treatment D (Reference 2) for ketamine and norketamine(e) MELT-100 Treatment B (Test 2) vs Treatment A (Test 1) for midazolam, l-hydroxymidazolam,ketamine, and norketamine Pharmacodynamics

[0236] All pharmacodynamic analyses were performed on data from the Safety Population. The RSSscores were summarized by treatment and by timepoint. Time to onset of sedation was summarized by treatment and presented graphically.

[0237] The primary cardiodynamic ECG assessment analysis was based on concentration QTc modelingof the relationship between the concentrations of midazolam and ketamine in MELT-100 (and the metabolites of 1-hydroxymidazolam and norketamine) and change from baseline in QTcF (delQTcF) with the intent to exclude the effect of delQTcF>10 msec at clinically relevant plasma concentrations. In addition, the effect of MELT-100 on the change from baseline in heart rate (HR), and PR and QRS intervals was evaluated at each postdose timepoint (a by-timepoint analysis). An analysis of categorical outliers was performed for changes in heart rate; PR, QRS, and QTcF intervals; T-wave morphology; and U-wave presence.

[0238] The relationship between plasma concentrations of midazolam and ketamine (and the metabolitesof l-hydroxymidazolam and norketamine) and the metabolites of 1-hydroxymidazolam and norketamine) and delQTcF was quantified using linear-mixed effects modeling approach with a model selection procedure. The full model had delQTcF as the dependent variable, plasma concentrations of midazolam, ketamine, 1-hydroxymidazolam, and norketamine as the explanatory variates, centered baseline QTcF (i.e., baseline QTcF for individual subject minus the population mean baseline QTcF for all subjects in the same treatment period) as an additional covariate, a fixed intercept, and random effects on intercept and slopes per subject. 103923302.1Atty. Docket No.: 109520-846634 Statistical methods: Safety:

[0239] All safety analyses were performed on data from the Safety Population. All quantitative safetydata were tabulated with descriptive summary statistics, including the following: arithmetic mean, SD, median, minimum value, maximum values, and number of non-missing observations (n).

[0240] Frequency counts and percentage were provided for categorical data. Data were summarized bytreatment sequence, treatment, and / or overall, as applicable. All observed baseline / predose and postdose values were summarized by treatment when data were available. Additionally, the corresponding change from baseline / predose assessment to each postdose assessment were also summarized by treatment. All tabulations involving change from baseline / predose comparisons included only those subjects with data at both the baseline / predose and postdose assessments.

[0241] Adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA,version 22.0, or later) terms and summarized by system organ class (SOC) and preferred term (PT) within SOC. The number and percentage of subjects reporting TEAEs were summarized by reported SOC and PT for each treatment and the population overall. TEAEs were also summarized by maximum severity and nearest relationship to study drug, by SOC and PT for each treatment.

[0242] A by-subject AE (including treatment-emergent) data listing, including but not limited toverbatim term, SOC, PT, severity, and relationship to study treatment, was provided. Deaths, SAEs, and other significant AEs, including those leading to early termination of study treatments were listed.

[0243] Vital signs, clinical laboratory values (hematology, serum chemistry, and urinalysis), and 12-leadECG parameters were summarized by treatment including any abnormal values flagged.

[0244] Physical examination and oral cavity examination data at each evaluation were listed. Clinicallysignificant abnormal findings were noted in the data listings. Weight and height were summarized. Neurocognitive assessments for each evaluation were listed. Summary of results: Pharmacokinetic Results: 103923302.1Atty. Docket No.: 109520-846634

[0245] Of the twenty-five (25) subjects that were enrolled, 25 subjects were included in the PKPopulation (for summary tables and figures) and 24 subjects were included in the PK Analysis Population (for statistical analysis).

[0246] Twenty-three (23) subjects were included in the statistical comparisons for Treatment A vs.Treatment C, Treatment A vs. Treatment D, and Treatment B vs. Treatment A comparisons. Twenty-four (24) subjects were included in Treatment B vs. Treatment C, and Treatment B vs. Treatment D comparisons.

[0247] Subject 219 was discontinued by the physician during Period 2 (Treatment A). Concentration-time data for Treatment A in Period 2 for Subject 219 were retained in the concentration listing but excluded from summary statistics, figures, PK analysis, and subsequent statistical analysis (i.e., Treatment A vs. Treatment C, Treatment A vs. Treatment D, and Treatment B vs. Treatment A). Concentration-time data for Subject 219 in Period 1 (Treatment D) were included in summary statistics, figures, and PK analysis.

[0248] Subject 205 was withdrawn from the study during Period 4 (Treatment A) due to an adverseevent. Concentration-time data for Treatment A in Period 4 for Subject 205 were retained in the concentration listing but excluded from summary statistics, figures, PK analysis, and subsequent statistical analysis (i.e., Treatment A vs. Treatment C, Treatment A vs. Treatment D, and Treatment B vs. Treatment A). Data from Periods 1 (Treatment C), 2 (Treatment D), and 3 (Treatment B) for Subject 205 were included in the summary statistics, figures, and PK analysis. Subject 205 was excluded from all statistical comparisons for Treatment A but included in comparisons for Treatment B (Treatment B vs. Treatment C, Treatment B vs. Treatment D).

[0249] Norketamine quantifiable predose concentrations were observed for Subjects 209 (Treatment A),218 (Treatment D), and 220 (Treatment D). Quantifiable predose norketamine concentrations for Subjects 209 and 220 were less than 5% of the respective Cmax values and were, therefore, included in the PK analysis without adjustment. The quantifiable predose norketamine concentration for Subject 218 was greater than 5% of the respective Cmax; Subject 218 was subsequently excluded from PK analysis of norketamine for Treatment D. Treatment A (MELT-1003 / 25 mg, Test 1) vs. Treatment C (Midazolam IV 3.5 mg, Reference 1)

[0250] The resulting PK parameters of midazolam after administration of Treatment A, Test 1, andTreatment C, Reference 1 are provided in TABLE 6. Midazolam Cmax, AUC0-t, and AUCinf were 103923302.1Atty. Docket No.: 109520-846634 approximately 81%, 54%, and 54% lower, respectively, after MELT-100 sublingual tablet 3 / 25 mg (Treatment A, Test 1) compared to midazolam IV 3.5 mg (Treatment C, Reference 1). Median Tmax was 19 min later for MELT-100 sublingual tablet 3 / 25 mg (30 min) compared to midazolam IV 3.5 mg (11 min). Mean T1 / 2 was similar for both treatments (6.75 h for MELT-1003 / 25 mg and 7.00 h for midazolam IV 3.5 mg).

[0251] The resulting PK parameters of 1-hydroxymidazolam after administration of Treatment A, Test1, and Treatment C, Reference 1 are provided in TABLE 7. For 1-hydroxymidazolam, Cmax was approximately 37% higher and AUCs were approximately 12% to 15% lower after MELT-100 sublingual tablet 3 / 25 mg (Treatment A, Test 1) compared to midazolam IV 3.5 mg (Treatment C, Reference 1). Median Tmax was 30 min later for MELT-100 sublingual tablet 3 / 25 mg (60 min) compared to midazolam IV 3.5 mg (30 min). Mean T1 / 2 was approximately 3.4 h shorter after for MELT-1003 / 25 mg (5.87 h) compared to that after midazolam IV 3.5 mg (9.31 h). Mean metabolite-to-parent ratios (MPR) for AUCinf were higher for MELT-1003 / 25 mg (0.294) compared to midazolam IV 3.5 mg (0.142).

[0252] A statistical analysis of the natural log-transformed systemic exposure of midazolam and1-hydroxymidazolam when comparing Treatment A, Test 1, and Treatment C, Reference 1 is provided in TABLE 8. Treatment B (MELT-1006 / 50 mg, Test 2) vs. Treatment C (Midazolam IV 3.5 mg, Reference 1)

[0253] The resulting PK parameters of midazolam after administration of Treatment B, Test 2, andTreatment C, Reference 1 are provided in TABLE 6. Midazolam Cmax was approximately 58% lower after MELT-100 sublingual tablet 6 / 50 mg (Treatment B, Test 2) compared to midazolam IV 3.5 mg (Treatment C, Reference 1); AUCs were similar for both treatments (geometric mean ratios were 97.61% and 97.65% for AUC0-t and AUCinf, respectively). Median Tmax was 34 min later for MELT-100 sublingual tablet 6 / 50 mg (45 min) compared to midazolam IV 3.5 mg (11 min). Mean T1 / 2 was similar for both treatments (6.88 h for MELT-1006 / 50 mg and 7.00 h for midazolam IV 3.5 mg)..

[0254] The resulting PK parameters of 1-hydroxymidazolam after administration of Treatment B, Test2, and Treatment C, Reference 1 are provided in TABLE 7. For 1-hydroxymidazolam, Cmax, AUC0-t, and AUCinf were approximately 212%, 106%, and 90% higher, respectively, after MELT-100 sublingual tablet 6 / 50 mg (Treatment B, Test 2) compared to midazolam IV 3.5 mg (Treatment C, Reference 1). Median Tmax was 24 min later for MELT-100 sublingual tablet 6 / 50 mg (54 min) compared to midazolam IV 3.5 mg (30 min). Mean T1 / 2 was approximately 2.5 h shorter after for MELT-1006 / 50 mg 103923302.1Atty. Docket No.: 109520-846634 (6.84 h) compared to that after midazolam IV 3.5 mg (9.31 h). Mean metabolite-to-parent ratios (MPR) for AUCinf were higher for MELT-1006 / 50 mg (0.280) compared to midazolam IV 3.5 mg (0.142).

[0255] A statistical analysis of the natural log-transformed systemic exposure of midazolam and1-hydroxymidazolam when comparing Treatment B, Test 2, and Treatment C, Reference 1 is provided in TABLE 9.

[0256] Treatment A (MELT-1003 / 25 mg, Test 1) vs. Treatment D (Ketamine IV 18 mg, Reference 2)

[0257] The resulting PK parameters of ketamine after administration of Treatment A, Test 1 andTreatment D, Reference 2 are provided in TABLE 10. Ketamine Cmax, AUC0-t, and AUCinf were approximately 86%, 75%, and 75% lower, respectively, after MELT-100 sublingual tablet 3 / 25 mg (Treatment A, Test 1) compared to ketamine IV 18 mg (Treatment D, Reference 2). Median Tmax was 20 min later for MELT-100 sublingual tablet 3 / 25 mg (30 min) compared to ketamine IV 18 mg (10 min). Mean T1 / 2 was approximately 5 h shorter after for MELT-1003 / 25 mg (5.22 h) compared to that after ketamine IV 18 mg (10.3 h).

[0258] The resulting PK parameters of norketamine after administration of Treatment A, Test 1 andTreatment D, Reference 2 are provided in TABLE 11. For norketamine, Cmax, AUC0-t, and AUCinf were approximately 163%, 43%, and 26% higher, respectively, after MELT-100 sublingual tablet 3 / 25 mg (Treatment A, Test 1) compared to ketamine IV 18 mg (Treatment D, Reference 2). Median Tmax was 28 min later for MELT-100 sublingual tablet 3 / 25 mg (75 min) compared to ketamine IV 18 mg (47 min). Mean T1 / 2 was approximately 3.3 h shorter after for MELT-1003 / 25 mg (10.5 h) compared to that after ketamine IV 18 mg (13.8 h). Mean metabolite-to-parent ratios (MPR) for AUCinf were higher for MELT-1003 / 25 mg (7.06) compared to ketamine IV 18 mg (1.50).

[0259] A statistical analysis of the natural log-transformed systemic exposure of ketamine andnorketamine when comparing Treatment A, Test 1 and Treatment D, Reference 2 is provided in TABLE 12. Treatment B (MELT-1006 / 50 mg, Test 2) vs. Treatment D (Ketamine IV 18 mg, Reference 2)

[0260] The resulting PK parameters of ketamine after administration of Treatment B, Test 2 andTreatment D, Reference 2 are provided in TABLE 10. Ketamine Cmax, AUC0-t, and AUCinf were approximately 72%, 45%, and 45% lower, respectively, after MELT-100 sublingual tablet 6 / 50 mg 103923302.1Atty. Docket No.: 109520-846634 (Treatment B, Test 2) compared to ketamine IV 18 mg (Treatment D, Reference 2). Median Tmax was 21 min later for MELT-100 sublingual tablet 6 / 50 mg (31 min) compared to ketamine IV 18 mg (10 min). Mean T1 / 2 was similar for both treatments (8.59 h for MELT-1006 / 50 mg and 10.3 h for ketamine IV 18 mg).

[0261] The resulting PK parameters of norketamine after administration of Treatment B, Test 2 andTreatment D, Reference 2 are provided in TABLE 11. For norketamine, Cmax, AUC0-t, and AUCinf were approximately 406%, 185%, and 149% higher, respectively, after MELT-100 sublingual tablet 6 / 50 mg (Treatment B, Test 2) compared to ketamine IV 18 mg (Treatment D, Reference 2). Median Tmax was 21 min later for MELT-100 sublingual tablet 6 / 50 mg (68 min) compared to ketamine IV 18 mg (47 min). Mean T1 / 2 was approximately 3.6 h shorter after for MELT-1006 / 50 mg (10.2 h) compared to that after ketamine IV 18 mg (13.8 h). Mean metabolite-to-parent ratios (MPR) for AUCinf were higher for MELT-1006 / 50 mg (6.74) compared to ketamine IV 18 mg (1.50).

[0262] A statistical analysis of the natural log-transformed systemic exposure of ketamine andnorketamine when comparing Treatment B, Test 2 and Treatment D, Reference 2 is provided in TABLE 13. Treatment B (MELT-1006 / 50 mg, Test 2) vs. Treatment A (MELT-1003 / 25 mg, Test 1): Proportionality Assessment

[0263] The resulting PK parameters of midazolam after administration of Treatment B, Test 2, andTreatment A, Test 1 are provided in TABLE 6. The resulting PK parameters of 1-hydroxymidazolam after administration of Treatment B, Test 2, and Treatment A, Test 1 are provided in TABLE 7. Midazolam Cmax, AUC0-t, and AUCinf were approximately 2.2-fold, 2.1-fold, and 2.1-fold higher, respectively, after MELT-100 sublingual tablet 6 / 50 mg (Treatment B, Test 2) compared to MELT-100 sublingual tablet 3 / 25 mg (Treatment A, Test 1). For 1-hydroxymidazolam, Cmax, AUC0-t, and AUCinf were approximately 2.2-fold, 2.3-fold, and 2.3-fold higher, respectively, after MELT-100 sublingual tablet 6 / 50 mg (Treatment B, Test 2) compared to MELT-100 sublingual tablet 3 / 25 mg (Treatment A, Test 1). Results suggest that midazolam and 1-hydroxymidazolam exposure increased in a dose proportional manner with an increase in midazolam dose from 3 mg to 6 mg. A statistical analysis of the natural log-transformed systemic exposure of midazolam and 1 hydroxymidazolam when comparing Treatment B, Test 2, and Treatment A, Test 1 is provided in TABLE 14.

[0264] The resulting PK parameters of ketamine after administration of Treatment B, Test 2, andTreatment A, Test 1 are provided in TABLE 10. The resulting PK parameters of norketamine after administration of Treatment B, Test 2, and Treatment A, Test 1 are provided in TABLE 11. Ketamine 103923302.1Atty. Docket No.: 109520-846634 Cmax, AUC0-t, and AUCinf were approximately 2.0-fold, 2.1-fold, and 2.1-fold higher, respectively, after MELT-100 sublingual tablet 6 / 50 mg (Treatment B, Test 2) compared to MELT-100 sublingual tablet 3 / 25 mg (Treatment A, Test 1). For norketamine, Cmax, AUC0-t, and AUCinf were approximately 1.9-fold, 2.0-fold, and 2.0-fold higher, respectively, after MELT-100 sublingual tablet 6 / 50 mg (Treatment B, Test 2) compared to MELT-100 sublingual tablet 3 / 25 mg (Treatment A, Test 1). Results suggest that ketamine and norketamine exposure increased in a dose proportional manner with an increase in ketamine dose from 25 mg to 50 mg. A statistical analysis of the natural log-transformed systemic exposure of ketamine and norketamine when comparing Treatment B, Test 2, and Treatment A, Test 1 is provided in TABLE 15. Safety Results: Adverse events:

[0265] A total of 15 (60.0%) subjects experienced 34 AEs; 14 (56.0%) of these subjects reported 21 AEsthat were considered treatment-related. Most of the AEs were mild to moderate in severity.

[0266] The number of subjects with treatment-related AEs was similar across most of the treatments,with the exception of fewer subjects (2, [8.3%]) with fewer treatment-related AEs (2 events) reported for the midazolam 3.5 mg IV treatment. The number of subjects with treatment-related AEs with the MELT-1003 / 25 mg and MELT-1006 / 50 mg treatments was 4 (16.0%) with 6 events and 5 (20.8%) with 7 events, respectively.

[0267] The most frequently reported AEs (>1 subject overall) were headache in 4 (16.0%), hypertensionin 3 (12.0%), dizziness in 2 (8.0%), nausea in 2 (8.0%), oxygen saturation decreased in 2 (8.0%), and vessel puncture site pain in 2 (8.0%) subjects.

[0268] The most frequently reported treatment-related AEs (>1 subject overall) were headache in 3(12.0%), dizziness in 2 (8.0%), hypertension in 3 (12.0%), and oxygen saturation decreased in 2 (8.0%) subjects.

[0269] The 3 treatment-related AEs of hypertension were reported with ketamine 18 mg IV, and the 2treatment-related AEs of oxygen saturation decreased were reported with MELT-1006 / 50 mg. The treatment-related AEs of headache and dizziness, 4 AEs and 2 AEs respectively, were reported with the treatments that contained midazolam. 103923302.1Atty. Docket No.: 109520-846634

[0270] Most of the AEs overall were of mild severity for 15 (60.0%) subjects; 3 (12.0%) subjectsreported moderate AEs, and 1 (4.0%) subject reported a severe AE.

[0271] One subject experienced a severe AE of syncope and a moderate AE of orthostatic hypotensionthat were considered related to MELT-1003 / 25 mg, resolved with IV fluids, and led to the subject being discontinued early from the study.

[0272] Adverse events of moderate severity were orthostatic hypotension in 1 (4.0%) subject, contactdermatitis in 1 (4.0%) subject, and dry skin in 1 (4.0%) subject. All of the AEs reported in this study resolved. No deaths or other SAEs were reported in subjects in this study. Clinical Laboratory Values

[0273] No clinically meaningful changes in mean values or trends in shifts from Day -1 to EOS / ET wereobserved for the hematology and serum chemistry parameters.

[0274] None of the out-of-range values for any laboratory test were considered clinically significant.

[0275] Vital Signs Mean changes from baseline in systolic and diastolic blood pressures were minimaland similar for the MELT-1003 / 25 mg, MELT-1006 / 25 mg, and midazolam 3.5 mg IV treatments at each timepoint, were highest at the 10-minute timepoint with the ketamine 18 mg IV treatment, but were minimal for this treatment by the 1-hour postdose timepoint.

[0276] Mean changes from baseline in pulse rate were minimal and similar for the MELT-1003 / 25 mgand MELT-1006 / 25 mg treatments at each timepoint, were highest at the 10-minute postdose timepoint, but were minimal for these treatments at the 1 hour postdose timepoint.

[0277] Mean changes from baseline in respiratory rates and pulse oximetry were minimal and similar formost of the treatments at each timepoint, with the exception of a small mean decrease from baseline in pulse oximetry for the midazolam 3.5 mg IV treatment at the 10-minute postdose timepoint and for the MELT-1006 / 50 mg treatment at the 30-minute postdose timepoint. The mean changes from baseline in pulse oximetry for each of these treatments were minimal at the 2-hour postdose timepoint. Electrocardiograms 103923302.1Atty. Docket No.: 109520-846634

[0278] The mean (SD), median, and ranges of each of the ECG parameters measured at Screening, Day -1, predose, and EOS / ET were similar and unremarkable at each timepoint.

[0279] Most shifts in ECG parameters were unremarkable. One subject had a normal PR duration atScreening and Day -1 that was abnormal 24 hours after receiving midazolam 3.5 mg IV in Period 4, but was not considered clinically significant.

[0280] Few subjects had ECG values that were considered outliers. Most of these subjects had QT, QTc,QTcB, and QTcF intervals >450 ms that occurred at baseline, and no changes from baseline for these subjects were >30 ms.

[0281] One subject had a QTcB interval of 457 ms 24 hours after receiving MELT-1003 / 25 mg inPeriod 4, which was out-of-range by only 7 ms. Physical and Oral Cavity Examinations

[0282] Most subjects had normal physical examinations and oral cavity examinations with none of theprotocol-defined abnormalities observed. One subject had a healing area of denuded skin surrounded by erythema of the left forearm at ET from an AE of second degree burns of the left forearm in Period 1 that was of mild severity, considered not related to study drug, was treated with topical bacitracin 400 units, neomycin 3.5 mg, polymyxin B 5,000 units ointment, and resolved on 08-Mar-2021. Neurocognitive Assessments

[0283] Most subjects had SPMSQ assessments that were unchanged at each timepoint measured. Onesubject had mild cognitive impairment 1 hour after receiving MELT 1006 / 50 mg in Period 3. This subject’s SMPSQ was assessed as normal mental functioning 2 hours postdose, and no AEs were reported for this subject in Period 3. Ramsay Sedation Scale

[0284] At 5 minutes after study medication administration, the vast majority of healthy subjects wererated as having an RSS score of 2 – corresponding to “subject is cooperative, oriented, and tranquil”; MELT-1003 / 25 mg in 25 subjects (100%), MELT-1006 / 50 mg in 24 subjects (100%), midazolam 3.5 mg IV in 22 subjects (91.7%), and ketamine 18 mg IV in 23 subjects (92.0%). At that same 5-minute postdose timepoint, 2 (8.3%) subjects had RSS scores of 3 – corresponding to “subject responds to commands only” with midazolam 3.5 mg IV; and 1 (4.0%) subject had an RSS score of 1 – corresponding to “subject is anxious and agitated or restless, or both” and 1 (4.0%) subject had an RSS score of 5 – 103923302.1Atty. Docket No.: 109520-846634 corresponding to “subject exhibits a sluggish response to light glabellar tap or loud auditory stimulus” both scores with ketamine 18 mg IV.

[0285] No subjects had an RSS scores <2 after the 10-minute postdose timepoint, and no subjects had anRSS score of 6 – corresponding to “subject exhibits no response” at any postdose timepoint. Higher levels of sedation (RSS scores >2) were more common at later timepoints, with the highest proportion of subjects with RSS scores >2 postdose observed with midazolam 3.5 mg IV (~54%), followed by ~46% of subjects with MELT-1006 / 50 mg, ~28% of subjects with MELT-1003 / 25 mg, and ~8% of subjects with ketamine 18 mg IV.

[0286] Although RSS scores of 2 at the 5-minute timepoint for MELT-100 at 3 / 25 mg and 6 / 50 mgsublingual doses were inconsistent with the median Tmax for each treatment, higher levels of sedation at the 30- and 35-minute timepoints (RSS scores of 2 through 4) were more consistent with the level of sedation expected at Tmax for MELT-100 sublingual tablets. Conclusions:

[0287] The purpose of this study was to characterize the single-dose PK parameters and doseproportionality of midazolam and ketamine (and their major metabolites) after sublingual administration of MELT-100 at 3 / 25 mg and 6 / 50 mg sublingual doses compared with midazolam 3.5 mg and ketamine 18 mg given IV. The safety and tolerability of MELT-100 were also assessed, as were the effects of MELT-100 on ECG parameters.

[0288] A total of 25 subjects were randomized and all received at least 1 dose of study treatment. Ofthose subjects randomized, 23 subjects completed the study with 2 subjects discontinuing early from the study, 1 due to physician decision (conduct toward the study staff) and 1 due to a treatment-related AE that was treated and resolved prior to discontinuation.

[0289] Most AEs were mild to moderate in severity, and the number of subjects with treatment-relatedAEs for the MELT-100 treatments was low (no more than 5 subjects). All of the mean changes from baseline in vital signs were known pharmacologic effects of the treatments, and all ECGs with abnormal findings were considered not clinically significant. Neurocognitive scores were as expected with 1 outlier of mild cognitive impairment 1 hour after receiving MELT-1006 / 50 mg that returned to normal mental functioning 2 hours postdose.

[0290] Although RSS scores of 2 at the 5-minute timepoint for MELT-100 at 3 / 25 mg and 6 / 50 mgsublingual doses were inconsistent with the median Tmax for each treatment, higher levels of sedation at 103923302.1Atty. Docket No.: 109520-846634 the 30- and 35- minute timepoints (RSS scores of 2 through 4) were more consistent with the level of sedation expected at Tmax for MELT-100 sublingual tablets. This may be due to several potential factors. (a) Because RSS scores at baseline were not assessed, and there was no impending surgicalprocedure increasing the potential to trigger symptoms of anxiety, it is unknown if this healthy subject population appeared cooperative, oriented, and tranquil (RSS score = 2) at 5 minutes postdose as a result of their resting “calm” state or due to medication. (b) Need for effective training on the use of RSS within the context of cataract surgery

[0291] Overall, MELT-100 at 3 / 25 mg and 6 / 50 mg single doses was well-tolerated when administeredin healthy subjects under fasted conditions.

[0292] Midazolam Cmax, AUC0-t, and AUCinf were approximately 81%, 54%, and 54% lower,respectively, after MELT-100 sublingual tablet 3 / 25 mg (Treatment A, Test 1) compared to midazolam IV 3.5 mg (Treatment C, Reference 1). For 1-hydroxymidazolam, Cmax was approximately 37% higher and AUCs were approximately 12% to 15% lower after MELT-100 sublingual tablet 3 / 25 mg (Treatment A, Test 1) compared to midazolam IV 3.5 mg (Treatment C, Reference 1).

[0293] Midazolam Cmax was approximately 58% lower after MELT-100 sublingual tablet 6 / 50 mg(Treatment B, Test 2) compared to midazolam IV 3.5 mg (Treatment C, Reference 1); AUCs were similar for both treatments. For 1-hydroxymidazolam, Cmax, AUC0-t, and AUCinf were approximately 212%, 106%, and 90% higher, respectively, after MELT-100 sublingual tablet 6 / 50 mg (Treatment B, Test 2) compared to midazolam IV 3.5 mg (Treatment C, Reference 1).

[0294] Ketamine Cmax, AUC0-t, and AUCinf were approximately 86%, 75%, and 75% lower,respectively, after MELT-100 sublingual tablet 3 / 25 mg (Treatment A, Test 1) compared to ketamine IV 18 mg (Treatment D, Reference 2). For norketamine, Cmax, AUC0-t, and AUCinf were approximately 163%, 43%, and 26% higher, respectively, after MELT-100 sublingual tablet 3 / 25 mg (Treatment A, Test 1) compared to ketamine IV 18 mg (Treatment D, Reference 2).

[0295] Ketamine Cmax, AUC0-t, and AUCinf were approximately 72%, 45%, and 45% lower,respectively, after MELT-100 sublingual tablet 6 / 50 mg (Treatment B, Test 2) compared to ketamine IV 18 mg (Treatment D, Reference 2). For norketamine, Cmax, AUC0-t, and AUCinf were approximately 406%, 185%, and 149% higher, respectively, after MELT-100 sublingual tablet 6 / 50 mg (Treatment B, Test 2) compared to ketamine IV 18 mg (Treatment D, Reference 2). 103923302.1Atty. Docket No.: 109520-846634

[0296] After administrations of MELT-1003 / 25 mg and MELT-1006 / 50 mg, midazolam and1-hydroxymidazolam exposure increased in a dose proportional manner with an increase in midazolam dose from 3 mg to 6 mg.

[0297] After administrations of MELT-1003 / 25 mg and MELT-1006 / 50 mg, ketamine and norketamineexposure increased in a dose proportional manner with an increase in ketamine dose from 25 mg to 50 mg.

[0298] Metabolite-to-parent ratios for midazolam and ketamine were higher after administration ofMELT-100 than after IV administration, indicating some oral absorption of both drugs.

[0299] Exposures to midazolam and ketamine after administration of MELT-1006 / 50 were less than orequal to those after administration of the IV reference standards, providing the necessary PK bridge. 103923302.1Atty. Docket No.: 109520-846634

[0300] TABLE 6: PK Parameters of Midazolam after Administration of MELT 100 Sublingual Tablet3 / 25 mg (Treatment A, Test 1), MELT 100 Sublingual Tablet 6 / 50 mg (Treatment B, Test 2), and Midazolam IV 3.5 mg (Treatment C, Reference 1) – PK Population. TABLE 6Treatment A: Treatment B:100 Sublingual MELT-100 Sublingual103923302.1Atty. Docket No.: 109520-846634

[0301] TABLE 7: PK Parameters of 1 hydroxymidazolam after Administration of MELT 100Sublingual Tablet 3 / 25 mg (Treatment A, Test 1), MELT 100 Sublingual Tablet 6 / 50 mg (Treatment B, Test 2), and Midazolam IV 3.5 mg (Treatment C, Reference 1) – PK Population. TABLE 7Treatment A: Treatment B:f103923302.1Atty. Docket No.: 109520-846634

[0302] TABLE 8: Statistical Analysis of the Natural Log-Transformed Systemic Exposure ofMidazolam and 1 hydroxymidazolam Comparing MELT 100 Sublingual Tablet 3 / 25 mg (Treatment A, Test 1) to Midazolam IV 3.5 mg (Treatment C, Reference 1) – PK Population. TABLE 8Midazolam103923302.1Atty. Docket No.: 109520-846634

[0303] TABLE 9: Statistical Analysis of the Natural Log-Transformed Systemic Exposure ofMidazolam and 1 hydroxymidazolam Comparing MELT 100 Sublingual Tablet 6 / 50 mg (Treatment B, Test 2) to Midazolam IV 3.5 mg (Treatment C, Reference 1) – PK Population. TABLE 9Midazolame103923302.1Atty. Docket No.: 109520-846634

[0304] TABLE 10: PK Parameters of Ketamine after Administration of MELT 100 Sublingual Tablet3 / 25 mg (Treatment A, Test 1), MELT 100 Sublingual Tablet 6 / 50 mg (Treatment B, Test 2), and Ketamine IV 18 mg (Treatment D, Reference 2) – PK Population. TABLE 10Treatment A: Treatment B:100 Sublingual MELT-100 Sublingual103923302.1Atty. Docket No.: 109520-846634

[0305] TABLE 11: PK Parameters of Norketamine after Administration of MELT 100 SublingualTablet 3 / 25 mg (Treatment A, Test 1), MELT 100 Sublingual Tablet 6 / 50 mg (Treatment B, Test 2), and Ketamine IV 18 mg (Treatment D, Reference 2) – PK Population. TABLE 11Treatment A: Treatment B:103923302.1Atty. Docket No.: 109520-846634

[0306] TABLE 12: Statistical Analysis of the Natural Log-Transformed Systemic Exposure of Ketamineand Nor-ketamine Comparing MELT 100 Sublingual Tablet 3 / 25 mg (Treatment A, Test 1) to Ketamine IV 18 mg (Treatment D, Reference 2) TABLE 12Ketamine103923302.1Atty. Docket No.: 109520-846634

[0307] TABLE 13: Statistical Analysis of the Natural Log-Transformed Systemic Exposure of Ketamineand Norketamine Comparing MELT-100 Sublingual Tablet 6 / 50 mg (Treatment B, Test 2) to Ketamine IV 18 mg (Treatment D, Reference 2) TABLE 13Ketamine103923302.1Atty. Docket No.: 109520-846634

[0308] TABLE 14: Statistical Analysis of the Natural Log-Transformed Systemic Exposure ofMidazolam and 1-hydroxymidazolam Comparing MELT-100 Sublingual Tablet 6 / 50 mg (Treatment B, Test 2) to MELT-100 Sublingual Tablet 3 / 25 mg (Treatment A, Test 1) TABLE 14Midazolam103923302.1Atty. Docket No.: 109520-846634

[0309] TABLE 15: Statistical Analysis of the Natural Log-Transformed Systemic Exposure of Ketamineand Nor-ketamine Comparing MELT 100 Sublingual Tablet 6 / 50 mg (Treatment B, Test 2) to MELT 100 Sublingual Tablet 3 / 25 mg (Treatment A, Test 1) TABLE 15Ketaminec103923302.1Atty. Docket No.: 109520-846634 Example 2: MELT-300 Sublingual Tablet Phase II Efficacy and Safety Study Introduction:

[0310] A Phase 2 efficacy and safety study of the MELT-300 formulation was conducted at nine siteswith over 300 enrolled subjects. MELT-300 is a sublingual, needle- and opioid-free formulation for procedural sedation during cataract surgery. MELT-300 combines fixed doses of midazolam (3 mg) and ketamine (50 mg) in one rapidly dissolving tablet (RDT) that is administered sublingually for procedural sedation (e.g., during cataract surgery). MELT-300 utilizes fast-dissolving delivery technology (Zydis®, Catalent Inc.) to rapidly dissolve the tablet for absorption across the sublingual mucosa.

[0311] The Phase 2 study was factorial-designed, randomized, double-blind, placebo-controlled, andincluded parallel-cohorts. Study design emphasized evaluation of efficacy and safety of MELT-300, and contribution of the midazolam and ketamine components towards sedation and intraoperative ocular analgesia in subjects undergoing cataract extraction with lens replacement (CELR). Comparisons were made of MELT-300 administration against: (i) placebo alone; (ii) sublingually delivered midazolam alone; and (iii) sublingually delivered ketamine alone. Primary efficacy endpoints included appropriate sedation during the cataract surgery and management of intraoperative pain during the surgery.

[0312] The formulation of the MELT-300 sublingual tablet is provided below in Table 16.

[0313] TABLE 16: MELT-300 Formulation103923302.1Atty. Docket No.: 109520-846634 MELT-300 Reference to Ingredient Function Quantity per tablet (mg) standardsarmacopoea; : at ona ormu ary; qs= quantum sats; / : not app cabe Results:

[0314] Overall disposition and subject accountability of a randomized subjects analysis set is provided inTABLE 17. Total subjects included in the randomized subjects analysis was N=338, with treatment arms of MELT-300 (N=86), midazolam (N=87), ketamine (N=85), and placebo (N=80).

[0315] The overall disposition and subject accountability of the full analysis set is provided inTABLE 18. Total subjects included in the full analysis was N=310, with treatment arms of MELT-300 (N=77), midazolam (N=81), ketamine (N=79), and placebo (N=73).

[0316] Demographics and subject baseline characteristics of the full analysis set are provided inTABLE 19. Hospital Anxiety and Depression Scale (HADS) and chronic pain ratings (e.g., severe pain, moderate pain, mild pain, or no pain) were collected from each subject. Preoperative intraocular pressure in each subject’s study and non-study eye was also measured.

[0317] Achievement of procedural sedation was evaluated for each subject (see TABLE 20). Success forprocedural sedation for this Phase 2 study was defined as achieving target sedation level (Ramsay Sedation Scale (RSS) scale level 2 or 3) at the start of surgery without the need for rescue sedation medication, and no need for intraoperative rescue sedation medication to maintain target sedation level. 103923302.1Atty. Docket No.: 109520-846634 63 / 77 (81.8%) subjects receiving MELT-300 achieved target sedation, compared to 52 / 81 (64.2%) subjects receiving 3 mg midazolam alone, 50 / 79 (63.3%) subjects receiving 50 mg ketamine alone, and 26 / 73 (35.6%) of subjects receiving placebo. p-Values between the MELT-300 treatment arm and the midazolam, ketamine, or placebo treatment arms were p= 0.0129, p=0.0096, and p < 0.0001, respectively.

[0318] Mean intraoperative analgesia by the numeric pain rating scale (Min=0; Max=9) was assayed foreach subject in the full analysis set at intraoperative timepoints: insertion of the speculum; corneal incision; insertion of phacoemulsion probe; insertion of the synthetic replacement lens. An average of the available timepoints was also calculated. TABLE 21 provides results for mean intraoperative analgesia by the numeric pain rating scale (carry forward). TABLE 22 provides results for mean intraoperative analgesia by the numeric pain rating scale, adjusted for site (carry forward). TABLE 23 provides results for mean intraoperative analgesia by the numeric pain rating scale (observed). Statistical analyses (e.g., least squares mean and difference, 95% confidence interval, and p-values) between treatment arms of MELT-300, midazolam alone, ketamine alone, and placebo are provided in TABLES 5-7.

[0319] Subject-rated worst pain during surgery by the numeric pain rating scale (Min=0; Max=9) wasassayed for each subject in the full analysis set, which is provided in TABLE 24. Statistical analyses (e.g., mean difference, 95% confidence interval, and p-values) between treatment arms of MELT-300, midazolam alone, ketamine alone, and placebo are provided.

[0320] The number of subjects achieving analgesia response (observed) in the full analysis set wasdetermined. Success in analgesia response was defined as NPRS < 4 at the available at the available four intraoperative timepoints and a failure otherwise (e.g., any interoperative pain rescue was assumed to be a failure. Results are provided in TABLE 25. The number of subjects completing the surgery is provided in TABLE 26, and the number of subjects completing the surgery without interruption is provided in TABLE 27. For this measure, subjects completing the surgery without interruption (other than rescue medication) due to pain or anxiety were considered successes. The number of subjects requiring rescue sedative medication and those requiring analgesic medication are provided in TABLES 28 and 29, respectively. For all TABLES 25-29, p-Values between pairs of treatments were calculated and are provided.

[0321] Post-operation, subjects were asked whether they would want the study drug again for a secondsurgery using an 11-point Likert scale of 0 (not likely at all) to 10 (extremely likely). Results are provided in TABLE 30. Statistical analyses (e.g., mean difference, 95% confidence interval, and p-values) between treatment arms of MELT-300, midazolam alone, ketamine alone, and placebo are provided. 103923302.1Atty. Docket No.: 109520-846634

[0322] The number of subjects receiving opioid concomitant medication postoperatively is provided inTABLE 31. Total dose is the sum of all opioids taken in milligrams for each subject in IV morphine equivalent.

[0323] Treatment-emergent ocular adverse events (TEAEs) by system, organ class, and preferred termare provided for the full analysis set. The study eye (TABLE 32) non-study eye (TABLE 33), or either eye (TABLE 34) was assessed. TEAES were defined as events that started on or after the date of the study drug administration through the end of Visit 4 or early withdrawal. Subjects with one or more adverse event within a level of Medical Dictionary for Regulatory Activities (MedDRA) were counted only once in that level. For the study eye, overall 2 / 85 (2.4%) of subjects in the MELT-300 treatment arm experienced a treatment-emergent ocular adverse event, compared to 7 / 87 (8.0%) for midazolam alone, 6 / 85 (7.1%) for ketamine alone, and 12 / 79 (15.2%) for placebo. TEAEs of special interest by system, organ class, and preferred term are provided in TABLE 35 for the full analysis set. 103923302.1Atty. Docket No.: 109520-846634 )l ) )l ) 0 a 8.02.14).92).14).97) ).12.51.9) )7) ) ) )3) )( 33 1 3 1 3 3 o)) ) ) ) ) ) ) ) ) )b e00.05.8.5.8.3.3.5. )c80 7 5.0.) ) )0.) )a5897589196879200 l =1( ( ( ( ( ( ( ( (5(0 0(0(00 5(0(N(6 9 6 9 3 9 8 2(0 0(0 0 P 08 4 7 4 7 7 6 7 1 1 g m 05))0). )0. ) )0. ) ) )0.. e59.9.9.2.8 0 0 0 0)0)0)0)0)0)0)0)0)snti=0125( 0125( 01298(801( ( ( ( ( ( ( (cmej aN((5 5( ( ( (0 0 0 0 0 0 0 0 t 4 5 54 5 97 57 5be8 8 8 8uKSdezi gmmod3))0. ) )0) ) ) ) )nam70. .0.0.1.8.0.al8 0 0 0 0)=0 640 640 392800) ) ) ) ) ) )( 0(0(0(0(0(0(0(R o1:z Nta (( (1( (1( ( (1(0 0 0 0 0 0 0 0 7 0 7 0 1 2edi8 4 8 4 78 8 7 78 SsMisylan 00) ) ) ) ) ) )A( 3- )60.8.8.8.8.5.7).8. ) )0. ) ) ) ) ) )T8 0 0848984899838892.000 0 0 0 0 0 y =1( ( ( ( ( (1( ( ( ( ( (tiLliEN((6 2( (1(0 0 0 0 0 0b4 58 24 58 77 27 58 1 1aM 8tnuoccciA tts ) ) ) ) ) ) ) ) ) )cita n % t(% n(% n(% n(% n(% n(% % % % n(n( ( (ejS n n nbuSdnanoit niositopaisivneoyd D Ditl laiutlaocveSfreotD o vor ltno O Poc e i: yotStautc7 nor s1 A t isn yitejb hPyeSla yn u n on pEtLinstienocBw AsS dSioU eAu siytsiit - cAd dh ylsis l tS Db nlecealo w i onlad T 7e1d]ezeiziti an yolcd eroavDlwE ycV onem mw Aanot telf aresn na4EiloF tt1.2 L n o odedeyo2 Beed dtatateArp n 3 Ar llP- mosdhrte ancv gis co otttsreA0ti3 320cnanaererfareoseoae ideryo htsi9[T S R R T T S u F P C Y N R W A P h Pro P L O V301Atty. Docket No.: 109520-846634 e) ) )rall) 0a8.0. 4) ) ) ) sre30 .4.2.8.1.3009 9 8 8 9egv=1 0 ( 1 9 9 9 9 9 (( aON(8 6( ( ( (tn 3 8 3 3 3 6 3 3 3 2 4 5e3 33 33 33crep,) ) ) )ydo) b0.0.8) ) )ute0c80.8.0.5.5.s00 08 8 5 7 7al=1 1 9PN((0( (9 9 9 9mo0 9( ( ( (7 97 67 8 8rf8 8 7 7noitagunm) ) )it) ) ) )n 05)50.00.00.00.8.8.0.oce80 0 00 08 80sini=1 1 1 1 9 901dmaN((5(5(5( (5 4(4(rot8 8 5fe8 8 8 8 8 n K osaerrgo Fm) ) ).l3)0.0.0).0) ) ).0.0.0.lam7ral80 0 0 0 0 0 0ev o=010 0 0 0 0 0zaN((17(1(1(1 1 1ordi8 78 78 7(8 7( (8 78 78opuMorgt0ne03- ))60).0. )8) ) ) )m .8.8.8.8.taT80 08 erL =010EN((1 98(98(98(98(9( th 6(6 5 5 5 5 5cM 8 8 8 8 8 8 8ae nidecizitsm ito.atdnyd Saru ststc eejhtbdus efun oitren bocmsilund)o l)a eh l w l C h aetnstcC noe oejhdeb )) )pnoPrsausp yrhbfO- eO- Potieroergrtus roh sia res b PS P 6 Ve11 1 1 2)8 g m atu 7yayayayayayan ne1D(D(D(De(D(D(cht 1.ErL1t 2t 2t 2t 2t 3en20t4tPo3BiAsi isi isi isi isi isi is:ietde32T V V V V V V V osNa9 3 b01Atty. Docket No.: 109520-846634 e) ) )r0) ) ) ) ) ) ) ) ) all)0.04.0.04.0.00 )) ) ) ) ) ) ).00.00.00.07.4.0.0 sare130 8 v= 1 4 0 8 ((1 4 0 ((1 0 ((0 0(0 0(0 0 0 0 0 01 01 01 0 8 9 1 9 9 0e1ga 0( ( ( ( ( ( ( ( ( ( ( (tON(0 0 1 5 0 0 1 5 0 0 0 0 0 0 1 01 01 0 0 6 8 0ne3 13 1 0 0 3 1 3 1 3 3 3 3 3 13crep,)o)) ) ) ) ) ) ) ) ) ) )ydube30.708.0.0408.0.040) ) ) ) ) ) ) )0.0 0 0 0 0 0 0 0 0 00.0 00.0 00.9.6.0. ts005 80cal=1(5(1(5(1( (0(0(0(0(0(0(0(01(1 101 9(9( 01moPN(3 04 3 0 3 3(3(3(3 0 2(3rf7 7 4 7 7 7 7 7 7 7 7noitagunm itn05))0. ) )6.0. ) )6.0). ) )0).0).0).0. )7) ).7.0.oce970 0 0 0 0)0) ) ) ) )0 0 0 0 0sini=0105( 0105( 01( ( (0(0(0(0(0( 01010101898901drmaN((9 0(0(0 0 0 0 0 0 0 0( ( ( ( ( ( (ote7 4 97 4 97 97 97 97 9 8 7 7 87 97fn K osaerrgo Fm) ).l3)0. )0) )0)0)0)0)0)0) )lam12. .2. .80 0 0)0)0)0)0) . . . . .0.0.r0) ) )0 0 0 0 0 0 0eal0 340 340 ( (0 0 00 0 0 0 0 0 0vo=1(1(1( ( ( ( ( (1 1 1 1 1 1 1ozraN((1 5(5(0 0 0 0 0 0 0 0( ( ( ( ( ( (8 3 18 3 18 18 18 18 18 1 1 1odi8 8 8puMorgt0n)) ) ) ) ) ) e03- )70. )5.0. )5.0) ) ).0 0 0 0 0 0 0mtT70 0 0)0)0)0)0)0)0)0) . . . . . . . a0 0 0 0 0 0 0 0erL =015EN((4( 015(4( 01( (0(0(0(0(0(0(0( 001010101010101th 7 5 7 5 7( ( ( ( ( ( ( cM 7 3 7 3 7 77 77 77 77 77 77 77ae nidecizits ) ) ) ) ) ) )m it% o.y at(% %% % % %dd n( ( ( ( ( (nu S n n n n n narststc eejhtbdus efun oitnrn oit ebocaisivneoym dundo Dit)a ut lleh liocveSf)alh otD olC aetw nstcor lono C noieoejhdeb Pcyottatc ) ) )y pnoPrsausnoArun prho bfhP itejn bOeO- Pe otiy u nn p -grts rtisrny ia redow A uctsiS oioeytsiitU eru oh sb a- cP S P 6 V) eg m d 8edzeh ztiSDb ndrlece lw voionla1 1 1 1 2 8oay DVld oneyayayayayayaatun n ee1i iw etwEcnlD D D D D Dcht 1.E m L o m d oddedteelfnaresataposdhr nea anici oscF tot( ( ( ( ( ( rott reAti1ti2ti2en20ti2ti2ti3ti4tP:o3B Ananaerermoseoaetiv g deytshtsisisisisisisi isietde32T R R T T C Y N R W ArP hoPro P L O V V V V V V V V osNa9 3 b01Atty. Docket No.: 109520-846634 l )) ) ) ) )2) ) ) ). )0.0. )6. ) ) )0. )6 7 2 1 1 2 5 6 2 o)) ) ) )b) 4. 3) 3.7.) 5).5).) 7. ) )3 e370(6( 0.803 607 207 .2 )0)0)0)0)0)09).71. )64.)0cal= 3 8;(77.6 2 327(7( (35(4( (38(1( (0(0(0(0( (0 32(7(1( (3 PN(8 5 7 6 7 2 1 7 4 9 7 6 6 1 7 6 1 5 4 3 6 1 5 g m 05))e94. )5) ) ) ) ) ) ) )37)070.9)0 .5.)02.8.)00.7.3. )0 00) ) ))0 . . ))0ni=(9(0;( 1287( 3564( 18711(0(0(0( ( 91180( (maN(74.7 5 0 5 97(7(97( (97( ( (0 0 0 0 97( (0 97 1 26 24 7 4 4 1 5 4 t 7 3 6 1 1 6 e K)teSgsimsy3))lam18)09. )70. 19)09).1).) 1) ) ) ) ).9.5.5.5.5.nal=( 0 908 1 )01)0)0)0)0)0)0 )0)01(9;(13 6(14 5(1881( ( ( ( ( ( 8118( (AoN81.6 05 8(5(6 8(9(2 8(6(0 0 0 0 0 18( (0 18llza (9 5 5 6 6 2 5 3 4 6 1 1 6 udiF:MteSsi0s0)) ) ) ) )yl 3- 7aT7)04. ) ) ) )7) 4.6.) 5.5.) 6.4.( 70.803 605 406 3)0)0)0)0)0)05.59.0)0)0n L = 7(8;(72A(EN(79.6 6 8 5 7(78( (74 5(77 2( ( ( ( ( (71 8( (7 9 7(5(2 7(9(8 0 0 0 0 0 7(5(2 0 7 6 1 5 3 4 5 1 1 6sMcitsiret )g)x)g)g) ) )cacriatsniD nait sSas (in Mis )nis%s )gn g is%s )n g is%s )nis%shainde;i(i(i(i( siCtmaeMnim n m n m n m n meS(M( ( ( ( (nin M n n n n nlesaBdrneadcniahlspaIcri evigfictaaomenaPN Dciraek:rehstal o91m OnirAr otaLEA o oLsenan ciainni aiitraoBir adnLciA)T 9s1rosa gesr rrfwaAr aIrnna ea nyopny1.]6EetLy( aae eyeH 2 BeCy5ela e eoteciwoticisikcnavirenreciniwoE 20napH- n yd 3 3 3 A geg 56 6=x lam cahalistam knhthtsino kn20[T A A < >eS MeuF R W B A N A U O E H N Ut9 S301Atty. Docket No.: 109520-846634ll)) ) ) ) )a013v= 1 ( 0 1 0 1 0 0 1 1 0 1 ON85 37.30.3 6 4 3 5 7 3 5 8 1 1 3 62 4 1 1 o))b3).7.))1)) )6) 7. ) ) )3) 5.3. .e3c79 00 .29 0 .20107 .2 )0)0030. 2)2030. 42 nal=4 5(PN3( 0.1;( 03(.3;(381( ( (3(6;( (6;oit((6(3 7 79.0 74.0 7(3 1 3 4(0 0 79.1 6 9 5 8 376.1 1 5 8 1aived dgradmn05))e90)7.0.)) ) ) ) )06. 7)06. 0)08.2. ) ))08).a210. tsn. 1)030. 12=i=753(4( (1 9( 0.1;0(2 9( 0.1 3;( 4985(10 ((0( (9(5 2;(9(5;0 DmaN(5 76.71.0 7 0 0 74.1 96.1 St4 43 1 3 76 21 5 7 5 1;e1 1)eKyethggir(mr3))m17).3.))9) ) ) ).) 4.) 7.3. ) )) 6).e) 8t.sial8 o=5440(5( (101(. 0102 1;( 01(. 8 07 20 0030. 22130. 52 n 2;( i18(1( ( (1(6;(0(5; s .lzlaN(7 4 86.0 86.0 8 1(0 0 0 86.1 5 9 86.1 5 9sudlari3 4 1 2 7 1 1 1ucevMo o=d Sn Oa00;p ))3) ) ) ) ) )- ))u 72.8.)01.)04.) 1.9. ) )) 1. 2) 2. 2 eorg T74 5 (20. 9(20. 9 0( 3 60 00(3( 0.20(3( 0.2ye tL =4(5(7(1;0 7(3;0 78(1( ( (75.51;74.51; tnEN(4 M 3 3 78.71.7 0 0 7 7 7 8 he4 1 3 46 31 51 51gir(m rtaeterxteh )) )dcag)x) ) ) ) )agxg gxgxsecits )niDS n D it%saniS naD a ni)niS n aaniDS naulniat( si(ind Mssii( Mssi%ss(iM; sas (iM;uc sn S n m( ae;e Mnndi m( ae;e Mnim(indn maeeMniindmaeeMnio=oitn M M n M M(n(n M M(n M M DaOvr;eeslb eaofyc)ES og nroeib H yssm m d merun(uteyS-pe eh EnoD td n y N noelda da ut e,ytcS,ereisaxbS elna eru nerocissSussysserAl aaseetreixn niiaerPtig n Prpsat9penaPiron1 PnietaPalal )H ec1.ED A cin L S S niaaPare eurcucgre20eoaoH=SP 3B D DorPdA D S A A h olidovert artm D:32nn mAet9 T O O H H C N M M SI I (o3H N01Atty. Docket No.: 109520-846634 )) tP 2 4w .sy p reorgrduaigsf soethmts 05))e93)r7a etnan 7)0 . .70 s ri=( 36630ehalmaN9 ( 7(0(t5 90.2 0tta .ue)lceoK 3rvelaol ci2 n po leoitatvdedegel]s zid m Stera3)) )Sg d m1 al8)02.8( 4.4653 0105Rr[at na0eln tso= 1( ( 0.9.aiaf)tezaN(8 2 9 0 0c toSdi5 2Sn n niaosisMoiittamoalyladet lintosin nSytaiA all sciehudetoF0ma t0) )Rmr:t)e3- 7) 8.2. 16 (no S T70( 18810090leoiirsL = 7t pisEN(7(3(40.0.v0elad SS ylM 6 1 <.astneos RnnietaeutscalA( mtde s enaes etrh eetoirttfg vitsi’a )rdgoat aryecirStsnis ) eusrigeani p egrlitaratsi%( lav-pvoeairtusfu S m(n p n neeh cnirodewaotrcte saforbdatsP t‘sdeegetne eihni efenottavrad neius d )Sh qsi naSc-in,RAhoitan oti(eccn d eta laecjossr lcideSbaearn u u S moi:Pdt0a ec noaid2moeortr padSEeL)nifresy asB1ob Atiysaecm siofaa e s elteul seucmsaeR TiD P Kaccre1.]7V (y2s sv- urh20tususP SoT 32 di3u siserer: :eetetfd:et320to[V Y N V Ve9 S oo N Neo3n N01Atty. Docket No.: 109520-846634 ))o) b))1) ;n) )ei50.1 3.) 3.) 3.) 3.) 9.2.) c70(20.90(2 01020. 01120. 010159 0t al= 3(1;0 3( M;(3(3;(2(3;(3( 2. ;2e0 (PN(76.1 71.20.0 1 70.0 3 73.0 3 7 8 4.9 . 04.S 2 2sisylanAglmlu0) ) ) ) )5) 5)0F: e9)704(.1( 0. 6);08(.10. 7);02(.20. 7);01(.20. 8;)05(.0.1562.0teni= 971.1 0 9(78.1 0 9(75.2 0 9(73.3 0 9( 7. ;7 6 10.(6SsmaN(1 1 2 31.0 21.2istey KlanA()drgamwr3)o m1))06.17)) ) ) )8)0 09. 7)01. 9)02. 9)05. 00.2.F al8( ( 0. ;(1( 0. ;(2( 0. ;(2( 0. ;(1 7 o= 11;0 . 0 0 18.1 0 19.3 0 16.4 0 1( 0.20 (yrrazaN(8 1 8 1 8 2 8 3 8 7 3.7 . 03.Cdi2 2(MelacSgnita 0R0)))9) ) ) ) ).) 5 ) 6 ) 67 1n3- 70iaT7(1( 0. 9 1 .29 1 .29 1 .29)00. 00.92.1;( ( 5. ;( ( 0. ;( ( 0. ;(2( 0. ;0(PL = 7 EN73.0 6 1 73.0 62.3 0 65.3 0 7 6 20.8c(1 2 7 3 7 3 7i5.05rM 2.2emuNeht)g) ) ) )ycbiD tsniS nxaag)niDS n g) )DxaniS n aag)niDxS n aag)niDxan)sS naerraiit sseatsi(iMsnde ;si(ixnde a sMsi(iMsnde ;si(iM nde ;si( aiM nde ;ME dtS maeMnimaeM maeMnimaenimaeniSSgl(n M M(n M(n M M(M n M M(M N M M L(anAevitsanreelpe toabnoert rmnIpnecnoialaeslpeM m ur:ulmeciote1 u cc htel2eEpan b sanhpys liLehtoie e ashthtv Bfic f fA Ato o ofstTninio o nln neni1.]8p2eoitraeoioignao rtrtrrepe203 33miesoesesvmi 290[TnICnInIA T301Atty. Docket No.: 109520-846634 e h htiTo).wbe3stdc7e=ce calffalPN(e pederxierfasan oig )5ttam 2.nioci00 p de5)e9, e03n71mimi= 9.7tnmaN0(-(2.ia0 yb ptt ee 23.nu K0e-mcstaerer rtetfag )d5)narum 4. 67.,tcnc3)0,m1al8 96710i,6oota8 66pehto=.zaN0(-(6.3.7m00-4. itserdi 2(0 1 0.ro,tn0eocM.-2.0rrsem n dr taaiaderpn ta hd)te)) ts ivr8 8=wles07 06.9.7.rreb d3- )7,9830,5120,E 521dto O.y T74.51.536 SmrL =0 7.1. .4. ; s aEN( -(00- 00- 0 nerm M 9(0.1(oitusm 041 . 02.aia us0vee edmh d dtrn aeti%5 %5 daedn 9 9e ) napeed citsaie(en uae(enc Iuaneutsrulctec)Ilaec)Ila eerC la=an atMniS SeCv-Mn e Cv-Mef% D 5v- SmoeLrefp S f Lriefp S f Lfi9(p;rf riD na .daeryraD Demasepareuewro ralah fvted u- .ueiqsp et dcncsrrasnaier caa, rf sel I ao er=nCvoe oae%cs5ducs n M9 erotiaS,Lecutrcoip e;n laerurrtpu scsvsrefnereremetfiuonialnoc-eo nriD,a spbtecmaztaensdenitai caenmpenial eneMuylceo P K M di ssnr-1.ps s s fSeusususn La ts20m:lO:o 3irerereoc=Iet eodoetm32oe9 T V V V3C N m Nht 01Atty. Docket No.: 109520-846634llo) ) )) u b e37))01)(.2) 30..902) 3.00.0) 3. 0)5 9.102 0.112 0.1015Fc:= 3(1;0(3(1;(3(3; (2(3; (3( 2.t2ealPN(76.1 71.0 2 70.0 7 33.0 7 8 34.S 2sisylanAg( ))m0)) ) )2).1.5dr59)04.a e7(1( 0. 6);08(.1( 0. 7);0( 2 7 )08 )05.(0.; ( 2( 0.; (1(57.w-ni= 9 1 71.0 9 1 78.0 9 2 750 9 3 7 0 97 6 1romaN(1 1.23.31.t 2FeyrKraC(etiSgrmof 3) m1))6)) ) ) )9) 1.) 2.)8 5.80 .10. 7 0 .10. 7 02 0.902 0.9010detalso=(1(u1.0;0(1(8.1;0(1(3; (0 1(4; (0 1(70.2 zN(8 1 8 89.86.83.ja1 2 3ddi2AMelacSgnita 0 ) ) ) ) )R0 n3- )7)09. 9)15.)16.)16.)7 00. 0i7aT(10.; (25. 9;( 2 0.9 ; ( 2 0.9 (20L = 7(31 0 6(31 0 6(3 0 6(3;0 7(6.2PEN7.7.72.75.75c(1 2i3 3.rM 2emuNeht)g) ) ) ) ) ) ) ) )yciDxg Dxg Dxg Dxg D t niS naniS naniS naniS naniS nbsit sas (iMs( aiMs( aiMs( aiMs( aiai indseatS m( ae ;sinde ;sinde ;sinde ;sindeeMnimaenimaenimaenimaeM(M M(M M(M(Mgln M n M n M n M M n ManAevitsanreelpe toabnrtoerp mstnInecninoialp oaesl epM m urecimi:ulm2 ueoteTh el2 cecEpa tn b shpysalLeniah oie evB )ttf si htfhtfA AeT Stsn]9iiocnio ofo s o n oln o n oe1.22 y 3l pe iatrae itit ga 03 nmiesnr r rroeses ev3290[A TnICnInIA301Atty. Docket No.: 109520-846634 d ob06n.).2.ay srae3c79 0tal=;( cem m PN(0.0f02. f2e udse exih ftsn ai)dg5t edm)2.nioul05)0.50e92. ,65 pe cn.76 0 89miidni=;( .07 2.t erramaN(0.9 08.-(0 yab ywt0 troe13.paf-nK0ered mt hteiarer e rt uacc)dsese)n rf rg76a,tocm)4.3)0.40 7.on2iessn .,0 0,8oiam1 3 87 0 6314peuopal=;( .07 73.1tr eo0z.2aN(01.-( .00-4.m(0i.toirucd8 ri2.,02 otpserM0-2.n0rr e seme-rerdtp ra aoer c td nt snne)ah 6)5)2tstiiacewp r-ts0 )6.9.7.=rr lyln o 03- ) 4070.2. ,0,0,EedOmT79;0 61822 484 616dto m:ehL =0.( 4.1.3.9 EN(02.0-7.00-1.00- 1 S 5. ;nseterotNhtM 2(i0(1.0(0 oi u.4.8 1. tai secw0 0 0aveen d dmaiecd draalraetvopedaec re e e napedercixtan sa)rnc)I enc)I enc)I etsr eran itMe raen a;e Cul aen eCul aen eCu =auttME drtM e%aMre %aMrle%aDmcoitaSniS SffM LS(Li5v- Sff5v- Sff5v- SourcD9(p Lipip;rD9(L D9(nfts iae ern udemasen eua mn ralas iave-mp u s ueqpt dssu na cssaa leerel,Idr=Coetn ae%mfa5eru M9h,T ccS Lec.ro; ne tlaet arn hee tsemvr ffa et icyderobni lo niD,uotcstecmaztaedi cn ase rniioan al ene fpo P K M dipsus s fMSsd 1.e2sun Letamirsuserereoc : i e 0rvr3 32=et aves9 T V V VIo b3C NocO01Atty. Docket No.: 109520-846634 ))o) b e3))1).) 9. 0 ) )c70(20. 9 6(10.1517. ) )180.. 7921)2 80.0.2 .8 02(159.0 al= 3(1;76.0 7(7.1;0(8(3.2;0(4(3.2;0 3( 22. ;20.(8 PN(1 6 1 5 2 4 2 73.0 24.2)teSsis gylm) )a0)))4)) ) ) ) )60.1n590 .A16 47.17310.27628. 8)03. 562.e7(llni= 9( 0. ;( ( 0. ;( ( 0. ;(1( 0. ;(1( 7. ;0(uN 1.1 0 57.1 0 61.2 0 35.2 0 9 0 10.2 Fma (7 1 7 1 6 2 5 2 70.02.:t2 2teeKSsisylangA(m) ) ) ))3)de) 6 ) 9) )9) )50.1 m10 .17 2 .1741 .19821.27)04.1072.0vral8( ( 0. ;( ( 0. ;( ( 0. ;( ( 0. ;( ( 0. ;(o= 1 0 81.0 98.1 0 75.2 0 39.3 0 1 8 20.6eszaN(1 7 1 6 2 5 2 81.04.bd2 2 Oi(MelacSgnita 0R0)))9) ) ) ).) 3)2)0 )5)80.2 2 n3- 70iaT7(1 L = 7( 0. 9 7 .2 1;( ( 0. 912 .2843 .28 0 .109.0 1;( ( 0.2;( ( 0.2;( ( 0. ;(73.0 071.0 6 0 56.3 0 7 43.7 7 20.9PENc(1 2 2 22.0i25.2rMemuNeht)g) ) ) ) ) )ycbiD tsniS nxaag D i niS nxaag)D i niS nxaag)niDS nxaag)niDxS nan)aaerraiit sseatsi(M nde ; ss(M S maeMniindmae ; ss(iM e Mniindmae ; ssi(iMsnde ;si(indeM ;eME dtMnimaeMnimaeniSSgl(n M M(n M M(n M M(n M M(M n M M L(anAevitsanreelpe toabnrtoernIpmstnecninoialoaeslpepeM m ur:ulmecimtieT3 u oh2 ceca teln b EpshpysalLen h oie eiash hv Btfitf tA AtTocofofninnio1.]o0peoi ln n traeoioi e20ntrtrgar333mies reses ev3290[TnIo CnInIA301Atty. Docket No.: 109520-846634 dn.o)aybe3s rac7tc mal=effm PN(e udse exih ft)sn aidg5tnedm 3. ioul00,pe c5) 74ni.e985midn7i=.00 4.t erramaN(-(0 yab ywrt6 te2.n pa orfK0- e ed mtahteirerr euat cc)dsese)n rf rg93a, ocm 5.3)0 8. to,nie sn 2620,9osuiam186 6 551peotpal=.09.3.4. r eozaN(-(d100-(0mii.0rtou. 4,ctirs2e.onp sr- M0- 0rr eemererd p rtaaoder cstnn te)ah ni c4) t ti a er078)3 s.9.7.=wp-trsr lyln o 003- )7,0183 ,0315 ,79EeddoO:mT7 L =5.1 72.2 7 24.6t6 S;m setehtEN(0- .( 00- .( 00- .( 0 nero NhtiM 2 1.7 3 oitus .e 03.01.0aiave cwe n d ed maid drcalraet avpdaeoercie ) e e napecdernctsaInc)Inc)Iienete CeuaenCeuaenCetusrarau n atMr le%ar lel=t%ar%a DcoitSef5v-MSef5v-M ef5v- Smour aS Lfi9(p Lfi9(p S Lfi9(p;rftsciD D D n a n eer deaumsenmeuan ralasveiamp u- eqspu u t dsscssan aal erel,I edr= oetnC fae%ma5erM9hu ,T c.cS Lec ro; ne tlaet arnehtsemvrefce fiy eronial to n Dd,uocbintsse m zaernt c at di cnaeo ianial e e fo PpsKsMsdifMSspeeutd 1.2 su un Lamirsersereoc : i er=av0r3 32Ietves9 T V V V o b3C NocO01Atty. Docket No.: 109520-846634siso))ylb 3) 2. 0aenc70(20.1 nial= 3(4; a70.0 p AlPN(4eluvitFa:retep S)os g5artism 3.n yl0i))0,ya5 ne97)00.( 2( 0. 804; 0.7n 3a(Ani= 9( 7)dm.4 01- 3. eaN(7 3(t30siwrea3.rK0- ehwtrooeFruyrlir afa g)6)C73.0. a( m3d))20,5 1,5nelam1)0 . 96073acal8(20. ;6.92.5stSo=(4 08N1.2.nigza (80.04 -(00-(0 onidti5 0 8p.3. eaM 0 0 mitRenviiataP) )reci1)re 07. 93 p 96.oa0)0.,0 0,rtm )) 6.733 ,293 niu3- 7 N T71(2( 0. 9;8 9 . 442.0 8.83rueL = 6 4 0079.-(8.00-5. 00 -(7.o 0fh ENt(3 M8(0.53 .1stelbyb0-2. .00-nealyiremt aavge arrt eufhtS) tgcig)D nxaec)I eec)I eec)I eos anitsniruit sSaatsii(ndM n n ;aeerCuln n aaeerCuln n aaeerCulraia4<D S m( aeeMniMef% fi5v9-ef%5v-ef%5v-pS ( p Mfi9(p Mfi9(p nnn M M D D DeeRPiawteN s Ptbsrt asdeeotenifW ra edu de st iaqs-iesR- .h n.tcelco n p)eejrbyacossr eruliuresga a ane isfSgr iPe a:utaage4S r lab2g nimnoE nim real aor artL u oniop fsiofdeBDb emazacire smA nctTtinaal edi emulaseu ccss1.]i1o P P pt sK M unv3usus=- P uaSsi2033 ) dsrosrsuserereS:e: eteu320[ten RtS E W V V V P oocs9 3 N N Ner 01Atty. Docket No.: 109520-846634 )) )02.58.P3 e7(3(3 04vitarep o gartm) )04).6.ni5)0(9 y e9 4 05 n n 777i= 0a(maN(6. e0sit9e7(9(0 w K 3 4rehto)ertueliSafsigsm) )yl3 7) ad)0anm1( .03.4 9 n 51a682al 8 7 7stAlo=l5z.2.niaN(( (0 0 o udi 18 33 8peF:4 mtMeiteSsviistayrelap nA0 ) ) )oa(0)0(9.21.rt)3- 7 4 75128457nirdeT7 7 1 8 uvL = orEN(7.04.7.fesM77(3(0 0 4.stelb b 3 4nOeali( mt avesae anrt eop) fhtsecigottsnies )usraia4R itsi%( la<aiatnv-pn SseS m(pegeRPln wNante sAbgt asdet enivenirafeeiu dhscqsiA -ies .hsntcelco. n p)eejacos rbs sr erulu ga aiafS:ni e it 5aP se aragle2abm n Eealim aornL)fao rtdB1obniopm zacisiof em Atiyaec at dire e suseu TsiDal es(P K M mlacc sa1.]2Vy2s s sunv=- P uSsi203 dtiu3 3utsissue orsuserereS: : eRetetu3c290[S V Y N V V V P oos3N N Ner 01Atty. Docket No.: 109520-846634 ))0.0 0( 0 )P37 0 3 7 g)0 m)0.0)5)0(00 e9 n 71(i=(- - maN(t9e7 K97 0 g)0 m)0.3)00)1(0 m l1a8(o=(- - zaN(di 181) M 8te0 Ssisyla )n0 )A0)0(7. )8 (3.ll3- 7 9 1 768u T= 2 - -F L:tEN(3.0eM77(6 1.sS7tnsi esymtlaaenrtA) ) f(ycig%( eoretsniu6i953srgt ssila0 0iaratmv-3.3.pn u S(p 0 0eS nenew htteb gtnsitetel eprau moqsC -ishtccnejo bsruaeS:P6a2m m E) eorL1onialofBybsiAti aecmaza eTsiD(altediu Pla]sKsMv-1.3V 2y23 dtius3utsissue orsuP03 erser:eet3290[S V Y N V V V o3N01Atty. Docket No.: 109520-846634 )Pseccusderged mis05) e9) )n ) o n 77.i=0(33.51c999ermaN(6((7 4 52.0ayt7teeiK x narteo Snsiais gpyoltamn3)) euAm1)0.80l(0)834d 31 )lal00o= 1 uN81( (2 01.00.n 0oiFza (18ta:dticieMdSesmis eyulcasnerAn(0 an 0))o3)hti- 7)7.tT7 p L =0(83.684253re79(1(2 0 0hturrEN(7 67 15.01.03.0.oetMst(nnIneoittmutneavoehrrtteti ) fnwycigoirnesroetsis )uifr igts%la a nrat im(nv-po u S(p nitp S neeuewrhtreett b nigtns tuitetel eorhtipau mwy oqsC -ireshtcc grnusejo bsr eh uaetg S:Pn ait72m melp Eealorm L)oniofBs ocAt1b Tniyaecmaazta ie sediutco Dllaej1.]4P (P K M y2s s sv- b P u203 dtiususus :S:3 3 3u siseorerereetet 290t[S V Y N V V V oo3N N01Atty. Docket No.: 109520-846634 )) ) )P 4 3 1 2seccusderged mis05)) ) )no e97)07.46. )30 3. .370cni=(93 3660er7( ( ( ( 0.amaN(9 4 5 0 0yt2 2 5teeiK x naro niatgpeoSmt3) ) ) es)s6.9. )4.uim18)06.20d y)l al=( 4ao 135(25(8(60 n nzaN(8 8 1 7(30.0oitald2 2 5 AiciluMdeF m:teeucSsseisryl0na0)) ) ) ) ah n3- 77)02.(8 1.4.08. 11 0407t7reA T(L = 719 18htEN(7(4(7( (30.<7.0 o noi1 8.(M 6sttnanceoitindeemtaevrMrtete ) fnivitacig t ni) eou698 srrofdseit ssi%( la091iapno Satv 0.0.iteS m(n - p 0 0 n eepuuncwrrs te eetbniR ts tgetu noihr ei ru atiuqeqswy R -ireshtcc grnusejo bsr eh uaetg S:Pnit8a2m melE)L1y eop nal rfm o Byyaleleobio mzasi csAtivivit ec ateediutcTsiD(tarar alP K Mlaejb1.]5Ve ey2p ps s sv- P uS203 dti3 3u s o-oausursus : :320tsi ee rtoerereetet9[S V YrPnIN V V V oo3N N01Atty. Docket No.: 109520-846634 ))P 3 g m 05))e95)5n7)0 . .5i =( 0 985 94 5maN(7(2( 5.3 74 0 teKte gSsmis3))ylm1aal8)02).8.3 9=( 3463082 n o 1(5( 8z N(8 5 6.07.0 Aal3 4l diuM F:teSsisyla 0n 0)) )A3- 7) 1.9.(T708 1 968231L =(74(5(2 4 4 noiEN(7 7 07.03.05.0t3 4.aMstcinedemtaMecirtsfe )glcig t n) eousrasinit sasi%( laiavpAtm n - p neS(neeucws te ebR tsgetnir ei ru auqeqsR -ishtccnejo bsruaeS:P9a2m m EeorL)on alfB1biosAtiyaecm za ieaaltediu TsiDl(P K Mav-1.]6Vy2s3 dtiusus2uP03 3utsisseorserser:eet3290[S V Y N V V V o3N01Atty. Docket No.: 109520-846634 derio) b))2ape371(.30.01 n c =(9;ual17.0 n PN(7 7amorferag )8eu m0.la05))1e9)17. 0 ,v84- pn7 i =(3 7( 0.0 1 1.82 d 6 1;019.n maN(7.t 7 -(0a,Ite 50.CeK0S - %5sis9,yelcanng) eA m0)73 rl.8 efl3))1.u,1,fi1)F m08. 0126411D::al8=(20.1 2 3 1(0;2.1 2.etteo SzaN(84.1 008- .( 00-1.o ( 0Nsdii5sM7.0.08. )y 0lyelkainlyAl(eyr)8)0 )3meeg 02.4.4.rtxru0 3- ))7)11. 01,4 1,00, e11 (ST7=(3( 0.0 1 6 76.1 8 74.7 4.89 01d L n EN679.1;00-6.00-5. 10 -(2. oo(7(0tceM 6(9)l2 1S.03.4.la .00- t4.a a 6.ry2.ole6fkni)il1gag)Dxaec)I eec)Iec)tIonitgcitAsniS n is( aiM n n aeerCuln n aaeerCeuln neaau n eerC la( si0L gtautsindrS m( ae ;eef%vMniMfMi5 9 -ef%v( p Mfi5 9 -ef%v( p Mfi5 9- f :(p oeecnDn M D D Dla eycd. sretfeutnreRSoitki .e gnaiLcitntvenad niaid orar pvWa- nsd1otcna1ejtg m s nimb =socunDudaSiS;er: a0 glrauof3 Astmvrae sE g LueroaletetnmrBDbnio zi saoirA yecmaTtdaltaecedinew penla]iutP K M dah1.7o S pt sus sifsususncSti20:w33 dn3 narerereocts320[E W V V V=Ietoe9 3 C Nt-t 01Atty. Docket No.: 109520-846634 o))b e3 0)c73.00. )0 0 al= 7( (N3 0 1 0 P(7(gmte05)) )Ss e9 0. 0. )isn7 i =970(00 - - 0( -- 0ylmaN(971(anteK AlluF:teSgsimsy3))1 0)lma0)a nl81.0 .0 - o= 8(- - - 0( -- - - 1 0 0A(zaN(81(ydileMvitarepotso0P 0)n3- )7 0)o7iT7.00. )0 L = 7(0 - - - - - - 0( -- - - - -taEN(71(0ci7 MdeMtnatim)e) %o x5ce9 ncn ger) e )ccits ) eu niD s S n aai(eM ne )ueIfCe rueIfCeunoita n %( la( av sinde ; e cnIlCafvi%lafvi%lavCtS n - p m( aeMniMer -pD5 - nD5 -din M Mefa 9(p n p a9(ofi e eipD M MOgniv2ieycaeDR nsotcdi)ejoingem b p u Oka(S: eT21vi syta3adire emoiD pnoemE pnialn alL o o o OyloioBtsb oecmaza foeb emazaAP altediesvitcatediTtn]ideP K M oarleP K M1.8o v2pis3 deususu Dlpsus s 033 ncess s seorerereato ots sursuserere3290[E R Y N V V V To P V V V301Atty. Docket No.: 109520-846634 o)) ) )be36.c734.8)- 0 -0(5 .1a19l= 7( ( (59.0;PN(1 2 19.0.7 0 1gm0)5))0.e9n7i=90.066 )0 7 0019( --maN((0( 2.0 9 0te7 Kgm3))0.m1)al810.06000 )9 - 0 -o= 8(1zaN(0( 2. -(- - - 0 1 0di8 M003- ))7)0.T770.08L = 7 0( 02 )10 3-- - - 0( -- - - - -EN(0(.0 0 7 M 7 ))%5 %5 cits ) eg u niDxs S na9 ai(e9(eM ne )u ne )u n ita n % t( la( av sinde;e cnIlCaae cnIlCaaeS n - p m( aeMniMerv- p Merv- p M n M MeffieffiD D –2yaD n odioipneOkaeT vi stadire emoip)em potsobnialo Of y glemn al( obio oecmazao v 8 ecmazatP altedies it - a tedinideP K M oaro v) s s sDe2lP K M1.pya s s s20piegususus lousu u3dncem( seorerereatotsoDnrsersere329 E R 8 Y N V V V T P o V V V301Atty. Docket No.: 109520-846634 o) be3c7al= PN(gm05)e9n7i=maN(teKgm3.)stm1n .tnal8e .o=mteeclazaN(aenvidirtaiuMfra qov esg r n iaom p men n m eeocihp warro00teof m3- )7b tsV T7tse Ietn L =tiEN( e rotcMrauirejqsp-iabu h htcishwcntae% o 5s se rci9rat-ofts(itee etsc)uPd m atnIleCav-a eriaarg Srefp mop ilfirf nliDsu nm.indianioitoimneaip o orfk ve e eatvira sd dtra edioiareulap d pv- o naott pllasso dnf=p oDfoaS; t,Im ulsapiCverec%hetter59 snir ,eiee of ccnsotneeul erdlnidaefoifv fiat1.n - o P20p DT 3donc :=Ie: :toetoet32o 9 E3C N N N01Atty. Docket No.: 109520-846634llu yF:toeb) )lr9)2. )a3) ) ) ) ) ) e.8.3.3.3.3.3. ) ) )8. ) ) )8) ).8 5rSec7s=%( 51(6(3(1(1(1(1 0 0 0 0. .( 1( ( (3( ( (3 3 2oi alsPN(n 21 5 3 1 1 1 1 1 0 0 3 0 0(3(3(24tiysliaV nfA o; degnyeEym e0 d 5) h5))t1)9)5)2)2) ) ) ) ) ) ) ) ) ) )thue8%.7.5.3.1.1 0(0(02(.12.1 0(02(0(0(.12.1 guS ni=( ( ( ( ( (:em0 0 0( (0 0( ( oyaN(n 6 5 3 1 1 1 1 0 0 1 1rtehttE(KnemmreecaTlpde grgruefmrer3)d.) ) ) )ylem7)P al8%0.86.44.31. )1 0)0)0) ) ) )1. ) )1. ) )3).3.duved o=( ( ( ( ( ( ( (0(0(0(1 0 ((1 0 ((2(2( tsfltanzaN(n 7 4 3 1 0 0 0 0 0 0 1 0 1 0 2 2 o hassdi ettnalMadieecC htna ron eygtlrfa nroOm0od ete0t)ns3- 5)) ) )8) ) )o nu%4.2.2.0)0)0)0)0)0)02.2. )0)0)0)0troy T S L =(2(1(1( (0(0(0(0(0(0(1 1 0( ( (0(0(0(0atceryEN(n 2 1 1 1 1. sMseitaabtthtAsiR.tnvisevttcneDndeEA veemts Maeysr ferroe taa o tvldudelh nevcaAgiefe el erRdnal s sreaini sucE norhtcAroifat)tiejiyt lrE bOadsnaAws usneucn o o n itoigtEt fTneorOce t ean tciislci(v pD ste reesbmeg n mlanermE-treoiocn t civeuemad ev dneErtlarn ees ah Mre etm -ttsea1neeysi uor2 e niditd 0 msecaces=vron a Adamodtnimd norilpeRt r eT:2a2peerna oirt pcD nd neo esa3 S ssTnoitdaoasnatsdnmoiegrnba c erMeo erE- alynis sefL nanerensignn u noiss;tmneh -tiase)1.4CnmAsetmes dridtinio nisiata ser e tvnwsgB Ate2argehtireredyd onamlos arplren peapre tc tnT SvrsATwdrpyeo osi s a iobaarooitaalesmta .l ejec]ROde stonihlbndlanhtp, lutgu reearwbure1.9is23 y3lDmrr csiadeetdapraegir oisefejyee ealnrer entchpoyraedcait cv n T recraseoada :arSP03 d: :320rbu y yuco oneiaefdnujoortavrt=ethetet9[n A M S P S E E O C F G PnIEnIC P CnInIE otioo3A N w N N01Atty. Docket No.: 109520-846634:te ySlrsisob)9))aey 73. )0) ) ) ) ) rlaec% na1 l =( ( (0 0(0 0(0 0 0o0(0(0(0 PN(n 14tiA s;ieVyfEo yddugnteSm e- 0n5) hoe5) 8) )=% 02(. ) ) ) )1 02)t(0(0(.12.h 1 guN ni(:emaN(n 0(1 0 0 0(1(1orhtyte tE(KnemmreecaTlpderg grurefmer3)d.) ) )ylem7)) ) ) )d vP al8% 01(.11.1 01(.1 0(0utesld o=(Nn 0(1(1 0(1 0(0ftanzaa (o e htssditalMan dieecC htn ona regtylrfa nOrodm0oenet0ts3)-5)) ) ) ) ) ) )o nuy T8=% 02S L( (.12.12.1 0 0( ( ( (0 0(0 0( tro c 0ateryEN(n 1 1 1.sstaabMeith Ast itR.tnvistDnevtcnedeeEA veyemtasr sMferoe taavl deortlehdugnif vecaeAe elrRdal srea nini sucEoAf rahty)tciejrtalrE bOawuneun Ast scoiEnfgrOte tciT(evoremn steeDb glaneesrem E-treciv vunnemdeeeEsda eh Mre etm -tt=vra on 1neer2T0msAd otRatmda nr:2 oDnoes 3pee3)sr italadte ege aEtsirrenbeeSsT- alynefetcaM o;tmehrtiaL S1.4Cen myeAsd idb nse-tsnwegBsi2nare shtire er niv atiee stcatAsTylv grT iswdra Arul sviesmt.l ejn e ROdeet stoni bntcre aea crbr 1.]0 n4ADmrrne csi3lldeetsefcaejdanoiyerrabuep yeoitn cujv w TauSeP203 ysiefnda : rd: :3o =ethetet 290[u F M S P P S E E VnIC E otioo3A N w N N01Atty. Docket No.: 109520-846634lluF:teob)) 9)2. )Se 3)8)3) )3)3)3)3) ) ) )8) ) )8)8)5)s c7%5a1 .6.3.1 0.1.1.1.1 0 0 0.3 0 0.3. .3.l=(Nn( ( ( ( (0( ( ( ( (0(0(0( (0(3 2 1 0( ( ( (isP(2 5 3 1 1 1 1 1 3 3 3 2 1yl1anA;ey gErme0h5)5) )ti e2) ) ).9.5.2. ) )2. ) ) ) )4) ).2 2) ) ) ) )2)2)n 8 i =%(8(5(3(1 0 ((1 0:0( (0 0(0(2.( 1.( 1 0 ((0(0(0(.1.( 1 0 ((EemNn 7 5 3 1 1 0 0 2 1 1 0 0 0 0 0ya (1 1 t Ee(K mreTdergrefmer3) ) ) ) ) ) ) ) )m7) ) 82.7.4.1.1. )0) ) ) ) ) )1. )1. )3.3. )P al=%(9(5 3 1 1(0(0(0(0(0(0(1 0(1 0(2 2 0(d oNn 8(5(3(1(1 0 0 0 0 0 0 0(0(0( (0nzaa (1 1 2 2ssdialMCnagrOm0e0t)s3- 5) )) ) ) ) ) ) ) ) ) ) ) ) ) ) )T8%5.34.4.0 0 0 0 0 0 0 0 02.2.0 0)0)0)0yS L =(Nn(2 3(2( (0(0(0(0(0(0(0(0(1 1 0( ( (0(0(0(0(0yE(2 2 1 1.sbMeisttinvievtcEAeysrroe tavlduAgerRalsucEsnroAfroitiyOtasld nraneun c n o oitogrOct eatcitiilciemnespDlE g -trn m eoioacinemtac dEr- stla n etes ruo Mmta1neeyir2 e niditd aes= A 0 mtnimsec cd norilapeRT:2a4peerna oit lap rmcD nd3 S ssTnoitdaoasnatsiretdn oieac erME- alynis sefcL1.nanerenasignn u 4CmAnoiss e;tsetnd m s dridbs tinioisiata serye eB ) Ate2nvargeh r T SsT tirere erey onitim noarpren psv e wdprdedosi asvilasiblpoi rises]1iA s ROders rtcosnyulob dntiiahrbla nlaoi chtoaaro nh p, la uttaalecgutcn re1.204 y3lDmade retsefejd palnegiretyebe eu oinrerncuj pn oydr ed nreacr itaseoev acada3 320ru y ycsio oneiaefo nujoortavrtra= 9[n A M S P S E E O V C F G PnIC EnIC P CnInIP E3A01Atty. Docket No.: 109520-846634ylraero4tisiVfodneehthguorhttnemecalpgurd;yldeuvtesfltoaehttan dieechtnroetyfalnrood neto nturoatcs etraahtAstR.tneDndeveemsMtaafertdeolhneif v cae el eda nierani shttc) iejE b AwusEstnfT(evoste renbeesm vreevunesdra ee ehtvrondatmodnreoes gre aenbo emreha-ttisneewsgmttcatna .leaejecrwb1T ure .20:arSP 3etd: :3ohtietoet 2o 9 3 N w N N01Atty. Docket No.: 109520-846634: yltreo)aS b 9)eseris c7% yal=( olaPN(n4tis niV A(fo mdre gn eT m ede0htr5)ree5) h 8 gfni=%(ueromPaN(nrthtde tnKneamssecalalpCg gnaurgrm3)d.yleOm7)duvemal8=%( tsletots z N(nfoahy adi ettanSy M diebe ch nts troereetyltfa nonI rdl 0o etai0)nncue3- 5)o8tro p T S L =%( atcEN(n.ss etrfMeaaoithtAst invistR.tnevtcneD deem EA veyets Maesr f rrot a o teavldudeleh cgaenif vel eAerRdalruo ea nirsanihtccfy)tiejE b Otrawn Astusneoig .reetE Tne flcbi(voreaD steesb mt l nEsa em vre-ithntcievune rdeeosda eh mfMre er ttna1ai=v Adooer2T0retiRatm D:2 r nrdeeosa5pced3)segebseren oerEteS- alhttM;tmehtiasL Ss1.4C enmene-t evnwsg B Ais2 vargem rsTylAT t eem.tcatn Odcesr talaejec1.] a2 nReej ee4ADmerrb vrwbure20tefus daT:arS:P:3 33llde syero =etdhetet 290[u F M S P N E otioo3A N w N N01Atty. Docket No.: 109520-846634 Conclusion:

[0343] MELT-300 (e.g., 3 mg midazolam and 50 mg ketamine) sublingual tablet achieved topline resultsand primary sedation endpoint in the Phase 2 efficacy and safety study. MELT-300 was statistically superior for procedural sedation compared to all comparator treatment arms, including midazolam 3 mg (p=0.0129) and ketamine 50 mg (p=0.0096).

[0344] MELT-300 treatment arm was 66% less likely to require rescue sedation pre-operativelycompared to the midazolam treatment arm. The MELT-300 treatment arm was also 50% less likely to require rescue sedation compared to midazolam (p=0.0198). Moreover, MELT-300 treatment arm had zero serious adverse events (N=77).

[0345] From this study, MELT-300 was shown to be a promising non-IV option for procedural sedation(e.g., for cataract procedures and other potential uses). Example 3: MELT-300 Sublingual Tablet Phase III Efficacy and Safety Study Introduction:

[0346] A Phase 3 efficacy and safety study of the MELT-300 formulation for procedural sedation insubjects undergoing cataract extraction with lens replacement (CELR) was conducted at twelve sites with approximately 528 enrolled subjects. MELT-300 is a sublingual, needle- and opioid-free formulation for procedural sedation during cataract surgery, which combines fixed doses of midazolam (3 mg) and ketamine (50 mg) in one rapidly dissolving tablet (RDT) that is administered sublingually for procedural sedation. MELT-300 utilizes fast-dissolving delivery technology (Zydis®, Catalent Inc.) to rapidly dissolve the tablet for absorption across the sublingual mucosa. Detailed Summary

[0347] An aim of the clinical trial was to determine MELT-300 efficacy for procedural sedation in adultparticipants undergoing CELR. The clinical trial investigates the safety of MELT-300. MELT-300 was compared to a similar placebo, and a comparator (sublingual midazolam) to confirm the benefit of inclusion of ketamine in the combined drug product.

[0348] Additional aims of the clinical trial include determining: 1) effectiveness of MELT-300 incomparison to placebo on procedural sedation for cataract surgery; 2) effectiveness of MELT-300 compared with midazolam on procedural sedation, to determine the contribution of ketamine component 103923302.1Atty. Docket No.: 109520-846634 and inform the risk of ketamine in MELT-300; 3) time to achieve preoperative target sedation level with MELT-300; and 4) which medical problems participants have when taking MELT-300 vs placebo.

[0349] Eligible participants were admitted to the study unit on Day 1. Participants were randomized priorto surgery 4:1:1 to: 1) MELT-300 (i.e., a single MELT-300 sublingual tablet which contains 3 mg midazolam and 50 mg of ketamine); 2) Midazolam (i.e., a single matching midazolam sublingual tablet, which contains 3 mg midazolam); and 3) Placebo (i.e., a single matching placebo sublingual tablet) The study was a Phase 3, randomized, double-masked, placebo-controlled, parallel-cohort, multicenter study.

[0350] Participants received study medication 30 (± 5) minutes, without food or water, before plannedsurgery start (defined as instillation of topical ocular anesthetic gel (3 drops of chloroprocaine hydrochloride ophthalmic gel)).

[0351] The effectiveness of MELT-300 was evaluated after study medication is administered beforesurgery, in the course of surgery (intraoperatively), and postoperative on Day 1 (end of surgery defined as just prior to drape removal). Efficacy assessments included assessments of sedation, need for rescue medication for sedation, need for rescue medication for pain, and the ability to complete the surgery.

[0352] The safety of MELT-300 was performed at baseline, in the course of surgery (intraoperatively),postoperatively on Day 1, and on Day 3 ± 1 day post dose of study medication. Safety assessment included monitoring of AEs, vital sign measurements, and physical examinations.

[0353] Comparisons were made of MELT-300 administration against: (i) placebo alone; (ii) sublinguallydelivered midazolam alone; and (iii) sublingually delivered ketamine alone. Primary efficacy endpoints included appropriate sedation during the cataract surgery and management of intraoperative pain during the surgery. Eligibility Criteria

[0354] Participants met at least the following criteria in order to be enrolled into the study:1) 2) Were to undergo unilateral primary CELR under topical anesthesia, with a phacoemulsificationdevice and insertion of an intraocular lens (no restrictions on lens type). 3) For women of childbearing potential (WOCBP), had a negative urine pregnancy test, and abstainfrom sexual activity or use a double barrier method (e.g. condom and diaphragm) of birth control from Day 1 and up to 2 days after study drug administration. 4) Were willing to refrain from alcohol consumption within 24 hours of randomization.103923302.1Atty. Docket No.: 109520-846634 5) Were competent to provide informed consent.6) Voluntarily provided informed consent in accordance with governing International Review Board(IRB) requirements and provide Health Insurance Portability and Accountability Act (HIPAA) authorization, prior to any procedures or evaluations performed specifically for the sole purpose of the study. 7) Indicate they understand and are able, willing, and likely to fully comply with study proceduresand restrictions.

[0355] Participants were excluded from the clinical trial if they met at least any of the following criteria:1) Subjects scheduled for simultaneous bilateral or 2nd-eye cataract surgery (subjects scheduled fora future 2nd eye cataract surgery are eligible for the study). 2) Known sensitivity to benzodiazepines or ketamine.3) Known sensitivity to -caines (including proparacaine, ester-type local anesthetics), benzalkoniumchloride (BAK). 4) Intraocular pressure (IOP) > 30 mmHg in the study eye or fellow eye at screening.5) History of iritis, or any ocular trauma with iris damage in the study eye.6) Presence of active corneal pathology other than dry eye per slit lamp and external eye exam atscreening in either eye. 7) Presence of extraocular / intraocular inflammation in either eye.8) Presence of active bacterial and / or viral infection in either eye.9) History of intraocular non-laser surgery in the study eye within the 3 months prior to day ofsurgery, or intraocular laser surgery in the study eye within 30 days prior to the day of surgery. 10) Requiring or planning other additional ocular surgery during the cataract surgery (e.g. glaucomasurgery ([minimally invasive or traditional], limbal relaxing incisions, etc.) or performing laser- assisted CELR. 11) Presence of active infection, mucositis, cold sores, canker sores, vesicles, viral lesions, localirritation / inflammation, or periodontal disease of the oral cavity. In addition, evidence of piercings of the tongue or anywhere in the oral cavity, his-tory of oral cavity piercings, history of significant dental disease, or history of dysphagia. 12) Women who are nursing a child or plan to nurse a child during the study.13) Have a history or clinical manifestations (e.g., signs, symptoms, laboratory values, diagnosticimaging, etc.) of significant gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, respiratory, or other medical condition that in the opinion of 103923302.1Atty. Docket No.: 109520-846634 the investigator might confound the study results or pose additional risk in administering the study procedures. 14) Use of disallowed medications including the following:a. Antihypertensive agent or diabetic regimen at a dose that has not been stable for at least30 days prior to Day 1, or which is not expected to remain stable throughout the study. b. Central nervous system (CNS) active drugs such as benzodiazepines, tricyclicantidepressants, serotonin and norepinephrine reuptake inhibitors (SNRIs), or selective serotonin reuptake inhibitors (SSRIs) that have not been stable for at least 30 days prior to Day 1, or which is not expected to remain stable throughout the study. c. Initiating the use of, switching to a different, or increasing the dose of a sleep medication(e.g. lorazepam, zolpidem, etc.) within 3 days of randomization. 15) Illicit drug use or alcohol abuse based on medical history, or currently engaged in il-licit drug useor alcohol abuse. a. Alcohol abuse is defined as 5 or more drinks in one sitting or 15 or more drinks in a weekfor men and 4 or more drinks in one sitting or 8 or more drinks in a week for women. A drink is considered a 1.5 oz shot, 12 oz of beer, or 5 oz of wine. b. prior to the time of screening and who have recovered and have been drug / alcohol free for at least that period of time (i.e., 5 years) can be enrolled C. Patients with a medical prior to the time of screening and have been marijuana free for at least that period of time (i.e.1 year) can be enrolled. 16) Creatinine clearance rate < 60 mL / min estimated using the CKD-EPI 2021cr (NKD) equation17) Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase(ALP) > 2.5 times upper limit of normal (ULN), or total bilirubin > 1.5 x ULN. In cases of documented Gilbert syndrome, subjects with elevated bilirubin levels will be permitted to enroll in the study if other liver function tests are with-in the specified limits. 18) Any other abnormal laboratory results or presence of any condition that the Investigator believeswould put the subject at risk or confound the interpretation of results.

[0356] Detailed descriptions of the study design arms and interventions, as well as primary andsecondary outcome measures are provided in TABLES 36-38.

[0357] TABLE 36: Phase III Arms and Intervention103923302.1Atty. Docket No.: 109520-846634 Participant Group / Arm Intervention / Treatment Ex erimental: MELT-300 Dru : MELT-300 sublin ual tablet t, t, t, et

[0358] TABLE 37: Phase III Primary Outcome MeasuresOutcomeMeasure Description Time Frame, ),103923302.1Atty. Docket No.: 109520-846634

[0359] TABLE 38: Phase III Secondary Outcome MeasuresOutcome Measure Measure Description Time FramePercenta e of Partici ants Rescue sedation medication (ie Preo erative (Da 1) and d103923302.1Atty. Docket No.: 109520-846634 Outcome Measure Measure Description Time Frameneed for rescue sedation103923302.1Atty. Docket No.: 109520-846634 Outcome Measure Measure Description Time Frame4. Neurocognitive AEs (i.e.,103923302.1Atty. Docket No.: 109520-846634 Outcome Measure Measure Description Time FrameMean Chan e from Baseline Preo erativeResults:

[0360] A summary of the disposition of all subjects in the analysis set is provided in TABLE 39. Overall,828 subjects were screened, with 531 subjects passing the screen (i.e., were randomized) and 297 subjects failing the screens for various exclusion reasons listed in TABLE 39, referencing the exclusion type numbers from TABLE 38. Total subjects included in the intent-to-treat (ITT) analysis set (e.g., all randomized subjects) was N=531, with treatment arms of MELT-300 (N=353), midazolam (N=89), and placebo (N=89). Total subjects included in the safety analysis set (e.g., all randomized subjects who received any study drug) was N=527, with treatment arms of MELT-300 (N=350), midazolam (N=89), and placebo (N=88). Total subjects included in the all-treated analysis set (e.g., all randomized subjects who received any study drug) was N=527, with treatment arms of MELT-300 (N=350), midazolam (N=89), and placebo (N=88). Total subjects included in the per-protocol (PP) analysis set (e.g., all randomized subjects who received any study drug and who had no significant protocol deviations that could complicate interpretation of efficacy and / or safety) was N=523, with treatment arms of MELT-300 (N=347), midazolam (N=89), and placebo (N=87).

[0361] A summary of protocol deviations in the intention-to-treat (ITT) dataset are provided inTABLE 40. Percentages shown for site-level protocol deviations were based on the number of sites.

[0362] Demographics and subject baseline characteristics of the intention-to-treat (ITT) analysis set areprovided in TABLE 41, which includes information on subject age, sex, ethnicity, race, caffeine consumption, and history of smoking and drug use.

[0363] Achievement of the primary endpoint (i.e., procedural sedation) was evaluated. Success for aprocedural sedation responder was defined as a subject that achieved the target sedation level (RSS level 2 or 3) by the start of surgery without the need for rescue sedation medication, no requirement for intraoperative sedation medication, and who was able to complete the surgery. Primary endpoint data for the intention-to-treat (ITT) analysis set is shown in TABLE 42), where comparisons between MELT-300 103923302.1Atty. Docket No.: 109520-846634 and midazolam are displayed in the midazolam column, and comparisons between MELT-300 and placebo are displayed in the placebo column.277 / 353 (78.5%) subjects receiving MELT-300 achieved target sedation, compared to 58 / 89 (65.2%) subjects receiving 3 mg midazolam alone, and 32 / 89 (36.0%) of subjects receiving placebo.

[0364] Treatment differences were tested using a Pearson's chi-square test where a p-value < 0.05indicated a difference, with a Fisher's exact test being used instead if any expected values were < 5. Treatment difference p-values between the MELT-300 treatment arm and the midazolam or placebo treatment arms were p=0.009 and p < 0.001, respectively. Risk difference effects were estimated by the risk difference in proportions (MELT-300 - Midazolam, and MELT-300 - Placebo) and 95% CIs, calculated using the Miettinen and Nurminen method. A supportive stratified analysis was performed using the Cochran–Mantel–Haenszel (CMH) row-mean score test to stratify by site grouping. A common risk difference effect was estimated by the common risk difference in proportions (MELT-300 - Midazolam, and MELT-300 - Placebo) and 95% CIs, calculated using the Miettinen and Nurminen method stratified by site grouping.

[0365] A sensitivity analysis of the primary endpoint of procedural sedation responders (ITT analysisset) did not reveal any significant differences (not shown). This sensitivity analysis utilized the last observation (collected after study drug administration) carried forward method for imputing missing preoperative RSS scores just prior to the start of surgery.

[0366] Analysis of the primary endpoint (e.g., procedural sedation response) was performed on the all-treated and per-protocol (PP) analysis sets, as shown in TABLE 43 and TABLE 44, respectively. In the all-treated analysis set, treatment difference p-values between the MELT-300 treatment arm and the midazolam or placebo treatment arms were p=0.005 and p < 0.001, respectively (see TABLE 43). In the per-protocol analysis set, treatment difference p-values between the MELT-300 treatment arm and the midazolam or placebo treatment arms were p=0.004 and p < 0.001, respectively (see TABLE 44).

[0367] Analysis of the first key secondary analysis of requirement for rescue sedation medication wasperformed. Requirement for rescue sedation medication was defined as a subject that received rescue sedation medication during the preoperative or intraoperative period. Group comparisons and statistics were analogous to those for TABLES 42-44. Data from the intention-to-treat analysis set is shown in TABLE 45. In the ITT analysis set, 68 / 353 (19.3%) of subjects receiving MELT-300; 30 / 89 (33.7%) of subjects receiving midazolam alone; and 55 / 89 (61.8%) of subjects receiving placebo required rescue sedation medication. Treatment difference p-values between the MELT-300 treatment arm and the 103923302.1Atty. Docket No.: 109520-846634 midazolam or placebo treatment arms in the ITT analysis set were p=0.003 and p < 0.001, respectively. Sensitivity analysis of the ITT analysis set was not conducted due to no subjects reporting the intercurrent event which would trigger the multiple imputation analysis. Data for the requirement for rescue sedation medication in the all-treated analysis set is shown in TABLE 46. In the all-treated analysis set, 68 / 350 (19.4%) of subjects receiving MELT-300; 30 / 89 (33.7%) of subjects receiving midazolam alone; and 55 / 88 (62.5%) of subjects receiving placebo required rescue sedation medication. Treatment difference p- values between the MELT-300 treatment arm and the midazolam or placebo treatment arms in the all- treated analysis set were p=0.004 and p < 0.001, respectively. Data for the requirement for rescue sedation medication in the per-protocol (PP) analysis set is shown in TABLE 47. In the PP analysis set, 68 / 347 (19.6%) of subjects receiving MELT-300; 30 / 89 (33.7%) of subjects receiving midazolam alone; and 55 / 87 (63.2%) of subjects receiving placebo required rescue sedation medication. Treatment difference p-values between the MELT-300 treatment arm and the midazolam or placebo treatment arms in the PP analysis set were p=0.004 and p < 0.001, respectively.

[0368] Analysis of the second key secondary analysis of preoperative procedural sedation responderswas performed. A preoperative procedural sedation responder was defined as a subject that achieved the target sedation level (RSS level 2 or 3) by the start of surgery without the need for preoperative rescue sedation medication. Group comparisons and statistics were analogous to those for TABLES 42-47. Data from the intention-to-treat analysis set is shown in TABLE 48. In the ITT analysis set, 289 / 353 (81.9%) of subjects receiving MELT-300; 65 / 89 (73.0%) of subjects receiving midazolam alone; and 34 / 89 (38.2%) of subjects receiving placebo were preoperative procedural sedation responders. Treatment difference p-values between the MELT-300 treatment arm and the midazolam or placebo treatment arms in the ITT analysis set were p=0.062 and p < 0.001, respectively. A sensitivity analysis of the primary endpoint of procedural sedation responders (ITT analysis set) did not reveal any significant differences (not shown). Data for preoperative procedural sedation responders in the all-treated analysis set is shown in TABLE 49. In the all-treated analysis set, 289 / 350 (82.6%) of subjects receiving MELT-300; 65 / 89 (73.0%) of subjects receiving midazolam alone; and 34 / 88 (38.6%) of subjects receiving placebo were preoperative procedural sedation responders. Treatment difference p-values between the MELT-300 treatment arm and the midazolam or placebo treatment arms in the all-treated analysis set were p=0.042 and p < 0.001, respectively. Data for preoperative procedural sedation responders in the per-protocol (PP) analysis set is shown in TABLE 50. In the PP analysis set, 287 / 347 (82.7%) of subjects receiving MELT- 300; 65 / 89 (73.0%) of subjects receiving midazolam alone; and 34 / 87 (39.1%) of subjects receiving placebo were preoperative procedural sedation responders. Treatment difference p-values between the 103923302.1Atty. Docket No.: 109520-846634 MELT-300 treatment arm and the midazolam or placebo treatment arms in the PP analysis set were p=0.039 and p < 0.001, respectively.

[0369] A secondary analysis of rescue sedation medication use (both preoperatively and intraoperatively)for the ITT analysis set is shown in TABLE 51. In the ITT analysis set, 37 / 353(10.5%) of subjects receiving MELT-300; 16 / 89 (18.0%) of subjects receiving midazolam alone; and 28 / 89 (31.5%) of subjects receiving placebo received preoperative rescue sedation medication. Treatment difference p- values between the MELT 300 treatment arm and the midazolam or placebo treatment arms in the ITT analysis set were p=0.052 and p<0.001, respectively. In the ITT analysis set, 30 / 353(8.5%) of subjects receiving MELT-300; 15 / 89 (16.9%) of subjects receiving midazolam alone; and 28 / 89 (31.5%) of subjects receiving placebo received intraoperative rescue sedation medication. Treatment difference p- values between the MELT-300 treatment arm and the midazolam or placebo treatment arms in the ITT analysis set were p=0.020 and p<0.001, respectively.

[0370] A secondary analysis of Ramsay sedation scale (RSS) scores for the ITT analysis set is shown inTABLE 52. The RSS scores are summarized for: the baseline, just prior to the start of surgery, the minimum and maximum preoperative score, the minimum and maximum intraoperative score, the minimum and maximum postoperative score, and the maximum overall score.

[0371] Evaluation of time to achieve preoperative target sedation level for the all-treated analysis set isshown in TABLE 53. The data provided includes the time to achieve preoperative target sedation level, which was defined as the time from the administration of study drug until the first Ramsay Sedation Scale (RSS) score of 2 or 3, calculated in minutes. Calculations were for subjects dosed with MELT-300 who achieved a preoperative RSS score of 2 or 3 using the Kaplan-Meier (KM) method. The analysis excluded subjects who receive preoperative rescue sedation medication. The data provided also includes a sensitivity analysis of time to achieve preoperative target sedation level, which was defined as the time from the administration of study drug until the first Ramsay Sedation Scale (RSS) score of 2 or 3, calculated in minutes. Calculations were for subjects dosed with MELT-300 who achieved a preoperative RSS score of 2 or 3 using the KM method. Sensitivity analysis censored subjects who receive preoperative rescue sedation medication at the time rescue sedation medication was first administered.

[0372] A plot of the Kaplan-Meier Curve for time to achieve preoperative target sedation level for theall-treated analysis set is provided in FIG. 5. A secondary analysis of surgery completion in the intention- to-treat (ITT) analysis set is provided in TABLE 54. In the ITT analysis set, 349 / 353(98.9%) of subjects receiving MELT-300; 89 / 89 (100.0%) of subjects receiving midazolam alone; and 87 / 89 (97.8%) of 103923302.1Atty. Docket No.: 109520-846634 subjects completed the surgery, and all of those subjects completing the surgery completed the surgery without intervention due to pain or anxiety.

[0373] In the intention-to-treat analysis set, 3 / 353(0.8%) of subjects receiving MELT-300; 1 / 89 (1.1%)of subjects receiving midazolam alone; and 2 / 89 (2.2%) of subjects received intraoperative supplemental analgesia (data not shown).

[0374] Surgeon satisfaction with the operative experience was measured postoperatively on Day 1 usinga 5-point Likert scale (5 = very satisfied; 4 = satisfied; 3 = neither satisfied nor dissatisfied; 2 = dissatisfied; 1= very dissatisfied). Results are provided in TABLE 55. Comparisons between MELT-300 and midazolam are displayed in the midazolam column, and comparisons between MELT-300 and placebo are displayed in the placebo column. The means were compared using 2-sample t-tests and the Satterthwaite method. The proportion of satisfied responses ('Very Satisfied' or 'Satisfied', pooled) were tested using a Pearson's chi-square test; and a Fisher's exact test was used instead if any expected values were < 5.

[0375] Patient satisfaction with the operative experience was measured at the Follow-Up visit using a 5-point Likert scale (5 = very satisfied; 4 = satisfied; 3 = neither satisfied nor dissatisfied; 2 = dissatisfied; 1= very dissatisfied). Results are provided in TABLE 56. Comparisons between MELT-300 and midazolam are displayed in the midazolam column, and comparisons between MELT-300 and placebo are displayed in the placebo column. The means were compared using 2-sample t-tests and the Satterthwaite method. The proportion of satisfied responses ('Very Satisfied' or 'Satisfied', pooled) were tested using a Pearson's chi-square test; and a Fisher's exact test was used instead if any expected values were < 5.

[0376] An overview of adverse events (AEs) is provided in TABLE 57 for the safety analysis set.Reported data includes an overall summary of the presence of any AEs, treatment-emergent ocular adverse events (TEAEs), treatment-related TEAEs, TEAE of special interest (TEAESI), serious AEs (SEAs), and treatment-emergent SAEs (TESAE). Categories were not mutually exclusive. Results include the number of subjects, percent of subjects, and number of events in each category, respectively. A summary of treatment-emergence adverse events (TEAEs) by location, system organ class, and preferred term for the safety analysis set is provided in TABLE 58. A summary of treatment-related treatment- emergent adverse events (TRTEAEs) by system organ class, and preferred term for the safety analysis set is provided in TABLE 59. No SAEs (overall), TESAEs, or treatment-related TESAEs were observed. No SAEs resulting in death or discontinuation of the study was observed. 103923302.1Atty. Docket No.: 109520-846634

[0377] TABLE 39: Summary of Disposition (All Subjects)MELT-300 Midazolam Placebo Overall Subjects Screened 828 (100.0)Subjects Randomized 531 (64.1)Screen Failures 297 (35.9)Exclusion 03 1 (0.1)Exclusion 06 3 (0.4)Exclusion 07 2 (0.2)Exclusion 10 1 (0.1)Exclusion 12 5 (0.6)Exclusion 13 7 (0.8)Exclusion 14 10 (1.2)Exclusion 15 25 (3.0)Exclusion 16 96 (11.6)Exclusion 17 6 (0.7)Exclusion 18 10 (1.2)Exclusion 02 13 (1.6)Exclusion 04 4 (0.5)Exclusion 07 124 (15.0)Analysis Sets Intent-to-treat (ITT) Analysis Set 353 (100.0) 89 (100.0) 89 (100.0) 531 (100.)Safety Analysis 350 (99.2) 89 (100.0) 88 (98.9) 527 (99.2)All-Treated Analysis Set 350 (99.2) 89 (100.0) 88 (98.9) 527 (99.2)Per-protocol (PP) Analysis Set 347 (98.3) 89 (100.0) 87 (97.8) 523 (98.5)Subjects Events Subjects Dosed 350 (99.2) 89 (100) 88 (98.9) 527 (99.2)Subjects Initiated Surgery 349 (98.9) 89 (100) 87 (97.8) 525 (98.9)Subjects Completed Surgery 349 (98.9) 89 (100) 87 (97.8) 525 (98.9)End of Study Status Completed 350 (99.2) 89 (100) 88 (98.9) 527 (99.2)Discontinued 3 (0.8) 0 1 (1.1) 4 (0.8)Primary Reason for Study Discontinuation Withdrawal by Subject 1 (0.3) 0 0 1 (0.2)Adverse Event 1 (0.3) 0 0 1 (0.2)Pregnancy 0 0 0 0Physician Decision 0 0 0 0Protocol Violation 1 (0.3) 0 1 (1.1) 2 (0.4)Lost to Follow Up 0 0 0 0Other 0 0 0 0

[0378] TABLE 40: Summary of Protocol Deviations (ITT Analysis Set)103923302.1Atty. Docket No.: 109520-846634 MELT-300 Midazolam Placebo Overall (N=353) (N=89) (N=89) (N=541) n(%) n(%) n(%) n(%) Any site-level deviation 3 (23.1)Regulatory or ICH-GCP 0Data Privacy 0IP (non-subject) 0Equipment or Facilities 0Training or Qualification 0 Safety Reporting 3 (23.1) Study Procedure (non-subject) 0Other 0Any subject-level protocol deviation 202 (57.2) 46 (51.7) 46 (51.7) 294 (55.4)Inclusion and Exclusion Criteria 13 (3.7) 2 (2.2) 19 (3.6) 19 (3.6)Study Visit Schedule 144 (40.8) 30 (33.7) 210 (39.5) 210 (39.5)Missed Procedure 79 (22.4) 20 (22.5) 117 (22.0) 117 (22.0)Investigational Product 1(0.3) 0 1 (0.2) 1 (0.2)Informed Consent 8(2.3) 5 (5.6) 16 (3.0) 16 (3.0)Prohibited Medication 0 0 1 (0.2) 1 (0.2)Other 0 0 0 0

[0379] TABLE 41: Summary of Demographics and Baseline Characteristics (ITT Analysis Set)MELT-300 Placebo Placebo (N=353) (N=89) (N=89) Age (years) n353 89 89Mean ± SD 69.1 ± 7.09 68.6 ± 7.99 67.9 ± 8.41Min, Max 30, 89 45, 84 36, 85Age Group – n (%)18 to < 65 years 77 (21.8) 18 (20.0) 25 (28.1)>= 65 years 276 (78.2) 71 (79.8) 64 (71.9)Sex – n (%)18 to < 65 years 216 (61.2) 57 (64.0) 53 (59.6)>= 65 years 137 (38.8) 32 (36.0) 36 (40.4)Ethnicity – n (%)18 to < 65 years 32 (9.1) 9 (10.1) 9 (10.1)>= 65 years 321 (90.9) 80 (89.9) 80 (89.9)Race – n (%)American Indian or Alaska Native 1 (0.3) 0 1 (1.1)103923302.1Atty. Docket No.: 109520-846634 MELT-300 Placebo Placebo (N=353) (N=89) (N=89) Asian 2 (0.6) 0 1 (1.1)Black or African American 22 (6.2) 0 2 (2.2)Native Hawaiian or Other Pacific 0 Islander 0 1 (1.1)White 320 (90.7) 88 (98.9) 83 (93.3)Other 5 (1.4) 0 1 (1.1)Multiple 1 (0.3) 0 1 (1.1)Unknown 2 (0.6) 0 0Caffeine per Day (cups) n353 89 89Mean ± SD 1.9 ± 2.00 2.1 ± 1.88 1.9 ± 1.75Median 2.0 2.0 2.0Min, Max 0, 18 0, 10 0, 10Smoking History – n (%)Never 235 (66.6) 50 (56.2) 52 (58.4)Former 80 (22.7) 28 (31.5) 24 (27.0)Current 38 (10.8) 11 (12.4) 13 (14.6)History of Illicit Drug or Alcohol Abuse – n (%) Yes 13 (3.7) 8 (9.0) 7 (7.9)No 340 (96.3) 81 (91.0) 82 (92.1)Drug / Alcohol-Free for >= 5 Years - n (%) Yes 13 (100.0) 8 (100.0) 7 (100.0)No 0 0 0

[0380] TABLE 42: Primary Analysis of Procedural Sedation Responders (ITT Analysis Set)MELT-300 Midazolam Placebo (N=353) (N=89) (N=89)MELT-300 vs comparator Main analysis: Pearson’s chi-square test: p-value 0.009 <.001Statistic 6.85 61.08Degrees of freedom 1 1Risk difference 0.133 0.42595% CI (0.031, 0.244) (0.313, 0.527)103923302.1Atty. Docket No.: 109520-846634 MELT-300 Midazolam Placebo (N=353) (N=89) (N=89) Supportive stratified analysis: CMH row-mean score test: p-value 0.008 <.001Statistic 7.06 66.38Degrees of freedom 1 1Common risk difference 0.155 0.41395% CI (0.060, 0.250) (0.323, 0.502)

[0381] TABLE 43: Supplementary Analysis of the Primary Endpoint: Procedural Sedation Responders(All-Treated Analysis Set) MELT-300 Midazolam Placebo (N=350) (N=89) (N=88) Procedural sedation responder - n (%) 277 (79.1) 58 (65.2) 32 (36.4)MELT-300 vs comparator Main analysis: Pearson’s chi-square test: p-value 0.006 <.001Statistic 7.66 61.94Degrees of freedom 1 1Risk difference 0.140 0.42895% CI (0.038, 0.251) (0.315, 0.530)Supportive stratified analysis: CMH row-mean score test: p-value 0.005 <.001Statistic 7.91 67.27Degrees of freedom 1 1Common risk difference 0.161 0.41395% CI (0.066, 0.256) (0.323, 0.504)

[0382] TABLE 44: Supplementary Analysis of the Primary Endpoint: Procedural Sedation Responders(PP Analysis Set) MELT-300 Midazolam Placebo (N=347) (N=89) (N=87) 103923302.1Atty. Docket No.: 109520-846634 MELT-300 Midazolam Placebo (N=347) (N=89) (N=87) Procedural sedation responder - n (%) 275 (79.3) 58 (65.2) 32 (36.8)MELT-300 vs comparator Main analysis: Pearson’s chi-square test: p-value 0.005 <.001Statistic 7.79 60.61Degrees of freedom 1 1Risk difference 0.141 0.42595% CI (0.039, 0.252) (0.311, 0.528)Supportive stratified analysis: CMH row-mean score test: p-value 0.004 <.001Statistic 8.37 66.21Degrees of freedom 1 1Common risk difference 0.163 0.41095% CI (0.068, 0.258) (0.319, 0.501)

[0383] TABLE 45: First Key Secondary Analysis of Requirement for Rescue Sedation Medication (ITTAnalysis Set) MELT-300 Midazolam Placebo (N=353) (N=89) (N=89)(%) 68 (19.3) 30 (33.7) 55 (61.8)MELT-300 vs comparator Main analysis: Pearson’s chi-square test: p-value 0.003 <.001Statistic64.03Degrees of freedom1Risk difference-0.425(-0.255, - (-0.528, - 95% CI 0.044) 0.313) Supportive stratified analysis: CMH row-mean score test: p-value 0.003 <.001Statistic 8.78 67.67Degrees of freedom 1 1103923302.1Atty. Docket No.: 109520-846634 MELT-300 Midazolam Placebo (N=353) (N=89) (N=89) Common risk difference -0.168 -0.402(-0.263, - (-0.493, - 95% CI 0.073) 0.310)

[0384] TABLE 46: Supplementary Analysis of the First Key Secondary Endpoint: Requirement forRescue Sedation Medication (All-Treated Analysis Set) MELT-300 Midazolam Placebo (N=350) (N=89) (N=88) Requirement for rescue sedation medication - n (%) 68 (19.4) 30 (33.7) 55 (62.5)MELT-300 vs comparator Main analysis: Pearson’s chi-square test: p-value 0.004 <.001Statistic 8.34 64.59Degrees of freedom 1 1Risk difference -0.143 -0.431(-0.253, - (-0.534, - 95% CI 0.042) 0.318) Supportive stratified analysis: CMH row-mean score test: p-value 0.003 <.001Statistic 8.54 68.86Degrees of freedom 1 1Common risk difference -0.166 -0.422(-0.261, - (-0.512, - 95% CI 0.072) 0.332)

[0385] TABLE 47: Supplementary Analysis of the First Key Secondary Endpoint: Requirement forRescue Sedation Medication (PP Analysis Set) MELT-300 Midazolam Placebo (N=347) (N=89) (N=87) Requirement for rescue sedation medication - n (%) 68 (19.6) 30 (33.7) 55 (63.2)103923302.1Atty. Docket No.: 109520-846634 MELT-300 Midazolam Placebo (N=347) (N=89) (N=87) MELT-300 vs comparator Main analysis: Pearson’s chi-square test: p-value 0.004 <.001Statistic 8.09 65.18Degrees of freedom 1 1Risk difference -0.141 -0.436(-0.252, - (-0.539, - 95% CI 0.041) 0.323) Supportive stratified analysis: CMH row-mean score test: p-value 0.004 <.001Statistic 8.36 69.73Degrees of freedom 1 1Common risk difference -0.165 -0.424(-0.260, - (-0.514, - 95% CI 0.070) 0.334)

[0386] TABLE 48: Second Key Secondary Analysis of Preoperative Procedural Sedation Responders(ITT Analysis Set) MELT-300 Midazolam Placebo (N=353) (N=89) (N=89)(%) 289 (81.9) 65 (73.0) 34 (38.2)MELT-300 vs comparator Main analysis: Pearson’s chi-square test: p-value 0.062 <.001Statistic 3.48 68.89Degrees of freedom 1 1Risk difference 0.088 0.43795% CI (-0.004, 0.196) (0.325, 0.539)Supportive stratified analysis: CMH row-mean score test: p-value 0.032 <.001Statistic 4.62 75.28Degrees of freedom 1 1103923302.1Atty. Docket No.: 109520-846634 MELT-300 Midazolam Placebo (N=353) (N=89) (N=89) Common risk difference 0.126 0.43295% CI (0.034, 0.218) (0.343, 0.520)

[0387] TABLE 49: Supplementary Analysis of the Second Key Secondary Endpoint: PreoperativeProcedural Sedation Responders (All-Treated Analysis Set) MELT-300 Midazolam Placebo (N=350) (N=89) (N=88) Preoperative procedural sedation responder - n (%) 289 (82.6) 65 (73.0) 34 (38.6)MELT-300 vs comparator Main analysis: Pearson’s chi-square test: p-value 0.042 <.001Statistic 4.13 70.10Degrees of freedom 1 1Risk difference 0.095 0.43995% CI (0.003, 0.203) (0.327, 0.542)Supportive stratified analysis: CMH row-mean score test: p-value 0.021 <.001Statistic 5.34 76.78Degrees of freedom 1 1Common risk difference 0.132 0.43295% CI (0.041, 0.224) (0.343, 0.522)

[0388] TABLE 50: Supplementary Analysis of the Second Key Secondary Endpoint: PreoperativeProcedural Sedation Responders (PP Analysis Set) MELT-300 Midazolam Placebo (N=347) (N=89) (N=87) Preoperative procedural sedation responder - n (%) 287 (82.7) 65 (73.0) 34 (39.1)MELT-300 vs comparator Main analysis: 103923302.1Atty. Docket No.: 109520-846634 MELT-300 Midazolam Placebo (N=347) (N=89) (N=87) Pearson’s chi-square test: p-value 0.039 <.001Statistic 4.26 68.75Degrees of freedom 1 1Risk difference 0.097 0.43695% CI (0.004, 0.204) (0.323, 0.540)Supportive stratified analysis: CMH row-mean score test: p-value 0.016 <.001Statistic 5.75 75.87Degrees of freedom 1 1Common risk difference 0.134 0.43095% CI (0.043, 0.226) (0.340, 0.519)

[0389] TABLE 51: Secondary Analysis of Rescue Sedation Medication Use (ITT Analysis Set)MELT-300 Midazolam Placebo (N=353) (N=89) (N=89)-n (%) 37 (10.5) 16 (18.0) 28 (31.5)MELT-300 vs comparator Pearson’s chi-square test: p-value 0.052 <.001Statistic 3.78 24.94Degrees of freedom 1 1Received intraoperative rescue sedation medication - n (%) 30 (8.5) 15 (16.9) 28 (31.5)MELT-300 vs comparator Pearson’s chi-square test: p-value 0.020 <.001Statistic 5.43 32.87Degrees of freedom 1 1

[0390] TABLE 52: Secondary Analysis of Ramsay Sedation Scale Scores (ITT Analysis Set)Visit MELT-300 Midazolam Placebo Score (N=353) (N=89) (N=89) Baseline 103923302.1Atty. Docket No.: 109520-846634 Visit MELT-300 Midazolam Placebo Score (N=353) (N=89) (N=89) Prior rescue sedation medication given 0 0 01 350 (99.2) 89 (100.0) 88 (98.9)2-3 0 0 04 0 0 05+ 0 0 0Missing 3 (0.8) 0 1 (1.1)MELT-300 vs comparator CMH row-mean score test: p-value - -Statistic - -Degrees of freedom - -Just prior to the start of surgery Prior rescue sedation medication given 36 (10.2) 17 (19.1) 28 (31.5)1 20 (5.7) 7 (7.9) 25 (28.1)2-3 290 (82.2) 65 (73.0) 34 (38.2)4 3 (0.8) 0 05+ 0 0 0Missing 4 (1.1) 0 2 (2.2)MELT-300 vs comparator CMH row-mean score test: p-value 0.006 <.001Statistic 7.58 75.89Degrees of freedom 1 1Maximum preoperative score Prior rescue sedation medication given 0 0 01 53 (15.0) 22 (24.7) 51 (57.3)2-3 294 (83.3) 67 (75.3) 37 (41.6)4 3 (0.8) 0 05+ 0 0 0Missing 3 (0.8) 0 1 (1.1)MELT-300 vs comparator CMH row-mean score test: p-value 0.015 <.001Statistic 5.89 76.77Degrees of freedom 1 1Minimum intraoperative score Prior rescue sedation medication given 46 (13.0) 25 (28.1) 37 (41.6)1 17 (4.8) 4 (4.5) 17 (19.1)2-3 284 (80.5) 60 (67.4) 33 (37.1)4 2 (0.6) 0 05+ 0 0 0103923302.1Atty. Docket No.: 109520-846634 Visit MELT-300 Midazolam Placebo Score (N=353) (N=89) (N=89) Missing 4 (1.1) 0 2 (2.2)MELT-300 vs comparator CMH row-mean score test: p-value <.001 <.001Statistic 11.11 74.26Degrees of freedom 1 1Maximum intraoperative score Prior rescue sedation medication given 46 (13.0) 25 (28.1) 37 (41.6)1 11 (3.1) 4 (4.5) 12 (13.5)2-3 289 (81.9) 60 (67.4) 38 (42.7)4 3 (0.8) 0 05+ 0 0 0Missing 4 (1.1) 0 2 (2.2)MELT-300 vs comparator CMH row-mean score test: p-value <.001 <.001Statistic 14.39 69.35Degrees of freedom 1 1Minimum postoperative score Prior rescue sedation medication given 66 (18.7) 29 (32.6) 55 (61.8)1 214 (60.6) 49 (55.1) 28 (31.5)2-3 66 (18.7) 10 (11.2) 4 (4.5)4 0 0 05+ 0 0 0Missing 7 (2.0) 1 (1.1) 2 (2.2)MELT-300 vs comparator CMH row-mean score test: p-value 0.002 <.001Statistic 9.68 62.42Degrees of freedom 1 1Maximum postoperative score Prior rescue sedation medication given 66 (18.7) 29 (32.6) 55 (61.8)1 177 (50.1) 45 (50.6) 27 (30.3)2-3 103 (29.2) 14 (15.7) 5 (5.6)4 0 0 05+ 0 0 0Missing 7 (2.0) 1 (1.1) 2 (2.2)MELT-300 vs comparator CMH row-mean score test: p-value 0.001 <.001103923302.1Atty. Docket No.: 109520-846634 Visit MELT-300 Midazolam Placebo Score (N=353) (N=89) (N=89) Statistic 10.67 63.60Degrees of freedom 1 1Maximum score overall Prior rescue sedation medication given 0 0 01 51 (14.4) 22 (24.7) 47 (52.8)2-3 296 (83.9) 67 (75.3) 41 (46.1)4 3 (0.8) 0 05+ 0 0 0Missing 3 (0.8) 0 1 (1.1)MELT-300 vs comparator CMH row-mean score test: p-value 0.009 <.001Statistic 6.77 71.59Degrees of freedom 1 1

[0391] TABLE 53: Evaluation of Time to Achieve Preoperative Target Sedation Level (All-TreatedAnalysis Set) MELT-300 (N=353) Time to achieve preoperative target sedation level Subject Events - n (%)Achieved preoperative target sedation level 293 (83.0)KM time-to-event estimates (minutes) (95% CI): Q1 10 (NE, NE)Median 15 (10, 15)Q3 15 (NE, NE)KM event-free survival rates (95% CI): 5Minutes 0.94 (0.91, 0.96)10 Minutes 0.53 (0.47, 0.59)15 Minutes 0.14 (0.11, 0.19)20 Minutes 0.03 (0.02, 0.06)25 Minutes 0.00 (0.00, 0.02)30 Minutes 0.00 (NE, NE)Sensitivity analysis of time to achieve preoperative target sedation level Subject Events - n (%)Achieved preoperative target sedation level 293 (83.0)Censored 37 (10.5)103923302.1Atty. Docket No.: 109520-846634 MELT-300 (N=353) KM time-to-event estimates (minutes) (95% CI): Q1 10 (NE, NE)Median 15 (NE, NE)Q3 15 (15, 20)KM event-free survival rates (95% CI): 5Minutes 0.95 (0.92, 0.97)10 Minutes 0.58 (0.53, 0.63)15 Minutes 0.23 (0.19, 0.28)20 Minutes 0.14 (0.10, 0.18)25 Minutes 0.06 (0.03, 0.10)30 Minutes 0.03 (0.00, 0.10)35 Minutes NE (NE, NE)

[0392] TABLE 54: Secondary Analysis of Surgery Completion (ITT Analysis Set)MELT-300 Midazolam Placebo (N=353) (N=89) (N=89) Completed the surgery - n (%) 349 (98.9) 89 (100.0) 87 (97.8)MELT-300 vs comparator Fisher’s exact test: p-value 0.588 0.348Completed surgery without intervention due to pain or anxiety - n (%) 349 (98.9) 89 (100.0) 87 (97.8)MELT-300 vs comparator Fisher’s exact test: p-value 0.588 0.348

[0393] TABLE 55: Analysis of Surgeon Satisfaction (ITT Analysis Set)MELT-300 Midazolam Placebo (N=353) (N=89) (N=89)N349 89 87Mean ± SD 4.8 ± 0.49 4.8 ± 0.56 4.7 ± 0.67Median 5.0 5.0 5.0Min, Max 2, 5 2, 5 2, 5MELT-300 vs comparator 2-Sample t-test: 103923302.1Atty. Docket No.: 109520-846634 MELT-300 Midazolam Placebo (N=353) (N=89) (N=89) Difference (95% CI) 0.02 (-0.11, 0.12 (-0.04, 0.15) 0.27) p-value 0.777 0.135T-statistic 0.28 1.50Degrees of freedom 124 110Surgeon Satisfaction Scores - n (%)5 = Very Satisfied 288 (81.6) 74 (83.1) 66 (74.2)4 = Satisfied 52 (14.7) 11 (12.4) 17 (19.1)3 = Neither Satisfied Nor Dissatisfied 7 (2.0) 3 (3.4) 1 (1.1)2 = Dissatisfied 2 (0.6) 1 (1.1) 3 (3.4)1 = Very Dissatisfied 0 0 0MELT-300 vs comparator Fisher’s Exact Test: p-value 0.310 0.302

[0394] TABLE 56: Analysis of Patient Satisfaction (ITT Analysis Set)MELT-300 Midazolam Placebo (N=353) (N=89) (N=89)N350 89 88Mean ± SD 4.8 ± 0.53 4.8 ± 0.55 4.6 ± 0.71Median 5.0 5.0 5.0Min, Max 1, 5 2, 5 1, 5MELT-300 vs comparator 2-Sample t-test: Difference (95% CI) 0.02 (-0.10, 0.19 (0.03, 0.15) 0.35) p-value 0.707 0.022T-statistic 0.38 2.32Degrees of freedom 132 113Patient Satisfaction Scores - n (%)5 = Very Satisfied 284 (80.5) 71 (79.8) 59 (66.3)4 = Satisfied 59 (16.7) 15 (16.9) 25 (28.1)3 = Neither Satisfied Nor Dissatisfied 3 (0.8) 2 (2.2) 2 (2.2)2 = Dissatisfied 3 (0.8) 1 (1.1) 1 (1.1)1 = Very Dissatisfied 1 (0.3) 0 1 (1.1)MELT-300 vs comparator Fisher’s Exact Test: p-value 0.431 0.243103923302.1Atty. Docket No.: 109520-846634

[0395] TABLE 57: Overview of Adverse Events (Safety Analysis Set)Melt Midazola 300 m Placebo Overall (N=350) (N=89) (N=88) (N=527) n (%) # n (%) # n (%) # n (%) # Location: Overall 72 16 104 16 Any AE(20.6) 112 16 (18.0) 24 (18.2) 4(19.7) 0 68 15 13 Any TEAE(19.4) 96 13 (14.6) 20 (17.0) 2 96 (18.2)8 Any Treatment-Related TEAE 25 (7.1) 32 2 (2.2) 4 4 (4.5) 7 31 (5.9) 43Any TEAESI 32 (9.1) 34 2 (2.2) 2 7 (8.0) 9 41 (7.8) 45Ketamine emergence delirium 0 0 0 0 0 0 0 0Respiratory AEs 10 (2.9) 10 1 (1.1) 1 1 (1.1) 1 12 (2.3) 12Cardiovascular AEs 13 (3.7) 14 1 (1.1) 1 5 (5.7) 6 19 (3.6) 21Neurocognitive AEs 1 (0.3) 1 0 0 0 0 1 (0.2) 1Abuse-related AEs 7 (2.0) 8 0 0 1 (1.1) 1 8 (1.5) 9Oversedation requiring the use of flumazenil 0 0 0 0 0 0 0 0Oral / pharyngeal AEs 2 (0.6) 2 0 0 1 (1.1) 1 3 (0.6) 3Any Treatment-Related TEAESI 14 (4.0) 15 1 (1.1) 1 4 (4.5) 5 19 (3.6) 21Any Grade 3+ TEAE 1 (0.3) 1 0 0 0 0 1 (0.2) 1Any Grade 3+ Treatment- Related TEAE 0 0Any SAE 0 0 0 0 0 0 0 0Any TESAE 0 0 0 0 0 0 0 0Any Treatment-Related TESAE 0 0 0 0 0 0 0 0Any Unexpected TEAE 24 (6.9) 28 6 (6.7) 9 6 (6.8) 6 36 (6.8) 43Any Unexpected Treatment- Related TEAE 0 0 0 0 0 0 0 0Any TEAE Resulting in Study Drug Interruption 0 0 0 0 0 0 0 0Any TEAE Resulting in Study Drug Withdrawal 0 0 0 0 0 0 0 0Any TEAE Resulting in Death 0 0 0 0 0 0 0 0Any Treatment-Related TEAE Resulting in Death 0 0 0 0 0 0 0 0103923302.1Atty. Docket No.: 109520-846634 Melt Midazola 300 m Placebo Overall (N=350) (N=89) (N=88) (N=527) n (%) # n (%) # n (%) # n (%) # Location: Non-Ocular 53 10 Any AE(15.1) 80 7 (7.9) 9 9 (10.2) 14 69 (13.1)3 48 Any TEAE(13.7) 64 4 (4.5) 5 8(9.1) 12 60 (11.4) 81Any Treatment-Related TEAE 24 (6.9) 31 2 (2.2) 3 4 (4.5) 7 30 (5.7) 41Any TEAESI 32 (9.1) 34 2 (2.2) 2 7 (8.0) 9 41 (7.8) 45Ketamine emergence delirium 0 0 0 0 0 0 0 0Respiratory AEs 10 (2.9) 10 1 (1.1) 1 1 (1.1) 1 12 (2.3) 12Cardiovascular AEs 13 (3.7) 14 1 (1.1) 1 5 (5.7) 6 19 (3.6) 21Neurocognitive AEs 1 (0.3) 1 0 0 0 0 1 (0.2) 1Abuse-related AEs 7 (2.0) 8 0 0 1 (1.1) 1 8 (1.5) 9Oversedation requiring the use of flumazenil 0 0 0 0 0 0 0 0Oral / pharyngeal AEs 2 (0.6) 2 0 0 1 (1.1) 1 3 (0.6) 3Any Treatment-Related TEAESI 14 (4.0) 15 1 (1.1) 1 4 (4.5) 5 19 (3.6) 21Any Grade 3+ TEAE 0 0 0 0 0 0 0 0Any Grade 3+ Treatment- Related TEAE 0 0Any SAE 0 0 0 0 0 0 0 0Any TESAE 0 0 0 0 0 0 0 0Any Treatment-Related TESAE 0 0 0 0 0 0 0 0Any Unexpected TEAE 6(1.7) 6 0 0 0 0 6 (1.1) 6Any Unexpected Treatment- Related TEAE 0 0 0 0 0 0 0 0Any TEAE Resulting in Study Drug Interruption 0 0 0 0 0 0 0 0Any TEAE Resulting in Study Drug Withdrawal 0 0 0 0 0 0 0 0Any TEAE Resulting in Death 0 0 0 0 0 0 0 0Any Treatment-Related TEAE Resulting in Death 0 0 0 0 0 0 0 0Location: Ocular Any AE 26 (7.4) 32 10 (11.2) 15 9 (10.2) 10 45 (8.5) 57Any TEAE 26 (7.4) 32 10 (11.2) 15 9(10.2) 10 45 (8.5) 57Any Treatment-Related TEAE 1 (0.3) 1 1 (1.1) 1 0 0 2 (0.4) 2103923302.1Atty. Docket No.: 109520-846634 Melt Midazola 300 m Placebo Overall (N=350) (N=89) (N=88) (N=527) n (%) # n (%) # n (%) # n (%) # Any TEAESI 0 0 2 (2.2) 0 0 0 0 0Ketamine emergence delirium 0 0 0 0 0 0 0 0Respiratory AEs 0 0 1 (1.1) 0 0 0 0 0Cardiovascular AEs 0 0 1 (1.1) 0 0 0 0 0Neurocognitive AEs 0 0 0 0 0 0 0 0Abuse-related AEs 0 0 0 0 0 0 0 0Oversedation requiring the use of flumazenil 0 0 0 0 0 0 0 0Oral / pharyngeal AEs 0 0 0 0 0 0 0 0Any Treatment-Related TEAESI 0 0 0 0 0 0 0 0Any Grade 3+ TEAE 1 (0.3) 1 0 0 1 (0.2) 1Any Grade 3+ Treatment- Related TEAE 0 0 0 0 0 0 0 0Any SAE 0 0 0 0 0 0 0 0Any TESAE 0 0 0 0 0 0 0 0Any Treatment-Related TESAE 0 0 0 0 0 0 0 0Any Unexpected TEAE 19 (5.4) 22 6 (6.7) 9 6 (6.8) 6 31 (5.9) 37Any Unexpected Treatment- Related TEAE 0 0 0 0 0 0 0 0Any TEAE Resulting in Study Drug Interruption 0 0 0 0 0 0 0Any TEAE Resulting in Study Drug Withdrawal 0 0 0 0 0 0 0 0Any TEAE Resulting in Death 0 0 0 0 0 0 0 0

[0396] TABLE 58: Summary of Treatment-Emergent Adverse Events by Location, System Organ Class,and Preferred Term (Safety Analysis Set) System Organ Class MELT-300 Midazolam Placebo Overall Preferred Term (N=350) (N=89) (N=88) (N=527) n(%) n(%) n(%) n(%) Location: Overall Any TEAE 68 (19.4) 13 (14.6) 15 (17.0) 96 (18.2)Cardiac disorders 4 (1.1) 1 (1.1) 0 5 (0.9)Tachycardia 2 (0.6) 1 (1.1) 0 3 (0.6)Bradycardia 2 (0.6) 0 0 2 (0.4)103923302.1Atty. Docket No.: 109520-846634 System Organ Class MELT-300 Midazolam Placebo Overall Preferred Term (N=350) (N=89) (N=88) (N=527) n(%) n(%) n(%) n(%) Eye disorders 24 (6.9) 9 (10.1) 9 (10.2) 42 (8.0)Vision blurred 7 (2.0) 5 (5.6) 4 (4.5) 16 (0.3)Foreign body sensation in eyes 5 (1.4) 2 (2.2) 1 (1.1) 8 (1.5)Eye irritation 2 (0.6) 2 (2.2) 2 (2.3) 6 (1.1)Eye pain 2 (0.6) 2 (2.2) 2 (2.3) 6 (1.1)Halo vision 1 (0.3) 1 (1.1) 0 2 (0.4)Photophobia 2 (0.6) 0 0 2 (0.4)Photopsia 2 (0.6) 0 0 2 (0.4)Visual impairment 2 (0.6) 0 0 2 (0.4)Abnormal sensation in eye 1 (0.3) 0 0 1 (0.2)Corneal oedema 1 (0.3) 0 0 1 (0.2)Diplopia 1 (0.3) 0 0 1 (0.2)Eye discharge 0 1 (1.1) 0 1 (0.2)Glare 1 (0.3) 0 0 1 (0.2)Lacrimation increased 0 0 1 (1.1) 1 (0.2)Ocular discomfort 1 (0.3) 0 0 1 (0.2)Periorbital discomfort 0 1 (1.1) 0 1 (0.2)Visual field defect 1 (0.3) 0 0 1 (0.2)Gastrointestinal disorders 4 (1.1) 0 1 (1.1) 5 (0.9)Nausea 3 (0.9) 0 0 3 (0.6)Hypoaesthesia oral 1 (0.3) 0 1 (1.1) 2 (0.4)General disorders and administration site conditions 4 (1.1) 0 0 4 (0.8)Fatigue 2 (0.6) 0 0 2 (0.4)Instillation site pain 1 (0.3) 0 0 1 (0.2)Pyrexia Infections and infestations 1 (0.3) 0 0 1 (0.2)Sinusitis 1 (0.3) 0 0 1 (0.2)Injury, poisoning and procedural complications 7 (2.0) 0 0 7 (1.3)Procedural nausea 4 (1.1) 0 0 4 (0.8)Procedural vomiting 2 (0.6) 0 0 2 (0.4)Corneal abrasion 1 (0.3) 0 0 1 (0.2)Post procedural hypotension 1 (0.3) 0 0 1 (0.2)Procedural pain 1 (0.3) 0 0 1 (0.2)Investigations 16 (4.6) 0 5 (5.7) 21 (4.0)Blood pressure increased 7 (2.0) 0 0 11 (2.1)Oxygen saturation decreased 8 (2.3) 0 0 9 (1.7)Blood pressure systolic increased 1 (0.3) 0 0 1 (0.2)Musculoskeletal and connective tissue disorders 3 (0.9) 0 0 3 (0.6)103923302.1Atty. Docket No.: 109520-846634 System Organ Class MELT-300 Midazolam Placebo Overall Preferred Term (N=350) (N=89) (N=88) (N=527) n(%) n(%) n(%) n(%) Back pain 1 (0.3) 0 0 1 (0.2)Myalgia 1 (0.3) 0 0 1 (0.2)Neck pain 1 (0.3) 0 0 1 (0.2)Nervous system disorders 11 (3.1) 3 (3.4) 2 (2.3) 16 (3.0)Headache 6 (1.7) 2 (2.2) 2 (2.3) 10 (1.9)Dizziness 2 (0.6) 0 0 2 (0.4)Amnesia 1 (0.3) 0 0 1 (0.2)Balance disorder 1 (0.3) 0 0 1 (0.2)Lethargy 1 (0.3) 0 0 1 (0.2)Nystagmus 0 1 (1.1) 0 1 (0.2)Paraesthesia 0 1 (1.1) 0 1 (0.2)Taste disorder 1 (0.3) 0 0 1 (0.2)Product issues 6 (1.7) 0 0 6 (1.1)Product after taste 6 (1.7) 0 0 6 (1.1)Psychiatric disorders 2 (0.6) 0 1 (1.1) 3 (0.6)Anxiety 2 (0.6) 0 1 (1.1) 3 (0.6)Respiratory, thoracic, and mediastinal disorders 4 (1.1) 1 (1.1) 1 (1.1) 6 (1.1)Hypoxia 2 (0.6) 1 (1.1) 0 3 (0.6)Cough 1 (0.3) 0 0 1 (0.2)Hiccups 0 0 1 (1.1) 1 (0.2)Nasal Discomfort 1 (0.3) 0 0 1 (0.2)Surgical and medical procedures 1 (0.3) 0 0 1 (0.2)Dental local anaesthesia 1 (0.3) 0 0 1 (0.2)Vascular disorders 0 0 1 (1.1) 1 (0.2)Hypertension 0 0 1 (1.1) 1 (0.2)Location: Non-Ocular Any TEAE 48 (13.7) 4 (4.5) 8 (9.1) 60 (11.4)Cardiac disorders 4 (1.1) 0 1 (1.1) 5 (0.9)Tachycardia 3 (0.9) 0 0 3 (0.6)Bradycardia 1 (0.3) 0 1 (1.1) 2 (0.4)Gastrointestinal disorders 3 (0.9) 0 0Nausea 2 (0.6) 0 0Hypoaesthesia oral 1 (0.3) 0 0General disorders and administration site conditions 3 (0.9) 0 0 3 (0.6)103923302.1Atty. Docket No.: 109520-846634 System Organ Class MELT-300 Midazolam Placebo Overall Preferred Term (N=350) (N=89) (N=88) (N=527) n(%) n(%) n(%) n(%) Fatigue 2 (0.6) 0 0 2 (0.4)Pyrexia 1 (0.3) 0 0 1 (0.2)Infections and infestations 1 (0.3) 0 0 1 (0.2)Sinusitis 1 (0.3) 0 0 1 (0.2)Injury, poisoning and procedural complications 5 (1.4) 0 0 5 (0.9)Procedural nausea 4 (1.1) 0 0 4 (0.8)Procedural vomiting 2 (0.6) 0 0 2 (0.4)Post procedural hypotension 1 (0.3) 0 0 1 (0.2)Investigations 16 (4.6) 0 5 (5.7) 5 (0.9)Blood pressure increased 7 (2.) 0 4 (4.5) 4 (0.8)Oxygen saturation decreased 8 (2.3) 0 1 (1.1)0 2 (0.4)Blood pressure systolic increased 1 (0.3) 0 0 1 (0.2)Musculoskeletal and connective tissue disorders 3 (0.9) 0 0 3 (0.6)Back pain 1 (0.3) 0 0 1 (0.2)Myalgia 1 (0.3) 0 0 1 (0.2)Neck pain 1 (0.3) 0 0 1 (0.2)Nervous system disorders 11 (3.1) 3 (3.4) 2 (2.3) 16 (3.0)Headache 6 (1.7) 2 (2.2) 2 (2.3) 10 (1.9)Dizziness 2 (0.6) 0 0 2 (0.4)Amnesia 1 (0.3) 0 0 1 (0.2)Balance disorder 1 (0.3) 0 0 1 (0.2)Lethargy 1 (0.3) 0 0 1 (0.2)Paraesthesia 0 1 (1.1) 0 1 (0.2)Taste disorder 1 (0.3) 0 0 1 (0.2)Product issues 6 (1.7) 0 0 6 (1.1)Product after taste 6 (1.7) 0 0 6 (1.1)Psychiatric disorders 2 (0.6) 0 1 (1.1) 3 (0.6)Anxiety 2 (0.6) 0 1 (1.1) 3 (0.6)Respiratory, thoracic, and mediastinal disorders 4 (1.1) 1 (1.1) 1 (1.1) 6 (1.1)Hypoxia 2 (0.6) 1 (1.1) 0 3 (0.6)Cough 1 (0.3) 0 0 1 (0.2)Hiccups 0 0 1 (1.1) 1 (0.2)Nasal Discomfort 1 (0.3) 0 0 1 (0.2)Surgical and medical procedures 1 (0.3) 0 0 1 (0.2)Dental local anaesthesia 1 (0.3) 0 0 1 (0.2)103923302.1Atty. Docket No.: 109520-846634 System Organ Class MELT-300 Midazolam Placebo Overall Preferred Term (N=350) (N=89) (N=88) (N=527) n(%) n(%) n(%) n(%) Vascular disorders 0 0 1 (1.1) 1 (0.2)Hypertension 0 0 1 (1.1) 1 (0.2)Location: Ocular Any TEAE 26 (7.4) 10 (11.2) 9 (10.2) 45 (8.5)Eye disorders 24 (6.9) 9 (10.1) 9 (10.2) 42 (8.0)Vision blurred 7 (2.0) 5 (5.6) 4 (4.45) 16 (3.0)Foreign body sensation in eyes 5 (1.4) 2 (2.2) 1 (1.1) 8 (1.5)Eye irritation 2 (0.6) 2 (2.2) 2 (2.3) 6 (1.1)Eye pain 2 (0.6) 2 (2.2) 2 (2.3) 6 (1.1)Halo vision 1 (0.3) 1 (1.1) 0 2 (0.4)Photophobia 2 (0.6) 0 0 2 (0.4)Photopsia 2 (0.6) 0 0 2 (0.4)Visual impairment 2 (0.6) 0 0 2 (0.4)Abnormal sensation in eye 1 (0.3) 0 0 1 (0.2)Corneal oedema 1 (0.3) 0 0 1 (0.2)Diplopia 1 (0.3) 0 0 1 (0.2)Eye discharge 0 1 (1.1) 0 1 (0.2)Glare 1 (0.3) 0 0 1 (0.2)Lacrimation increased 0 0 1 (1.1) 1 (0.2)Ocular discomfort 1 (0.3) 0 0 1 (0.2)Periorbital discomfort 0 1 (1.1) 0 1 (0.2)Visual field defect 1 (0.3) 0 0 1 (0.2)General disorders and administration site conditions 1 (0.3) 0 0 1 (0.2)Installation site pain 1 (0.3) 0 0 1 (0.2)Injury, poisoning and procedural complications 2 (0.6) 0Corneal abrasion 1 (0.3) 0Procedural pain 1 (0.3) 0Nervous system disorders 0 1 (1.1) 0 1 (0.2)Nystagmus 0 1 (1.1) 0 1 (0.2)

[0397] TABLE 59: Summary of Treatment-Related Treatment-Emergent Adverse Events by SystemOrgan Class and Preferred Term (Safety Analysis Set) 103923302.1Atty. Docket No.: 109520-846634 System Organ Class MELT-300 Midazolam Placebo Overall Preferred Term (N=350) (N=89) (N=88) (N=527) n(%) n(%) n(%) n(%) Any Treatment-Related TEAE 25 (7.1) 2 (2.2) 4 (4.5) 31 (5.9)Cardiac disorders 2 (0.6) 0 0 2 (0.4)Tachycardia 1 (0.3) 0 0 1 (0.2)Bradycardia 1 (0.3) 0 0 1 (0.2)Eye disorders 1 (0.3) 0 0 1 (0.2)Visual impairment 1 (0.3) 0 0 1 (0.2)Gastrointestinal disorders 2 (0.6)Hypoaesthesia oral 1 (0.3)Nausea 1 (0.3)Injury, poisoning and procedural complications 4 (1.1) 0 0 4 (0.8)Procedural nausea 4 (1.1) 0 0 4 (0.8)Procedural vomiting 2 (0.6) 0 0 2 (0.4)Investigations 6 (1.7) 0 3 (3.4) 9 (1.7)Blood pressure increased 3 (0.9) 0 2 (2.3) 5 (0.9)Oxygen saturation decreased 3 (0.9) 0 1 (1.1) 4 (0.8)Nervous system disorders 5 (1.4) 2 (2.2) 1 (1.1) 8 (1.5)Headache 2 (0.6) 1 (1.1) 1 (1.1) 4(0.8)Dizziness 1 (0.3) 0 0 1 (0.2)Lethargy 1 (0.3) 0 0 1 (0.2)Nystagmus 0 0 1 (0.2)Paraesthesia 0 1 (1.1) 0 1 (0.2)Taste disorder 1 (0.3) 1 (1.1) 0 1 (0.2)Product issues 6 (1.7) 0 0 6 (1.1)Product after taste 6 (1.7) 0 0 6 (1.1)Psychiatric disorders 1 (0.3) 0 0 1 (0.2)Anxiety 1 (0.3) 0 0 1 (0.2)Respiratory, thoracic, and mediastinal disorders 1 (0.3) 1 (1.1) 1 (1.1) 3 (0.6)Hypoxia 1 (0.3) 1 (1.1) 0 2 (0.4)Hiccups 0 0 1 (1.1) 1 (0.2)Surgical and medical procedures 1 (0.3) 0 0 1 (0.2)Dental local anaesthesia 1 (0.3) 0 0 1 (0.2)103923302.1

Claims

Atty. Docket No.: 109520-846634 CLAIMS What is claimed is:

1. A method of inducing procedural sedation in a subject, the method comprising sublinguallyadministering a pharmaceutical composition comprising midazolam and ketamine, wherein the administration achieves a level of sedation for procedural sedation that lasts for a time period of 45 minutes or less.

2. The method of claim 1, wherein the procedural sedation lasts for a time period of 30 minutes orless.

3. The method of claim 1, wherein the procedural sedation lasts for a time period of 15 minutes orless.

4. The method of claim 1, wherein the level of sedation achieved is measured via the Ramsaysedation scale.

5. The method of claim 1, wherein the level of sedation achieved is greater than achieved byadministering midazolam alone or ketamine alone.

6. The method of claim 1, wherein the midazolam is present in the pharmaceutical composition inan amount from about 0.2 mass% to about 5.0 mass%.

7. The method of claim 1, wherein the ketamine is present in the pharmaceutical composition in anamount from about 1.0 mass% to about 10.0 mass%.

8. The method of claim 1, wherein the weight ratio of midazolam to ketamine in the pharmaceuticalcomposition is about 1:5 to about 1:20.

9. The method of claim 8, wherein the weight ratio of midazolam to ketamine in the pharmaceuticalcomposition is about 3:25.

10. The method of claim 1, wherein the pharmaceutical composition comprises about 3 mg ofmidazolam and about 25 mg of ketamine.

11. The method of claim 8, wherein the weight ratio of midazolam to ketamine in the pharmaceuticalcomposition is about 3:

50. 103923302.1Atty. Docket No.: 109520-84663412. The method of claim 1, wherein the pharmaceutical composition comprises about 3 mg ofmidazolam and about 50 mg of ketamine.

13. The method of claim 1, wherein the pharmaceutical composition comprises a matrix former.

14. The method of claim 13, wherein the matrix former comprises mannitol, gelatin, or a combinationthereof.

15. The method of claim 13, wherein the matrix former is present in the pharmaceutical compositionin an amount from about 40% to about 95% by weight of the pharmaceutical composition.

16. The method of claim 13, wherein the matrix former is present in the pharmaceutical compositionin an amount from about 80% to about 95% by weight of the pharmaceutical composition.

17. The method of claim 13, wherein the pharmaceutical composition is a freeze-dried composition.

18. The method of claim 1, wherein the pharmaceutical composition further comprises a sweetener.

19. The method of claim 1, wherein the pharmaceutical composition further comprises a flavoringagent.

20. The method of claim 1, wherein the sublingual administration results in a Cmax of midazolam inthe subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, at least about 70% lower, or at least about 80% lower than a Cmax of midazolam resulting from intravenous administration of an equivalent amount of midazolam.

21. The method of claim 1, wherein the sublingual administration results in a Cmax of midazolam inthe subject of less than or equal to about 140 ng / mL.

22. The method of claim 1, wherein the sublingual administration results in a Cmax of1-hydroxymidazolam in the subject that is at least about 25% greater, at least about 50% greater, at least about 100% greater, or at least about 200% greater than a Cmax of 1-hydroxymidazolam resulting from intravenous administration of an equal amount of midazolam.

23. The method of claim 1, wherein the sublingual administration results in a Cmax of1-hydroxymidazolam in the subject that is greater than or equal to about 6 ng / mL. 103923302.1Atty. Docket No.: 109520-84663424. The method of claim 1, wherein the sublingual administration results in a Cmax of ketamine inthe subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, at least about 70% lower, or at least about 80% lower than a Cmax achieved from intravenous administration of an equal amount of ketamine.

25. The method of claim 1, wherein the sublingual administration results in a Cmax of ketamine inthe subject of less than or equal to about 275 ng / mL.

26. The method of claim 1, wherein the sublingual administration results in a Cmax of norketaminein the subject that is at least about 10% greater, at least about 25% greater, at least about 50% greater, at least about 100% greater, at least about 150% greater, at least about 200% greater, at least about 300% greater, or at least about 400% greater than a Cmax of norketamine achieved from intravenous administration of an equal amount of ketamine.

27. The method of claim 1, wherein the sublingual administration results in a Cmax of norketaminein the subject of greater than or equal to about 30 ng / mL.

28. A method of inducing procedural sedation in a subject, the method comprising:sublingually administering to the subject a first dose of a pharmaceutical composition comprising midazolam and ketamine; and sublingually administering to the subject a second dose of the pharmaceutical composition after the sublingual administration of the first dose, wherein the procedural sedation lasts 45 minutes or less.

29. A solid pharmaceutical composition formulated for sublingual and or buccal administrationcomprising about 3 mg of midazolam and about 50 mg of ketamine.

30. A pharmaceutical composition suitable for sublingual administration to a subject in need thereof,the pharmaceutical composition comprising: midazolam in an amount from about 0.2 mass% to about 5.0 mass% of the pharmaceutical composition; ketamine in an amount from about 1.0 mass% to about 10.0 mass% of the pharmaceutical composition; and a matrix former. 103923302.1Atty. Docket No.: 109520-84663431. The pharmaceutical composition of claim 30, wherein the matrix former is present in thepharmaceutical composition in an amount from about 40 mass% to about 95 mass% of the pharmaceutical composition.

32. The pharmaceutical composition of claim 30, wherein the matrix former is present in thepharmaceutical composition in an amount from about 80 mass% to about 95 mass% of the pharmaceutical composition.

33. The pharmaceutical composition of claim 30, wherein the matrix former is present in thepharmaceutical composition in an amount of about 90 mass% of the pharmaceutical composition.

34. The pharmaceutical composition of claim 30, wherein the matrix former comprises gelatin,mannitol, cellulose derivatives (e.g., methylcellulose, ethylcellulose, hydroxypropylcellulose, hypromellose, carboxymethylcellulose, etc.), agar agar, carob gum, xanthan gum, pectin, chitosan, starches, trehalose, sucrose, acrylic acid polymers, or acrylate polymers.

35. The pharmaceutical composition of claim 30, wherein the matrix former comprises gelatin,mannitol, or combinations thereof.

36. The pharmaceutical composition of claim 30, wherein the ketamine is present in the pharmaceuticalcomposition in an amount from about 4.0 mass % to about 6.0 mass %.

37. The pharmaceutical composition of claim 30, wherein the ketamine is present in the pharmaceuticalcomposition in an amount of about 5.0 mass %.

38. The pharmaceutical composition of claim 30, wherein the ketamine is present in the pharmaceuticalcomposition in an amount from about 20 mg to about 80 mg.

39. The pharmaceutical composition of claim 30, wherein the ketamine is present in the pharmaceuticalcomposition in an amount from about 40 mg to about 60 mg.

40. The pharmaceutical composition of claim 30, wherein the ketamine is present in the pharmaceuticalcomposition in an amount of about 50 mg.

41. The pharmaceutical composition of claim 30, wherein the midazolam is present in thepharmaceutical composition in an amount from about 1.0 mass % to about 3.0 mass %.

42. The pharmaceutical composition of claim 30, wherein the midazolam is present in thepharmaceutical composition in an amount of about 2.5 mass %.

43. The pharmaceutical composition of claim 30, wherein the midazolam is present in thepharmaceutical composition in an amount from about 1 mg to about 10 mg.

44. The pharmaceutical composition of claim 30, wherein the midazolam is present in thepharmaceutical composition in an amount from about 1 mg to about 5 mg.

45. The pharmaceutical composition of claim 30, wherein the midazolam is present in thepharmaceutical composition in an amount from about 2 mg to about 4 mg.

46. The pharmaceutical composition of claim 30, wherein the midazolam is present in thepharmaceutical composition in an amount of about 3 mg. 103923302.1Atty. Docket No.: 109520-84663447. The pharmaceutical composition of claim 30, wherein the weight ratio of midazolam to ketamineis from about 1:5 to about 1:

20.

48. antiemetic medicament, an antihistamine medicament, a pain reliever, a non-steroid anti- inflammatory drug (NSAID), or a combination thereof.

49. The pharmaceutical composition of claim 30, further comprising a binder, antioxidant, adjuvant,pH adjuster, synergist or preservative.

50. A pharmaceutical composition suitable for sublingual administration to a subject in need thereof,the pharmaceutical composition comprising: midazolam in an amount from about 1 mg to about 10 mg; ketamine in an amount from about 20 mg to about 80 mg; and a matrix former in an amount from about 40 mass% to about 95 mass% of the pharmaceutical composition.

51. A pharmaceutical composition suitable for sublingual administration to a subject in need thereof,the pharmaceutical composition comprising: midazolam; ketamine; and a matrix former in an amount from about 40 mass% to about 95 mass% of the pharmaceutical composition, wherein the weight ratio of midazolam to ketamine is from about 1:5 to about 1:

20. 103923302.1

Images